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Symbols and Abbreviations 
 
 
 
BCS    Biopharmaceutical Classification System 
DoE    Design of experiments 
DSC    Differential scanning calorimeter 
FDA    Food and Drug Administration 
GIT    Gastro-intestinal tract 
GMD    Geometric mean diameter 
HSM    Hot stage microscopy 
LSP    Lansoprazole 
MC    Moisture content 
MCC    Microcrystalline cellulose 
MFT    Minimum film-forming temperature (°C) 
PAT    Process Analytical Technology 
PPI    Proton pump inhibitor 
RH    Relative humidity 
rpm    Round per minute 
RSD    Relative standard deviation (%) 
SEM    Scanning electron microscopy 
STAVEX:   Statistische Versuchsplanung mit Expertensystem 
Tg    Glass transition temperature 
TGA    Thermogravimetric analysis 
t0.5    Half-life 
t0.9    Shelf-life 
USP:    United States Pharmacopoeia  
v/v    Percent by volume 
w/w    Percent by weight 
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1. Summary 
 
Pharmaceutical product development is a complex and creative design process, that involves 
many factors, many unknowns, many disciplines and has a multiple iterations and a long life-
cycle. In the development of pharmaceutical dosage forms, one of persistent challenges is 
getting an early stability assessment providing an understanding of critical formulation and 
process parameters. In depth and science based knowledge, whether to use one excipient or 
another, or to apply one process before the other, could help shortening the process time and 
as a consequence save the money which is one of the goals of pharmaceutical industry.  
 
Pelletization processes are usually lengthy and expensive. Processing of a single batch may 
sometimes require hours or even days to be completed, and it can result in a non-robust 
process. Formulation of a stable delivery system for lansoprazole is extremely difficult. 
Lansoprazole belongs to class II drugs of the Biopharmaceutical Classification System (BCS), 
characterized by low solubility and high permeability. Furthermore, lansoprazole degrades in a 
highly acidic and highly basic environment, and it is also unstable under conditions of high 
temperature and also high humidity, with a decrease in the amount of lansoprazole and 
discoloration of the material being noted on storage under such conditions Tetsuro et al., 1992. 
Additionally, a strong pH-dependent solubility of the drug was observed. There is therefore a 
need for a pharmaceutical delivery system which protects the active substance both during 
storage as well as the passage through the stomach. 
 
The aim of this study was on the one hand the multifactorial investigation of crucial parameters 
involved in the stability of lansoprazole pellets focusing on the formulation parameters and 
preparation technique and on the other hand application of Arrhenius equation as a comparative 
technique in stability of pellets as a solid dosage form.  
Firstly, thermal characterization of lansoprazole has been conducted in order to clarify the 
differences reported in the literature and elucidate the reason of the uncommon behaviour when 
different heating rates were applied. Combining a differential scanning calorimeter (DSC), 
thermogravimetric analysis (TGA) and hot-stage microscopy (HSM) technique, the results 
confirmed that the melting point depression at low heating rates was due to eutectic behavior of 
the drug with its decomposition products formed at low heating rates. Even when the high 
heating rates (30 and 40°C/min) were applied melting point of lansoprazole did not show 
independence on the heating rate and difference in the melting point was 1°C. Combination of 
different techniques and highly dynamic and standardized methods for determination of thermal 
properties of decomposable substances should be used.  
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Series of experiments were devised to study the effects of various formulation and processing 
variables on preparation and the stability of lansoprazole in order to examine some of the 
precautions which can be taken to minimize the loss of activity. Lansoprazole pellets were 
prepared using two different pelletizing techniques, solution suspension layering in bottom 
spraying fluidized bed and direct pelletization in rotor processor. Firstly, in a solution suspension 
layering, influence of type of neutral pellet (sugar based and microcrystalline cellulose based), 
type of stabilizing agent (influence of neutral and weak basic microenvironmental pH), presence 
of protective HPMC coating, type of aqueous enteric polymer based on shellac or methacrylic 
acid copolymer (Marcoat 125® or Eudragit L30 D-55®) and the coating levels on surface 
morphology, porosity, dissolution and stability of enteric coated pellets containing acid-liable 
drug, was evaluated.  
Furthermore, the aim was to investigate the feasibility of rotary processor for preparing 
lansoprazole loaded pellets based on Balocel®, which is a pre-mixed excipient blend containing 
microcrystalline cellulose, lactose and sodium carboxymethyl cellulose. Since pelletization in 
fluidized bed rotary processor is a multivariable process and the final characteristics of 
produced pellets are affected by several factors, in order to achieve a controlled, robust process 
and to optimize desired pellet properties, experimental design has been applied using expert 
design system STAVEX. The most important process variables related to the geometric mean 
diameter of lansoprazole pellets and the moisture content at the end of liquid addition phase, 
according to the pre-experiments, included spray rate and rotor speed, while the most influential 
formulation variable was a level of drug load. The study revealed that even though the process 
has been optimized to obtain pellets of optimum size and shape, another crucial property of 
pellets, dissolution, was disregarded and was confounded by another factor which could not be 
controlled (inlet air humidity) and which was not included in the design. This led to a conclusion, 
that no matter how comprehensive pre-experimental part of the design is, screening design 
should be applied. 
Accelerated degradation, studying the temperature effects in the presence of moisture on the 
degradation rate constant of lansoprazole in pellets prepared using different pelletization 
techniques, has been applied. In order to obtain rapid degradation with science based 
screening approach, Arrhenius equation has been used as a screening and comparative 
technique to describe a breakdown of lansoprazole in a solid dosage form and it has proved to 
be helpful tool in obtaining information on the most important formulation parameters and the 
optimum formulation of lansoprazole pellets for stability.  
Solution suspension layering technique proved to be more controllable process and more 
advantageous in terms of pellets size, shape and stability, but more time consuming in 
comparison to the direct pelletization. Study has confirmed that the key mechanism in obtaining 
a stabile lansoprazole delivery system is not only suppression of proton attacks but also a 
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limitation of its solubility in the moisture layer, since it was found that in the pellets, lansoprazole 
degrades following apparent zero-order kinetics. With weak basic microenvironmental pH in the 
pellets it was possible to keep the degradation and solubility of lansoprazole on a low level. 
Sugar core stabilized lansoprazole in a way of incorporating the drug in the core forming a less 
porous active layer on the surface, disabling a contact of water and the active substance. 
Presence of the protective layer has been justified since it increased the stability of lansoprazole 
acting as a physical barrier between the drug and the free carboxyl groups of enteric coating 
polymer. Predicted shelf-lives of pellets on room temperature should be confirmed with the data 
obtained in a real time stability testing under the same conditions of relative humidity.     
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2. Theoretical section 
 
2.1. PAT and quality by design 
The goal of Process Analytical Technology (PAT) initiative, as Food and Drug Administrations 
(FDA’s) new concept of quality assurance in the 21st century, is to understand and control the 
manufacturing process and formulation. Nowadays it is generally acknowledged that “quality 
can not be tested into products; it should be built-in or should be by design” according to the 
ICH Guideline Q8 – Pharmaceutical Development, released on 10th November 2005. The main 
goal of PAT is to ensure product quality applying systems for designing, analyzing and 
controlling manufacturing through timely measurement (i.e. during processing) of critical quality 
and performance attributes of raw and in-process materials and processes. 
Formulations nowadays are usually developed under high-time pressure on the basis of “trial 
and error” experiments which often result in non-robust product (Leuenberger and Lanz, 2005). 
They are variable and complex systems influenced not only by formulation parameters, meaning 
the properties of active substance and excipients, but also in the large number of processes 
involved in manufacturing. 
The benefits claimed by the FDA for the industry introducing the PAT concept are better 
understanding of the process, an introduction of real time release, a reduction of cycle times, 
less batch failure, a better management of change controls and regulatory relief (Orelli, 2005). 
2.1.1. Experimental design techniques 
Experimental design techniques such as factorial design and optimization are useful tools in the 
characterization of pharmaceutical processes by studying the effects of variables affecting them 
and their possible interactions (Paterakis et al., 2002). 
Statistical experimental design provides an economical way to efficiently gain the most 
information while expanding the least amount of experimental effort (Stesko, 1986). Application 
of statistical design of experiments using modern software tools helps in understanding of how 
formulation and process factors impact product performance, and at the same time shortens the 
time and costs required for development of the new product. Specially designed expert systems 
enable us to gain the necessary process knowledge and this way high quality of pharmaceutical 
products can be achieved (Feiler and Solot, 2006).   
The choice of statistical design of experiments (DoE) leads in general to a linear (factorial) or 
quadratic (central composite design) regression model, which permits the prediction of system 
properties (response surface methodology) within a variable space (Leuenberger and Lanz, 
2005). 
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In the experiment we deliberately change one or more of process factors in order to observe the 
effect the changes have on the chosen responses. The final goal is to obtain data which can be 
analyzed to yield valid and objective conclusion in order to find the optimal settings of all factors 
and responses. 
The first step in designing the experiments is to decide on the response variables and the 
second one is to select the factors and determine their levels which might influence those 
response variables. 
Factors or process variables represent the physical property which can be changed in the 
experiment in order to influence the response. Levels of factors should be chosen carefully in 
order to avoid impracticable or impossible combinations (i.e., very thin tablets and very high 
compression force) and their difference should be neither too big nor too small. The term “level” 
stands for upper and lower value of the factor. Pre-experimental runs are suggested in order to 
determine the levels of factors in order to be in the effective range so that the process could be 
carried out.  
Factor can be either quantitative or qualitative. Quantitative factor is described by amount or the 
size of the factor (i.e., amount of excipient, compression force, spray rate, etc.), while qualitative 
factor represents presence or absence of excipient, different packaging, different auxiliary 
materials, etc. 
Response variables are the objectives of the study which can be influenced by changing the 
level of factors. Some of the examples are dissolution time, hardness of tablets, disintegration 
time, etc. 
Sometimes it is necessary to eliminate the influence of extraneous factors when running an 
experiment and this can be done by blocking. 
The combination of an appropriate design of experiments and an adequate statistical evaluation 
of their results leads to experiments with high significance. The designs are chosen, so that the 
minimum experiments give maximum of information. 
STAVEX (Statistische Versuchsplanung mit Expertensystem) is an expert system developed by 
Ciba-Geigy AG and AICOS Technologies AG for statistical experimental design and evaluation 
of a series of experiments (process controls, product optimization or validation, etc) (Aicos, 
1999). Stavex differentiates between three phases in experimental design: 
• Screening 
• Modeling 
• Optimization 
The type of study carried out will depend on the stage of the project. In particular, experimental 
design may be carried out in stages, and the experiments of a factor study may be augmented 
by further studies to a design giving the detailed information needed for true optimization 
(Lewis, 2006). It is suggested by the experts, to perform each stage of the design, whenever it 
   Theoretical section 
 
  6 
is applicable in respect to time and money. According to the response variables and the process 
factors chosen, STAVEX generates different possible factorial designs, among which the user 
may choose the most appropriate one.  
Screening 
Screening represents the first phase of sequential experimental design and it is used when the 
number of factors exceeds 8. The main purpose of this design is to find the most important 
factors so that the unimportant factors are eliminated using linear models, without finding the 
dependence of the response variables, or estimating interactions between the factors.  
Modeling 
Modeling is performed when the number of experiments is moderate (between 4 and 8) and an 
attempt is made to estimate the effect of relevant factors using linear models with interactions, 
so possible interactions and maybe also quadratic effects are considered.  
Optimization 
Optimization is employed when the number of factors is small (less than 4, possibly 4). It can be 
employed when the most important factors are already know or determined. Optimization phase 
tries to find the optimal settings (minimum and maximum) for the identified important factors and 
prediction power of the model should be validated by confirmatory experiments (Aicos, 1999). In 
optimization the experimental design analysis determines two optima, the “global” and the one 
lying in the “experimental area”, so called local optima. The following results are shown: 
• Factors with their optimum levels 
• Response variables with their optimum values 
• 90% confidence intervals for these optimum values 
The quality of model can be characterized by different parameters. The coefficient of correlation 
or so called goodness of fit R2 gives information about weather the model fits with the collected 
data. A high R2 stands for a well fitted model. However, R2 is very sensitive since each variable 
or the process run added to the model increases the value of R2 (Kablitz, 2007). For this reason, 
corrected goodness of fit, Rc2 is used to evaluate the model and it is adjusted for the degree of 
freedom and does not increase automatically with adding variables. Second parameter which is 
used for evaluation of the model is a normal plot of model deviations. With the use of Shapiro-
Wilk test it is possible to determine if there are significant deviations of model from normality or 
not. Below 5%, deviation from normality is significant (Aicos, 2000). The third parameter used 
for evaluation is analysis of variance of model deviations, with the F-test for the equality of 
means (are the mean values similar at different levels, with corresponding p-value) and Bartlett 
test for equality of variances (are the variances similar at the different values, with 
corresponding p-value). Furthermore, in the case of optimization phase, one of the ways to 
determine the prediction power of the model in the 90% confidence interval is to conduct the 
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confirmatory experiment. A p-value<0.1 indicates a significant effect of the factor on the 
analyzed response variable (Aicos, 1999). 
2.2. Proton-pump inhibitors (PPI’s) 
2.2.1. Properties of proton-pump inhibitors 
Lansoprazole belongs to a class of compounds called proton pump inhibitors (PPI) which 
inhibits gastric acid secretion regardless of the primary stimulus and is applied in the therapy of 
gastric and duodenal ulcerative disease, for the treatment of the heartburn and other symptoms 
associated with Gastroesophageal Reflux Disease (GERD), for the treatment of erosive 
esophagitis and long term treatment of pathological hypersecretory conditions, including 
Zollinger-Ellison syndrome. The key action mechanism of the PPI’s is inhibition of H+/K+-
adenosine triphosphate (also known as acid pump or proton pump), an enzyme present in the 
gastric parietal cells (Horn, 2000). These drugs are metabolized in the parietal cells to active 
sulfenamide metabolites that inactivate the sulfhydryl group of the proton pump, thus reducing 
the hydrogen ion secretion. Absorption of the most PPI’s takes place in the proximal small 
intestine (Horn and Howden, 2005). 
Group of proton pump inhibitors includes derivatives of benzimidazole, like omeprazole, 
lansoprazole, pantoprazole, rabeprazole, etc. 
 
 
 
Figure 2.1. Structural formula of omeprazole, lansoprazole and pantoprazole. 
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All PPI’s are extensively protein-bound, and all undergo hepatic metabolism. All of the currently 
available delayed-release proton pump inhibitors have a short elimination half-life (t1/2) of 
between 1 and 2 hours. Aside from bioavailability in the first few days of oral dosing, there are 
no substantive differences among currently available delayed release PPI’s with respect to 
pharmacokinetics (Table 2.1) (Horn and Howden, 2005). 
 
Table 2.1. Pharmacokinetics of delayed-release proton-pump inhibitors 
 Esomeprazole Lansoprazole Omeprazole Pantoprazole 
     
Absolute bioavailability (%) 64 – 90 >80 40 77 
Time to peak plasma level (h) 1.5 1.7 0.5 – 3.5 2 – 4 
Plasma half-life (h) 1.0 – 1.5 1.5 0.5 – 1.0 1.0 
Plasma protein binding (%) 97 97 95 98 
Hepatic metabolism Yes Yes Yes Yes 
 
Lansoprazole belongs to class II drugs of the BCS, characterized by low solubility and high 
permeability. It exists in two polymorphic forms designated as form A and form B. Form B is 
unstable and is completely converted to the stable form A under physical stress (milling) or even 
after some time at ambient temperature (Kotar et al., 1996).  
 
 
 
Figure 2.2. Chemical structure of lansoprazole, C16H14F3N3O2S, 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-
trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-
methyl]sulfinyl]benzimidazole 
 
Lansoprazole has been found to have absolute bioavailability lower than 80%, time to peak 
plasma level 1.7 hours, plasma half-life 1.5 hours and binding to plasma proteins in 97% (Horn 
and Howden, 2005).  
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Lansoprazole is applied as a racemic mixture and converted by acid environment of parietal 
cells into an achiral active sulfenamide, which reacts with the accessible cysteins of the gastric 
(H+, K+)-ATPase.  
The reduction of gastric acid secretion acts as a negative feedback mechanism, resulting in an 
increase in serum gastrin level. Furthermore, lansoprazole increases stomach pH to reduce 
stomach pepsin secretion and activity and also increases serum pepsinogen level. In addition 
lansoprazole has an inhibitory effect against Helicobacter pylori present in patients with 
stomach and duodenal ulcer. This contributes to increase in concentration and effects of 
antibiotics used in combination with lansoprazole such as amoxicillin, clarithromycin, by 
inhibition of gastric acid secretion, or maybe by a direct antibiotic effect of lansoprazole whose 
mechanism has not yet been established. 
Proton-pump inhibitors (PPIs) is a group of drug compounds that has an acidic pKa value at 8-9 
and basic pKa at 3-5 and it is known that lansoprazole as well as other derivatives of 
benzimidazole, is susceptible to degradation in neutral and acid media. Thus the drug degrades 
as soon as it comes in contact with the gastric contents or if exposed to humidity during storage. 
As an example, lansoprazoles half-life is 4 minutes in a methanol-phosphate (5/95, v/v) pH 3 
buffer (Oernskov et al., 2003). At 25°C the t½ is approximately 0.5 hours at pH 5.0 and 
approximately 18 hours at pH 7.0. Regarding the structure of lansoprazole, which is a derivative 
of 2-[[pyridyl]-methyl]sulphynyl]benzimidazole, it can possess three dissociation constants in the 
range of 1-14, two basic and one acidic, since the pKa of pyridine is 5.2, while the pKa values of 
benzimidazole is 5.5 as a base, and 12.3 as an acid (Kotar et al., 1996). Lansoprazole has a 
pKa value of 8.78 and 3.82 determined by capillary electrophoresis (Oernskov et al., 2003). 
Ekpe and Jacobsen 1999, have investigated the effect of various pH levels and salts on the 
stability of lansoprazole, omeprazole and pantoprazole and found out that lansoprazole is the 
least stable compound. As a pH value increased, the rate of degradation decreased. The 
stability of investigated PPI compounds in salt solutions were found to be in the following order: 
phosphate buffer < trisodium citrate ≤ citrate buffer ≤ acetate buffer < citric acid ≤ calcium 
carbonate etc., but none of the used salt solutions has improved the stability of any of the tested 
PPIs. Degradation kinetics of the compounds in salt solutions appeared to be second-order 
reaction. There is therefore a need for a pharmaceutical delivery system which protects the 
active substance both during storage as well as the passage through the stomach. As it has 
been reported by Ekpe and Jacobsen 1999, in the study the rate of degradation of omeprazole, 
lansoprazole and pantoprazole was least accelerated in calcium carbonate followed by sodium 
bicarbonate, but the buffers used in this study did not improve the stability of any of the drug 
substances under investigation. 
Another study conducted by DellaGreca et al., 2006, on degradation of lansoprazole and 
omeprazole in the aquatic environment, has revealed that lansoprazole was stable in pH 7 and 
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pH 9 for 72 hours in the dark. It was determined that 40% of lansoprazole degrades in water 
after 72 hours in the dark, and when irradiated with a solar simulator more than 80% of drug 
was degraded. According to DellaGreca et al., 2006, isolated degradation products from drugs 
in aqueous suspension are presented in the Figure 2.3. 
 
 
 
Figure 2.3. Isolated degradation products from lansoprazole and omeprazole in aqueous suspension 
DellaGreca et al., 2006 
 
Unfortunately, attempts to characterize the red-colored mixture failed, due to its complexity and 
changeable nature. Probably, this red material consists of a mixture of very liable degradation 
products, and it has been previously reported by Brandstrom et al. 1989 and DellaGreca et al., 
2006. 
2.2.2. Employed ways of stabilization of proton-pump inhibitors 
Formulation of stable delivery system for lansoprazole is extremely difficult. The numerous 
available patents all deal with methods and techniques for stabilizing LSP against the stomach 
environment. For the drug to be therapeutically active after oral administration, it must be 
protected from contact with the acidic gastric juice and be transferred intact to the neutral or 
alkaline part of the gastrointestinal tract, where rapid absorption can occur. Lansoprazole is also 
unstable under conditions of high temperature and also high humidity, with a decrease in the 
amount of lansoprazole and discoloration of the material being noted on storage under such 
conditions (Tetsuro et al., 1992). Since as pharmaceutical ingredient, lansoprazole must be 
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stored and transported, often for long time periods, the issue of the instability of the primary 
active material must also be addressed.  
There exist an extensive number of patents claiming the formulation of a stable dosage form of 
lansoprazole. There are several methods and techniques used to stabilize lansoprazole. A 
number of different approaches to stabilize substituted benzimidazoles have been suggested 
and they all claim to succeed. 
Subcoating has been proposed as a method to improve acid resistance for enteric coated 
dosage forms. Polymer subcoats seal the substrate from the aqueous enteric film coating, thus 
preventing the migration of water-soluble drugs into polymeric film, as well as preventing drug-
polymer interactions (Bruce and J.J., 2003). In the case of substituted benzimidazoles, 
subcoating or seal coating has been described in a numerous patent literature as a barrier 
between an enteric coating and acid liable drug to prevent degradation of the compound, since 
the polymers for enteric film coatings contain free carboxyl groups which can increase 
degradation of acid liable drug. Direct contact of lansoprazole and enteric coating polymer can 
lead to solid-solid interactions and degradation of lansoprazole, therefore the presence of 
subcoting can be justified. 
It has been demonstrated that the pH of the diffusion layer at the surface of a dosage form 
resembles that of a saturated solution of a drug and excipients in a dissolution media and 
represents the microenvironment pH of the system (Doherty and York, 1989). During 
dissolution, medium that may eventually penetrate the pellet core, or during storage moisture 
may penetrate into the core, resulting in a saturated solution of a drug and excipients. In the 
case of lansoprazole if the micro-environmental pH is too low, and moisture penetrates in the 
core, the drug will degrade and the initial amount of drug will decrease during storage. Too 
basic pH (lansoprazole degrades even at the high basic pH) will create saturated diffusion layer 
at the surface which can cause ionization of the carboxylic groups of the enteric polymer. 
Presence of subcoating can be essentially important in this case.  
In addition to subcoating, necessity of presence of pH adjusters in the core of pellets containing 
substituted benzimidazoles, was described in a number of patent applications. In the strictest 
sense, the term pH is not defined in a solid system. For it to have a meaning there must be 
some water mediation (Carstensen, 2000). With addition of pH adjusters it is possible to control 
the pH of the microenvironment. Incorporation of pH adjusters such as has been utilized to 
maintain the micro-environmental pH in a range that will increase drug solubility and improve 
stability during manufacture and storage. If it is desired to control the pH of the 
microenvironment than citric, tartaric and fumaric acids are the acids of choice. They are, 
however, all corrosive, and their pharmaceutical handling is far from ideal. In the case of alkali, 
sodium bicarbonate, sodium carbonate, and magnesium and calcium oxides are common 
(Carstensen, 2000). Alkaline materials, which are capable of providing pH ≥ 7 when present 
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alone in water and which are pharmaceutically approved include: organic basic salts (Na-
stearate); inorganic basic salts (heavy Mg-carbonate, Mg-oxide, precipitated Ca-carbonate and 
Ca-hydroxide) and others. In addition the core is coated with an enteric coat. This will protect 
the drug from contact with the gastric juice during the passage through the stomach into the 
neutral or alkaline part of the GI tract where rapid absorption can occur. The variation in assay 
and color of solid lansoprazole over time on storage at various temperatures and humidity’s was 
studied in detail by Tetsuro et al., 1992. The study shows that after 4 months at 40° C and 75% 
room humidity lansoprazole turns pale brown, and even in the absence of humidity under the 
same conditions, lansoprazole turns pale yellowish brown. The unusually high instability of 
lansoprazole even under weak acidic conditions is due to proton attack on the sulfoxide group. 
Lansoprazole seems to be especially sensitive to such attack compared to the other members 
of the 2- (2-pyridylmethyl) sulfinyl- benzimidazole family of drugs. Lansoprazole is unstable also 
under strongly basic conditions, but its degradation is minimized under weakly basic conditions. 
Therefore the degradation of lansoprazole in dosage forms can be minimized when formulated 
with stabilizing compounds suitable to produce such a weakly basic pH (Tetsuro et al., 1992). 
Also it has been reported that too alkaline core can cause ionization of the enteric polymer and 
result in an increase of film permeability and film failure. 
2.3. Solid-state chemical decomposition 
Solid-state chemical decomposition of drugs has been the subject of many papers and the 
problem is further more complicated when the drug is formulated in a complex matrix such as a 
tablet or capsule (Table 2.2). Drug degradation occurs by four main processes: hydrolysis, 
oxidation, photolysis and trace metal catalysis. Hydrolysis and oxidation are the most common 
pathways, and in general light and metal ions catalyse a subsequent process.  
 
Table 2.2. Factors affecting formulation stability 
Drug & Excipient Formulation Environment 
Chemical structure Drug:excipient ratio Temperature 
Impurity profile Processing method Relative humidity 
Physical form Mixing/milling Packing 
Moisture content Powder packing Light 
Particle size  Oxygen 
Surface area   
Morphology   
 
Numerous studies have confirmed the importance of temperature and humidity as two of the 
most important variables that significantly affect the chemical stability of drugs in the solid state. 
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It is well known that products degrade faster when they are subjected to stress conditions, such 
as temperature, pH, humidity, etc. The most common acceleration factor is temperature and it’s 
relationship is well characterized by the Arrhenius equation (Magari et al., 2004). 
The length of time the product is stable at the recommended storage condition is referred to as 
the shelf-life. The source of the solvent for the solid-state decomposition reactions may be 
(Connors et al., 1986b): 
• A melt from the drug itself or an ingredient in the formulation that has a low melting point 
• Residual moisture of solvent from the production process 
• Moisture adsorbed onto excipients  
• Adsorbed atmospheric moisture 
• A solvate or hydrate that loses its bound solvent with time or temperature fluctuations 
Solid state degradation curves have a sigmoid shape with a lag phase followed by an 
acceleration phase. The acceleration phase can be apparent zero order, apparent first order, or 
higher orders with respect to drug, depending on the conditions of the experiment, such as 
humidity and temperature, and the mechanism of the degradation process.  
Since only a fraction of the solid drug is in solution in the tablet or other solid dosage form, the 
overall loss of drug often follows apparent-zero-order kinetics. The word “apparent” is used here 
because more factors affect the magnitude of this activation energy than simply the effect of the 
temperature on the rate-controlling chemical reaction.  
An apparent zero-order degradation curve, quite often seen for the decomposition of 
pharmaceutical products, can be rationalized as follows. The drug, drug-excipient blend, or 
tablet, adsorbs a thin layer of water on the surface of the solid product. The drug dissolves to 
the extend of its solubility in this water and only the dissolved drug decomposes. Temperature 
affects the solubility of the drug in a solvent layer, it increases the intrinsic rate of reaction, and it 
may alter the availability of solvent in which reaction occurs (Connors et al., 1986b).  
When moisture is present in excess, decomposition is often accounted for by solution kinetics of 
a saturated solution, in which case, barring complications, the decomposition is zero order. If 
the decomposition is diffusion controlled, than it still appears zero order, but the solubility term is 
replaced by a smaller, constant concentration (Carstensen, 1974). Studies conducted on aspirin 
tablets in a microcrystalline cellulose base showed that aspirin degrades by a first-order reaction 
but other published data imply that the trend reverts to a zero-order pattern with higher moisture 
contents (Lee et al., 1965). It has already been mentioned that the excipient can have a positive 
or negative effect on stability of drug. Excipients that on partial dissolution in an adsorbed 
moisture layer may change the local pH to a level where it can be deleterious to drug stability 
will consequently accelerate the degradation of the drug. On the other hand, an excipient may 
stabilize the drug if it maintains a favorable local pH for optimal stability. Quite often 
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measurement of the pH of slurry of a possible tablet formulation can indicate whether stability 
could be a problem.  
2.3.1. Arrhenius testing as a comparative technique in prediction of 
stability of solid dosage forms  
In order to obtain rapid stability results for a product, it became a practice to store the product at 
elevated temperatures in order to force a degradation of active material in a short period of time. 
The loss of activity in a unit of time is defined as the degradation rate. This rate depends on the 
required activation energy for the chemical reaction, and is product specific (Magari et al., 
2004). 
The FDA guidelines state that the relationship can be adequately described by a linear, 
quadratic or cubic function on arithmetic or a logarithmic scale. Linear arithmetic is zero order 
and linear logarithmic is first order (FDA’s guideline on submitting documentation for the stability 
of human drugs and biologicals). 
Accelerated stability testing may be defined as the methods by which product stability may be 
predicted by storage of the product under conditions that accelerate change in a defined and 
predictable manner (Young, 1990).  
In order to have an idea about the decomposition kinetic at determined temperature, the 
Arrhenius plotting is carried out. Natural logarithm of the absolute value of the decomposition 
constant k being plotted against reciprocal of the absolute temperatures T, see Equation 2.1 
and Figure 2.4. Apparent activation energy Ea can be calculated by the slope of Equation 2.1.  
 
RT
Ea
Ak
−= exp  Equation 2.1 
 
In the Equation 2.1, R is the gas constant (1.99 cal/degree-mole or 8.314 J/mol K) and A 
represents frequency or steric factor which expresses the probability that the molecules contain 
a favorable orientation and will be able to proceed in a collision, T is the absolute temperature 
(t°C + 273.16°C). Ea is called activation energy of the chemical reaction. Activation energy is a 
measure of a barrier which prevents the reactants from immediately becoming products. Usual 
range of activation energies is about 12 to 24 kcal/mol for many reactions (50 – 96 kJ/mol). 
It has to be kept in mind that this Ea does not have the same meaning as the activation energy 
for reactions in slutions Florence and Attwood, 2006. The Ea value in the solid state is affected 
not only by changes in the solubility of the drug in the moisture layer but also by the intrinsic 
rate of reaction. Linear regression can be extrapolated to the room temperature and thus shelf 
life of the product can be predicted.  
Assumption must be made that the mechanism operative at the experimental temperatures is 
the same as at the extrapolated temperature (often room temperature). 
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In order for the reaction to proceed and overcome the activation energy, the temperature, 
orientation, and energy of the molecules must be substantial; this equation manages to sum up 
all of these things. This equation fits experimental data well over wide temperature range and 
it’s a good approximation to the true temperature dependency of a reaction. It implies that a plot 
of the logarithm of the rate constant against the inverse of the absolute temperature is a straight 
line (Young, 1990). The easiest way to check the validity of Arrhenius law for the product is to 
plot the results within the available range. The most common causes for the invalidity of 
Arrhenius law are either that the degradation mechanism changes above a critical temperature 
or that there are two or more simultaneous decay mechanism with the different rate constants 
and heats of activation (Young, 1990).  
 
 
 
Figure 2.4. An example of Arrhenius plot  
 
However, under certain conditions, Arrhenius equation is not applicable, particularly when 
higher-order reactions are involved and exponential relationship is not appropriate basis for 
approximation of degradation pattern of these reactions. 
In the cases when storage temperature is very different from the range of temperatures used in 
the experiment, the prediction of shelf-life may be incorrect or the relationship between the 
temperature and the log of degradation rate is not linear (Magari et al., 2004).  
Even though accelerated stability testing based on the use of Arrhenius equation shortens 
development time, it still involves time-consuming step of initial determination of the order of 
decomposition reaction. For a relatively small amount of degradation (around 10%) it is not 
possible to distinguish between zero, first order and simple second order kinetics using curve 
fitting techniques; consequently, the assumption of the first-order kinetics for any decomposition 
reaction should involve minimum error (Florence and Attwood, 2006). In most instances it is not 
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necessary to determine whether the component degrades according to a zero or a first order 
reaction, because over the area of interest both models can be approximated by a straight line 
(Bourdreau, 1984). 
One purpose of a stability program should be to define stability of solid dosage form as a 
function of moisture content. The need for consideration of the effect of moisture on stability has 
been stressed by Carstensen, 1974, who stated that stability programs should always include 
samples that have been artificially stressed by addition of moisture, even though this may 
produce many experimental problems (Florence and Attwood, 2006).    
In this study isothermal accelerated stability testing of a product as a function of moisture 
content has been employed in order to obtain degradation of the drug in the solid dosage form 
in a short period of time. The aim of the study was to apply Arrhenius equation for obtaining 
information on the most stable formulation as a comparative technique and to predict the 
stability in solid dosage form.  
2.3.2. Order models 
A number of empirical models have been used to represent pharmaceutical product decay with 
time. The usual model is based on reaction order where the rate of disappearance of the 
product is proportional to its concentration raised to an order (Young, 1990). 
The order of a chemical reaction determines the shape of the concentration-time profile of a 
drug or drug product, whereas the rate constant determines its slope (Connors et al., 1986a). 
Overall order is defined as the sum of the exponents of the concentration terms in the rate 
equation. 
 
EBA →+  
Equation 2.2 
 
[ ]mnmn BAkdtdC ⎥⎦⎤⎢⎣⎡+−=− )(  Equation 2.3 
 
The most important orders of interest in the pharmaceutical sciences are integral orders, those 
in which the sum of n and m is 0, 1, or 2, with the order being equal to the number of the 
molecules involved in the rate-determining step of the reaction. Since a true reaction of this type 
can only occur in solution, solid dosage decay is usually described as pseudo-order of apparent 
order (Young, 1990). 
Knowledge of the order of a reaction is of a great importance in stability determination of drug 
substances, in particular in solution. The problem is frequently to judge whether the 
concentration-time profiles are linear (zero order) or curved (first or other order). The nature of 
any degradation relationship will determine the need for transformation of the data for any linear 
regression analysis. Usually relationship can be represented by a linear, quadratic or cubic 
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function on an arithmetic or logarithmic scale. Statistical methods should be employed to test 
the goodness of fit of the data on all batches to assume degradation line or curve. 
A zero-order reaction has a rate which is independent of the concentration of the reactant. 
Increasing the concentration of the reacting species will not speed up the rate of the reaction. 
kr =       
r = reaction rate 
k = reaction rate coefficient with units concentration/time 
 
If this differential equation is integrated it gives an equation which is often called the integrated 
zero-order rate law: 
 
[ ]C  = concentration of the chemical of interest at a particular time 
[ ]0C = initial concentration   
  
Integrated rate equation links concentrations of reactants or products with time. Reaction is zero 
order if concentration data are plotted versus time and the result is a straight line. The slope of 
the resulting line is the zero order rate constant k. 
For a zero-order reaction the half-life t50 is given by Equation 2.7. 
 
0
0
50 2k
C
t
⎥⎦
⎤⎢⎣
⎡
=
 
Equation 2.7 
 
 
The shelf life, t90, of a drug is usually taken to be the time for [ ]C  to reach 0.90 [ ]0C , that is, 
10% decomposition: 
 
[ ]
0
0
90
1.0
k
Ct ⋅=  Equation 2.8 
 
A first-order reaction depends on the concentration of only one reactant, other reactant can be 
present, but each will be zero-order. The rate law for first-order reaction is: 
 
     →C products 
dt
Cd
r ⎥⎦
⎤⎢⎣
⎡
−=
 
Equation 2.4 
 
0kdt
Cd =− ⎥⎦
⎤⎢⎣
⎡  Equation 2.5 
 
 
Equation 2.6 
 
[ ] [ ]00 CtkC +−=
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[ ]Ckr =  Equation 2.9 
 
k = first order rate constant with units of 1/time 
 
⎥⎦
⎤⎢⎣
⎡⎥⎦
⎤⎢⎣
⎡
=− Ckdt
Cd
1
 
Equation 2.10 
 
which integrates to:  
 
[ ] tkC
C
1
0
ln −=⎥⎦
⎤⎢⎣
⎡  
Equation 2.11 
 
[ ] [ ] tkCC 10lnln −= Equation 2.12
[ ] [ ] tkeCC 10 −= Equation 2.13
A plot of [ ]Cln versus time t gives a straight line with slope equal to the reaction rate constant. 
The half-life is the time for [ ]C  to become[ ] 2/Co , that is one half of the original concentration. 
The half life of a first-order reaction, substituting[ ] [ ] 2/0CC = , can be determined using 
Equation 2.14:  
 
ak
t 2ln2/1 =
 
Equation 2.14 
The shelf life, t90, of a drug is usually taken to be the time for [ ]C  to reach 0.90[ ]0C , that is, 
10% decomposition: 
 
1
90
105.0
kt =
 
Equation 2.15 
Accelerated aging by temperature, followed by shelf life prediction (Arrhenius equation) should 
be used with precaution when working with solid dosage forms. Because of the high degree of 
variability is usually associated with stability data, it is best if the order of degradation is 
determined a priori based on the known behavior of the product. If the order must be 
determined from the stability data alone the traditional approach would be to display graphically 
the determined amount of the drug decomposed after various time intervals according to the 
linear equations for the various orders of reactions until a straight line plot is obtained 
comparing the coefficient of determination, R2. Since this method suffers form a number of 
deficiencies, particularly if the experimental data are noisy, quantitative measure of the 
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uncertainty of the parameters can be assessed using least squares linear regression. In the 
study data were plotted according to various orders and tested using linear regression for zero 
and first order kinetics.  
2.4. Pellets as solid dosage form 
Solid dosage formulation and design usually involves a serious of compromises, since 
producing the desired properties frequently involves competing objectives. The correct selection 
and balance of excipient materials and processes in a solid dosage formulation, to achieve the 
desired response is not in practice easy to achieve (Peck et al., 1989). Furthermore it is 
essential to develop tablet formulations and processing methods which may be validated. 
Pellets are of a great interest to the pharmaceutical industry for a variety of reasons. Pelletized 
products not only offer flexibility in dosage form design and development, but are also utilized to 
improve the safety and efficiency of bioactive agents. 
Pellets range in size, between 0.5 to 1.5 mm, though other sizes could be prepared, depending 
on the processing technique. Pharmaceutical pellets are agglomerates of fine powder particles, 
nearly spherical or cylindrical in shape with a narrow particle size distribution (Kleinebudde and 
Knop, 2007).  
The technological advantages of spherical particles include the following: 
1. Good flowability due to uniform size and spherical shape. This enables uniform and 
accurate filling of the capsules. 
2. High physical integrity, meaning flow with minimal friction and dust generation 
3. Superior properties for coating due to spherical shape, low area to surface volume, 
smooth surface and ability to withstand mechanical stress. 
When pellets containing the active ingredient are administered in vivo in the form of suspension, 
capsules, or disintegrating tablets, they offer significant therapeutic advantages over a single 
unit dosage forms (Ghebre-Sellassie, 1989a). Because pellets disperse freely in the 
gastrointestinal tract, they invariably maximize drug absorption, reduce peak plasma 
fluctuations, and minimize potential side effects without appreciably lowering drug 
bioavailability. Pellets also reduce variations in gastric emptying rates and overall transit times. 
Thus, intra and inter-subject variability of plasma profiles, which are common with single unit 
regimens, are minimized. 
When formulated as modified-release dosage forms, pellets are less susceptible to dose 
dumping than the reservoir-type, single unit formulations. 
Pellets also allow the combined delivery of two or more bioactive agents that may or may not be 
chemically compatible, at the same site or at different sites within the gastrointestinal tract.    
In addition pellets have a low surface area-to-volume ratio and provide an ideal shape for the 
application of film coatings. The specific surface area of pellets having a defined particle size is 
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smaller due to the spherical shape and smooth surface. This allows the use of less film forming 
polymer to achieve a required film thickness and reduces coating process (Kleinebudde and 
Knop, 2007).  
Pellets are frequently used in gastric resistant or modified release forms. Recently, coated 
pellets are compressed to rapidly disintegrating tablets. For those purposes small pellets with 
the mean diameters below 0.5 mm are most suitable. Such pellets can be produces by the 
direct pelletization methods. 
2.4.1. Pelletizing techniques 
Pelletization is an agglomeration process that converts fine powders or granules of bulk drugs 
and excipients into small, free-flowing, spherical or semi-spherical units, referred to as pellets 
(Ghebre-Sellassie, 1989a). The type of coating technique strongly affects the film microstructure 
and, thus, the release mechanism and rate from pellets coated with polymer blends (Lecomte et 
al., 2004). There are several manufacturing techniques for production of spherical pellets. 
Broadly, they can be grouped in different ways according to production technique used, type of 
equipment or the intensity of mechanical forces involved. One of the more reacent methods for 
production of spherical pellets is rotary processing also called centrifugal granulation. In this 
type of equipment wet spheronisation, drying and coating can be performed in one closed 
system (single-pot). The most widely used pelletization processes in the pharmaceutical 
industry are extrusion/spheronization, solution/suspension layering, powder layering and direct 
pelletization. Pelletization processes are usually lengthy and expensive. Processing of a single 
batch may sometimes require hours or even days to be completed. Other pelletization 
processes that either have limited application or are still at the development stage include 
spherical agglomeration or balling, spray congealing/drying, and emerging technologies such as 
cryopelletization and melt spheronization. 
The layering technique is the process in which drug in powder, solution or suspension form is 
layered onto seed materials (generally, a coarse material or nonpareil). This process leads to 
heterogeneous pellets, which consist of an inner core region and an outer shell region of a 
different composition (Kleinebudde and Knop, 2007). 
2.4.1.1. Extrusion - spheronization 
Extrusion-spheronization is a multistep process  involving dry mixing of the active compound 
with excipients, granulation of wetted mass, extrusion of the mass, transfer of the mass to 
spheronizer to produce spherical shape, drying of the wetted mass in a dryer, and at the end 
screening to obtain required particle size.  
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2.4.1.2. Solution/suspension layering 
Solution/suspension layering involves the deposition of successive layers of solution and/or 
suspension of drug substance and binders on starter seeds, which may be inert materials or 
crystals/granules of the same drug. Consequently, conventional coating pans, fluidized bed 
centrifugal granulators, and Wurster coaters have been used successfully to manufacture 
pellets. The efficiency of the process and the quality of pellets produced are in part related to 
the type of the equipment used (Ghebre-Sellassie and Knoch, 2002).  
As a starter seeds usually sugar spheres consisting of a sugar-starch mixture are used or 
recently microcrystalline cellulose pellets and the pure drug crystals.  
The most common configuration for bottom spray coating is known as the Wurster system. In 
this study solution/suspension layering of neutral pellets has been conducted applying novel 
fluidized bed technology from Hüettlin (see Figure 2.5). 
This technology claims to improve the product movement in defined direction in all the 
equipment by the Diskjet gas distribution plate. Furthermore, a 3-component spray nozzle is 
used in order to improve the film formation on the pellets due to constant and reproducible drop 
size distribution. Accessibility of clogged nozzles without stopping and interrupting the process 
makes the equipment advantageous in respect to Wurster system. Hüettlin’s three component 
nozzle is an air nozzle with an additional channel through which a second gas or component 
can be introduced to create a special microclimate around the nozzle which prevents excessive 
spray drying or clogging of the nozzle. Such microclimates near nozzle apertures are very 
useful when a film former with a relatively high minimum film-forming temperature (MFT) is 
used. The MFT of aqueous shellac suspensions, for example, lies between 35 and 55°C, 
depending on the plasticizer selected (Bauer et al., 1998).  
 
  
 
 
Figure 2.5. Bottom spraying fluidized bed from Hüettlin  
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Only a limited number of papers are available on the aqueous-based solution/suspension 
layering process in Hüettlin fluidized bed equipment. The most obvious difference between 
bottom spraying fluidized bed from other producers and the equipment used in this study is the 
presence/absence of Wurster insert. 
The technology is applied to produce enteric coated lansoprazole pellets suggesting to improve 
lansoprazole stability in acidic media, due to the enhancement of the polymer film formation on 
the surface of the pellet. On the other hand enteric coating assures immediate release in alkalic 
media at the site of the action. 
 
 
 
Figure 2.6. Principle of the solution and suspension layering process  
 
2.4.1.3. Powder layering 
Powder layering involves the deposition of successive layers of dry powder of drug or excipients 
or both, on preformed nuclei or cores with the help of a binding liquid (Ghebre-Sellassie and 
Knoch, 2002). Equipment which revolutionized powder-layering process as a pelletization 
technique is tangential spray of centrifugal fluidized bed granulator/rotary fluidized bed 
granulator. 
 
 
Figure 2.7. Principle of the powder layering process www.glatt.com,  
   Theoretical section 
 
  23 
Powder layering process can be chosen instead of the solution/suspension layering process in 
cases when the solution or suspension is too thick, or has a low potency , but the high pellets 
potency is required, when the process is too long, when the drug is not stable in the solution or 
comparatively low pellets density is desired (for rapid disintegration) (Jones, 2005a). 
Owing to the simple process and equipment requirements layering processes are widely used 
for pelletization. Some of the disadvantages are: 
• low amount of drug loading – not suitable for high-dose drugs 
• final composition of pellets can vary if spray loss occurs 
2.4.1.4. Direct pelletization 
Direct pelletization process leads to formation of homogeneous pellets which have 
microscopically uniform structure and no core can be detected. The pelletization of powdered 
starting materials is facilitated by the addition of binder liquid and a suitable movement of wetted 
powders. The impact and acceleration forces that occur in this process result in the formation of 
agglomerates, which become rounded out into uniform and dense pellets. The speed of rotation 
has a direct influence on the density and size of the pellets. The solidification of the pellets is 
achieved by drying the liquid. Direct pelletization processes are mainly performed in high shear 
mixers and fluidized bed equipment (Kleinebudde and Knop, 2007).  
 
 
 
Figure 2.8. Principle of the direct pelletization process www.glatt.com,  
 
Pelletization by wet granulation in fluidized bed rotary processor is a multivariable process in 
which several factors affect the final characteristics of produced pellets. The knowledge of these 
variables and their influence on the final pellet properties is essential in achieving a controlled 
process and desired pellet properties. Application of experimental design techniques, such as 
factorial design and optimization, present a useful tool for identification and correlation of 
significant factors that affect the process  in order to develop a robust process (Korakianiti et al., 
2000). 
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Properties of pellets obtained using direct pelletization in rotary tangential processor have been 
found to depend on process parameters like spray rate, rotor speed, type of rotor plate used 
(smooth and rough), gap space between the rotor disc and the unit wall, amount of liquid added, 
atomization pressure, inlet air temperature, etc.  
Material consideration and variables 
Pelletization material 
Suitable formulation for spheronization should possess certain plasticity. Necessary plasticity 
can be achieved with addition of water or binder solution to suitable powder mixture. Because of 
its unique properties microcrystalline cellulose (MCC) represents a key excipient in the 
production of pellets by direct pelletization in rotary processor and extrusion/spheronization 
process.  
Rotary processing was found to be effected by formulation variables such as type of MCC and 
content, type of filler and particle size of constituens (Kristensen et al., 2000). MCC is most 
widely used excipient in rotary processing due to its unique pelletization properties. One of the 
crucial factors for formation of pellets in rotary processor is the amount of MCC in a formulation. 
Generally, an amount of 15% to 30% (w/w) MCC has been reported necessary to produce 
spherical agglomerates with suitable properties (Kristensen and Schaefer, 2000). MCC not only 
gives the plasticity to wetted mass, but also emit binding properties that are essential to obtain 
pellet strength and integrity. More MCC results in larger agglomerates, wider size distribution, 
less friable and more spherical agglomerates (Kristensen and Schaefer, 2000). The actual 
amount needed to obtain pellets depends on the formulation used; type of other excipients as 
well as on the type of rotary processor. It has been found that MCC content is more critical 
when water soluble excipients, like lactose are used compared to the insoluble calcium 
hydrogen phosphate (Kristensen and Schaefer, 2000). However, a controllable spheronization 
process with consistent and acceptable characteristics required the content of MCC to be at 
least 20% (w/w) of the starting materials. A decrease in amount of MCC resulted in higher 
deposition and adhesion of moistened material, the formation of larger agglomerates to stick to 
the wall and the rotating plate of product container. 
One disadvantage of MCC is that pellets containing MCC tend to swell in contact with liquid and 
do not disintegrate. As a conequence, especially drug substances having a low aqueous 
solubility, are released slowly from pellets containing MCC. In a rotary processor, the addition of 
of croscarmelose sodium as a disintegrant has been found to result in a faster release 
(Kristensen et al., 2002). It has been reported that MCC is not suitable for immediate release 
dosage forms of drugs with low aqueous solubility, wihout any additional excipient or 
disintegrant, but for sustained release form (Pisek et al., 2005).  
Lactose was shown to be more suitable as a substituent for a portion of MCC than other fillers, 
like mannitol or calcium carbonate. Lactose 200 mesh was most commonly used in related 
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studies. The aqueous solubility of lactose enhanced the binding properties of the moistening 
liquid and plasticized moistened mass, thereby increasing the potential for granule growth with 
small moisture increment. 
Balocel Sanaq 
Balocel Sanaq is a unique excipient prepared by a special manufacturing process manly used 
for production of pellets and granulates. It is a powder premix which consists of 50% (w/w) 
microcrystalline cellulose, 35 % (w/w) lactose and 15 % (w/w) sodium carboxymethylcellulose.  
Amount of granulation liquid 
The other crucial formulation factor for direct pelletization is the amount of water or granulation 
liquid added. A linear relation between the amount of water (based on dry mass) and the 
fraction of MCC has been found (Figure 2.9) (Kristensen and Schaefer, 2000).   
The moisture content of the mass at the end of the liquid addition is critical for the formation of 
pellets. The moisture content is influenced by the temperature, humidity, and flow rate of the 
fluidizing and atomizing air, and by the liquid addition rate. To control the process, the moisture 
content of the mass at the end of the liquid addition has to be exactly controlled using infrared 
moisture sensor or the alternative approach to the end point control might be to use indirect 
methods such as measuring the power consumption of the friction plate motor or torque on the 
shaft of the friction plate (Kristensen et al., 2000). 
Disadvantages of MCC 
Pellets based on MCC as a pelletization aid possess properties which are in some cases 
disadvantageous. Pellets containing MCC tend to swell but do not disintegrate during the 
application and as a consequence they release the drug according to a matrix release profile 
(Vecchio et al., 1994). Because of this reason, it has been hard to formulate MCC based pellets 
suitable for immediate release containing drug with low solubility, since the dissolution rate is 
too low. In this case MCC matrix pellets represent sustained release carrier system, where drug 
solubility plays a dominant role in dissolution behavior (Pisek et al., 2005). The retarding effect 
can further more be intensified by the size of the pellets. Smaller pellet fractions containing less 
MCC have better release profile than the pellets of bigger pellets fractions. 
Combination of MCC with water soluble excipients and addition of disintegrants can be useful in 
order to achieve an immediate release profile. 
Fraction of drug 
Maximum fraction of the drug which can be incorporated in the pellets and the influence of the 
drug fraction on the process and product properties depend on the physico-chemical properties 
of the drug. With increase in the fraction of the drug, less pelletization aid is available, which can 
lead to process failure in production of pellets with wanted properties.  
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Particle size of drugs 
Drugs with small particle size tend to adhere to the wall of product container and prevent rope-
like movement of the wet mass required for the spheronization. Furthermore, this effect is more 
pronounced when a higher fraction of drug tends to be incorporated in the pellets.  
Process variables 
Spray rate 
It has been determined that the lower spray rate applied in the process leads to the longer 
processing time resulting in a lower porosity of the pellets (Holm et al., 1996). Higher spray 
rates results in higher water content, shorter processing time and larger pellets, since there is 
shorter time for liquid to evaporate. A higher spray rate is also found to lead to a broader size 
distribution (Paterakis et al., 2002).  
Rotor speed 
The rotor speed in direct pelletization process affects mixing, liquid distribution, pellets growth 
and the shape of pellets. In some studies an increase in rotor speed led to larger pellets, with 
higher bulk density and improved roundness (Rashid et al., 1999) while in other studies it has 
been noted that increase in rotor speed led to production of smaller pellets (Korakianti, 2002). It 
has been suggested to use different rotor speeds during different stages of pellet production 
(Liew et al., 2000). Low – high – low pattern is proposed, suggesting the use of a low rotor 
speed during mixing and early wet-massing phase, until the mass is slightly wetted, which 
makes it more cohesive and less susceptible to be blown out of chamber, higher speed during 
the spheronization phase, and lowering the speed during drying phase. This pattern was also 
recommended by other authors since it leads to a more controllable agglomeration process 
(Kleinebudde and Knop, 2007). The effect of the rotation speed, however, depends on the 
actual formulations (Vertommen, 1996).  
Moisture content 
The moisture content at the end of the liquid addition stage is critical for the process. There is 
sensitive relation between moisture content and particle size, and moisture sensitivity depends 
strongly on the formulation, especially the fraction of pelletization aid. For formulation 
pelletization, process parameters have to be adjusted according to the physico-chemical 
properties of the drugs and excipients in the formulation and the desired characteristics of 
pellets, e.g. size. Correlation between the MCC content in the formulation and the water content 
at the end of liquid addition phase is presented in the Figure 2.9.   
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Figure 2.9. Correlation between the MCC content and the water content at the end of the liquid addition 
(Kristensen and Schaefer, 2000) 
 
2.4.2. Pelletization equipment 
Different manufacturing techniques are used for the production of spherical pellets. They can be 
broadly grouped according to the type of equipment used, the intensity of the forces which are 
involved in the production or by technique used. The production of spheroid pellets process 
does not differ a lot from the wet granulation process, in which moistening liquid is required. 
This also means that the equipment involved in the wet granulation can be used for production 
of pellets like fluidized bed granulator and high-shear mixer. Different types of spherical pellets 
require different type of equipment. Production of homogenous pellets is usually carried out in 
extruder spheronizator, high-shear mixer and rotary fluidized bed, while the production of 
heterogeneous pellets is carried out in top spraying or different types of bottom spraying 
fluidized bed equipment.  
Fluidized bed equipment 
The introduction of an expansion space between the product container and the filter chamber, 
and the inclusion of a liquid-spray nozzle in that space, gave rise to fluid bed agglomeration and 
in more resent years, unique processes for the coating of granulates, pellets and powders have 
expanded the use of granulation manufacturing equipment (Olsen, 1989). 
In general, the main processing option can be characterized by spray nozzle position and 
orientation and by design principle of fluidization gas distribution into the processing chamber. 
Different processing options were created in order to manufacture different products in fluid bed 
equipment (Table 2.3) (Jacob, 2007).  
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There are three basic configurations in fluidized bed processing: 
 
• top-spray processing (Figure 2.10, B) 
• bottom-spray processing and Wurster processing (Figure 2.10, A; Figure 2.11) 
• rotor processing (tangential spray) (Figure 2.10, C) 
 
 
 
 
Figure 2.10. Schematic of a fluidized bed apparatus: (A) bottom spray with Wurster column insert; (B) top 
spray technique; (C) tangential spray technique (Felton, 2007) 
 
The last two configurations are used for pelletizing and coating in laboratory, pilot and 
commercial scale equipment. The type of process used may significantly influence finished 
dosage form properties. 
 
Table 2.3. Application of different types of fluidized-bed equipment 
APPLICATION TOP SPRAY BOTTOM/WURSTER ROTOR 
Drying +++   
Spray granulation/drying +++ + ++ 
Pelletizing  
Solution/suspension layering + +++ +++ 
Dry powder layering   +++ 
Direct pelletization   ++ 
Coating (fine particles/pellets)    
Organic solvent +* +++ ++ 
Water based ++* +++ +++ 
Hot melt +++* + + 
*substrate size and density are critical 
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Conventional fluidized bed granulator 
First powder, later granules or pellets are fluidized in the cylindrical product container by an air 
stream. The inlet air passes a screen or a perforated plate, fluidizes the particles and leaves the 
product container through a filter. This exhaust air filter prevents product losses and air 
pollution. The fluidizing air can be heated to the desired temperature to dry or melt the fluidized 
product. The molten binder or binder solution is sprayed onto the fluidized particles through a 
nozzle which has to be heated in case of molten binder. The spray nozzle is usually an air-
atomizing nozzle which uses pressurized air to produce droplets from a liquid. The droplet size 
can easily be controlled by the atomizing air pressure. The position of the nozzle is above the 
fluidized product in most cases (Figure 2.10, B) (Kleinebudde and Knop, 2007).  
 
 
 
Figure 2.11. Schematic representation of the Wurster product chamber and process: (A) product 
chamber; (B) partition, (C) orifice plate; (D) nozzle and (E) expansion chamber (Felton, 2007) 
 
Rotary fluidized bed processor 
Since conventional fluidized bed granulator was not the method of choice for production of 
pellets, there was a need to modify the equipment in order to achieve highly spherical and high 
density pellets. Single-pot spheronizer system in which the whole cycle of liquid addition, 
agglomeration, spheronization, drying and coating can be performed is a rotary fluidized bed 
processor (Gu et al., 2004). 
A rotary fluidized bed processor has a rotating friction plate instead of a screen at the bottom of 
the product container (see Figure 2.12). The inlet air passed through an air gap between the 
rotating plate and the wall of the product container. The movement of the particles in the 
equipment is helical and is the result of three forces:  
• the centrifugal force from the rotating plate which tends to push the material towards the 
wall of the processing chamber  
• the fluidizing force from the air stream through the gap  
• the force of gravity allowing the product to fall towards the centre of the rotor plate. 
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Figure 2.12. Schematic representation of centrifugal fluid-bed equipment, Glatt GPCG  
 
 
This movement is described in different literature in different terms like of rope-like tumbling, 
twisted rope, spiral, spiral helix and others. The achievement of ideal product movement is of a 
high importance. In the beginning of the process this type of the movement is difficult to achieve 
because of the dry or moderate wet powder, but at the end of the process, in the spheronization 
phase, the movement is of a critical importance (Kleinebudde and Knop, 2007). If the movement 
does not occur in the spheronization phase, no spherical pellets will be obtained.  
The nozzle or the nozzles in the rotary processor are often positioned tangentially in the wall of 
the container in the height of the fluidized product (Kleinebudde and Knop, 2007). 
 
2.5. Mathematical description of fluidized bed 
In typical fluidized-bed processor, the fluidizing gas enters the bed through an air distributor 
plate at the bottom of processor. The gas passes up through the bed of solids, setting them to 
the motion and causing it to fluidize. This gas/solid mixture behaves much like the liquid of a 
similar bulk density. In the upper part of fluidized bed, an expansion chamber slows down the 
particle velocity thrown up by bursting bubbles at the bed surface. During the fluidization of 
particles the filter bags are preventing elutriation of fines with the exit gas from the process 
vessel (Parikh, 2006). When the rate of air flow increases, the pressure drop across the bed 
also increases until, at a certain rate of flow, the frictional drag on the particles equals the 
effective weight of the bed. Mentioned conditions and the velocity of air corresponding to it, are 
termed incipient fluidization and incipient velocity, respectively. This relationship between the air 
velocity and pressure drop is shown in Figure 2.13. 
 
   Theoretical section 
 
  31 
 
Figure 2.13. Typical pressure drop curve as a function of gas velocity 
 
With the increase in the air velocity, at one point bed behavior changes from packed bed to 
suspended particles, and this superficial velocity required to first suspend the bed particles is 
known as minimum fluidization velocity and presents a lower limit of operating velocities. 
Corresponding approximate pressure drop can then be used to approximate pumping energy 
requirements. Usually, in the agglomeration process operating air velocity is five to six times 
higher than the minimum fluidization velocity. At the point of incipient fluidization, the pressure 
drop of the bed will be very close to the weight of the particles divided by a cross-sectional area 
of the bed (W/A). For the fluidized bed normally used in pharmaceutical industry density of gas 
is much less than the density of the solids, so the balance of the forces can be presented with 
the following equation: 
A
Wpmf =Δ
 
Equation 2.16 
 
Which can also be expressed as: 
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Equation 2.17 
 
 
Where  Δp =  pressure drop 
  H = fluidized bed height 
  A = bed cross sectional area 
  ε    = void space of the bed at minimum fluidization 
  εmf  = porosity of the bed at minimum fluidization 
  ρp  = particle density 
  ρf  = fluid density 
  g = gravitational acceleration 
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At the same time, the estimated pressure drop in packet beds at minimum fluidization is best 
described by the Equation 2.19: 
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Equation 2.18 
 
 
where:  μ =  fluid viscosity 
  Umf  =  minimum fluidization velocity  
  D  =  the particle diameter 
 
The first summand in Equation 2.19 represents the laminar flow component, whereas the 
second one stands for the turbulent flow component. The minimum fluidization flow is reached 
when the upward drag force exerted by the fluid on the particles is equal to the apparent weight 
of particles in the bed.   
As the velocity of the gas is further increased, the bed continues to expand and its height 
increases with only a slight increase in the pressure drop. At a certain velocity of fluidizing air, 
known as entrainment velocity, particles are carried over by the gas. Particular fluidization is 
called particular in the case when the volumetric concentration of solid particles is uniform 
throughout the bed at all times.  
Aggregative fluidization is when the concentration of particles is not uniform throughout the bed 
and changes with time. Different types of fluidized bed can be distinguished, depending upon 
the movement of bubbles through the bed. Figure 2.14 shows various types of fluidized beds.  
A slugging bed is a fluid-bed in which the gas bubbles occupy entire sections of the product 
container and divide the bed in two layers. 
A boiling bed is a bed in which the gas bubbles are approximately the same size as the solid 
particles. 
A channeling bed is a fluidized-bed in which the gas forms channels through which most air 
passes. 
A spouted bed is a bed in which the gas forms a single opening through which some particles 
flow and fall on the outside. 
The pattern of movement of the gas in and out of bubbles depends upon several factors, 
including minimum fluidization velocity and particle size. These movements affect heat transfer 
between the air bubbles and particles. Air distributor at the bottom of the product container has 
a controlling influence on the uniform distribution of the gas, minimization of dead areas and 
maximization of particle movement. 
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Figure 2.14. Various types of fluidized beds 
 
The extent of segregation can be controlled in part by maintaining high fluidizing air velocities 
and high-bowl-height-to-bowl-diameter ratio. The standard velocities for are based upon the 
cross-sectional area at the bottom of the product container. The air velocity can be calculated 
according to the following equations: 
 
Velocity (m/sec)= Air flow (cubic meter per hour – CMH) ÷ Area (m2) x 3600 
 
Equation 2.19 
 
Air flow (cubic meter per hour – CMH) = Air flow (CFM) x 1.696 
 
Equation 2.20 
 
 
Low air velocities of 0.8 – 1.4 m/s are required for drying, while in the early stages of drying high 
air velocities are required in order for product to lose its moisture. Air flow velocities are normally 
between 1.0 – 2.0 m/s. 
The energy required to heat the granules is small compared to energy necessary to evaporate 
the solvent. Due to the intense mixing of the particles the exit gas and the particles have the 
same temperature. The mass energy balance limitations are quite evident: 
• The exit gas humidity cannot exceed the saturation humidity in the gas at the exit 
temperature. Once the air is saturated, no more liquid can be removed from the system. 
• The energy required to evaporate the liquid cannot exceed that available from the 
incoming gas. 
Collapse of the fluidized bed will happen if any of these limits is exceeded. 
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2.6. Theory of pellet formation and growth 
2.6.1. Bonding forces 
Attraction between solid particles 
The mechanism of pellet formation can be explained through the mechanism of granule 
formations since the same forces cause solid particles to adhere to each other when they are 
brought close enough together. 
Attractive forces are short-range forces that cause solid particles to adhere to each other only if 
they are brought close enough together. Attractive forces may be molecular (valence and Van 
der Waals), electrostatic or magnetic.  
Valence forces are effective only up to distance of 10°A, and since the surface roughness can 
lead to a separation greater than 10°A they can be excluded from the pellet-forming bond. Van 
de Waals forces are thought to be the ones which make the most significant contribution to all 
intermolecular attractive effects. 
Electrostatic forces are found with fine powders and are produced during size reduction or due 
to interparticle friction, or sometimes only the contact between the particles can produce these 
forces. The electrical double layer that develops whenever particles touch each other is much 
more significant and generates adhesional forces that are permanent.  
Magnetic forces are rarely found to be pellet-forming bonds. However, should they exist, they 
are expected to produce very strong bondings between particles (Ghebre-Sellassie, 1989b). 
 
Interfacial forces and capillary pressure in movable liquid surfaces 
Formation and growth of pellets can be divided in four stages (see Figure 2.15): 
 
1. Pendular state 
2. Funicular state 
3. Capillary state 
4. Droplet state 
 
The initial step in wet agglomeration process is the step of bringing liquid binder into contact 
with powder particles and attempt to distribute this liquid evenly throughout the fluidized 
particles. This leads to formation of initial agglomerates and it is referred to as nucleation 
(Dybdahl, 2005). 
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Figure 2.15. Different formal spatial structures of liquid-bound agglomerates depending of liquid 
saturation 
 
When liquid is added in the powder mixture, part of the void space in a randomly packed 
material is filled with a liquid forming lens-like rings (liquid bridges) at the contact points between 
the particles forming agglomerates. The number of contact points of any particle is a function of 
the distribution and surface geometry of the adjacent particles.  
This state where the ratio of the liquid to the void volume is low is called pendular state (Figure 
2.15). Mutual attraction of particles is brought about the surface tension of the liquid and the 
negative suction pressure generated at the liquid bridges. 
 In the funicular state, as in the pendular state, liquid bridges containing gas and pores filled 
with liquid are present, but here the liquid forms a continuous phase and pockets of air are 
dispersed throughout the agglomerate (Figure 2.15). 
The capillary state is reached when all the void space in agglomerate is fully occupied by liquid 
but the quantity of liquid is not sufficient enough to surround the agglomerate (Figure 2.15). 
Capillary pressure and interfacial forces create strong bonds between the particles, which 
disappear once the liquid evaporated. 
In the droplet state the liquid completely envelopes the agglomerate. The primary particles are 
held together only by the surface tension of the droplet. There is no interparticle capillary 
bonding and this situation almost never happens in fluid beds. 
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Adhesional and cohesional forces in bonding bridges that are not freely movable 
Viscous binders and thin adsorption layers provide bonds that are based on immobile liquid 
bridges. Highly viscous binders adhere to the surface of solid particles and generate strong 
bonds that are similar in characteristic to those that exist with solid bridges. 
Thin-adsorption layers are also immobile and can form strong bonds between neighboring 
particles by either smoothing surface roughness and increasing particle contact area or by 
decreasing the effective interparticle distance and allowing the intermolecular attractive forces to 
participate in the bonding mechanism.  
 
Solid bridges 
Liquid bridges are only temporary structures and more permanent bonding is achieved with 
evaporation of the solvent during further fluidization and formation of solid bridges. Solid bridges 
are formed by different mechanisms: 
1. Crystallization of dissolved substances. As the dissolved medium evaporated, the 
dissolved solids crystallize out and form bonds at the contact points 
2. Hardening binders. Upon drying or curing, binders which are used during pelletization, 
harden and form solid bridges. 
3. Melting. Substances that melt on the input of energy tend to solidify when cooled forming 
solid bridges, and their strength depends on the chemical composition of the melted 
material. 
2.6.2. Elementary growth mechanism 
The most classified pelletization process which involves a rotating drum has been divided into 
three consecutive regions: nucleation, coalescence, layering and abrasion transfer. 
Nucleation (Figure 2.16, A) occurs whenever a powder is wetted with liquid and presents first 
stage of the pellets growth. The primary particles are drawn together and attached together by 
liquid bridges which are pendular in nature. The size of primary particles, the viscosity of the 
bonding particles, the moisture content, wettability of the substrate and the processing 
conditions influence  the size, the rate and the extend of nuclear formation.  
Nucleation is followed by a transition phase with two major mechanism, coalescence and 
layering. Coalescence phase is characterized with formation of large-sized particles by random 
collision of nuclei containing slight excess of moisture. Although the number of nuclei is 
reduced, the total mass of the system remains unchanged during this step. Layering (Figure 
2.16, C) involves successive addition of fines and fragments on surface of nuclei. The number 
of nuclei remains the same, but the total mass of in the system increases due to increasing 
particle size as a function of time. The fragments and fine particles are formed during the 
process in the stage of particle size reduction due to attrition, breakage and shatter. 
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The final phase is called ball growth and the main mechanism in this phase is the abrasion 
transfer (Figure 2.16, D) which involves the transfer of materials from one granule formed to 
another without any preference in either direction. Particles will experience a change in size as 
long as the conditions that lead to the transfer of material exist. 
 
 
Figure 2.16. Pellet growth mechanisms. (A) Nucleation, (B) Coalescence, (C) layering and (D) abrasion 
transfer (modified from Ghebre-Sellasie 1989) (Kristensen, 1987) 
 
In the case of solution/suspension layering growth of pellets involves deposition of successive 
layers on existing nuclei, which may be inert seed, crystal or granule. 
In solution suspension layering, the drug particles are dissolved or suspended in the binding 
liquid, with or without the binder. Droplets of the binding liquid spread on the surface of the 
nuclei. During drying, liquid evaporates and the dissolved substances crystallize out and 
capillary forces which are formed draw the particles towards each other and towards the inert 
seed, forming solid bridges. In suspension layering, particles have low solubility and are bonded 
by solid bridges formed from the hardening binder, meaning that higher concentration of binder 
might be necessary.  
In this process fines are produced as a result of attrition or spray drying, especially when the 
process is not optimized.  
2.7. Coating of pellets 
Film coating consists mainly of polymers, which are applied to the cores in the form of solutions 
or dispersion in which other excipients are dissolved or suspended. After drying of solvent or 
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dispersing agents, the polymer and other excipients remain on the cores as coherent, uniform 
film. Film formation from solutions or dispersions occurs by different mechanism (Bauer et al., 
1998). First functional polymers have been used to coat pharmaceutical solid dosage forms for 
protective, decorative and functional purposes. 
2.7.1. Mechanism of film formation 
A film forming polymer in polymeric dispersion is atomized and deposited from the nozzle onto 
the surface of pellets intended for coating. Polymeric dispersion contains submicron-size 
spheres and each sphere consists of hundred of polymer chains. Deposited on the surface, they 
coalesce into a continuous film as the aqueous phase evaporates, since interfacial tension 
between water and polymer pushes particles into contact point in a close-packed arrangement 
(Figure 2.17). Energy required for the coalescence of spheres results from the surface tension 
of the polymer generated by the negative curvature of the particle surface may be described by 
Frankel’s equation: 
 
Nr
t
π
γθ 232 =  Equation 2.21 
 
Where:  θ   =  one-half the angle of coalescence (contact angle) at time t   
γ   =  the surface or interfacial tension  
r  =  the radius of a sphere  
N   = the viscosity of the spheres  
 
This equation illustrates the inverse relationship between internal viscosity (N) of the spheres 
and the driving forces (γ) necessary to fuse or coalesce discrete particles. It is evident that 
smaller radius polymer spheres require less driving force (capillarity) to completely fuse or 
coalesce.  
2.7.2. Glass transition temperature 
Film formation of polymer dispersions is correlated to the glass transition temperature of the 
polymer itself, because the flexibility of the polymer chains changes as the temperature 
decreases or increases. The glass transition temperature (Tg) is the temperature at which the 
viscosity of a melted polymer increases considerably on cooling, or decreases noticeably on 
heating. In molecular terms, it is the temperature at which the flexibility of polymer chains 
changes by several orders of magnitude.  
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Figure 2.17. Schematic representation of the film formation process for and aqueous polymeric 
dispersion: (A) atomization of polymeric dispersion; (B) deposition of the polymeric dispersion on the 
substrate surface; (C) packing of the polymer spheres with water filling the void spaces; (D) formation of 
continuous polymeric film (Felton, 2007).  
2.7.3. Minimum film - forming temperature 
The term minimum film formation temperature (MFT) is the temperature in degrees Celsius 
above which a continuous film is formed under distinct drying conditions (Lehman, 1997). It is 
an important parameter to determine appropriate bed temperature of the fluidized bed 
apparatus (Frohoff-Huelsmann et al., 1999). The coated dosage forms are than cured, namely 
treated at high temperatures for short time. This procedure completes the film formation, 
especially in the case of dispersions with high MFT (over 40°C) (Dashevsky et al., 2005).   
Many polymers which are used for film coating of pharmaceutical dosage forms have brittle 
properties at ambient temperature. In the literature it is known that MFT values decrease with 
increasing level of plasticizer, with the increasing standing time of the aqueous polymer 
dispersion and in some cases with increasing amount of pore former. The dispersion medium 
water also has a plasticizing effect. 
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2.7.4. Film-formers for enteric resistance coating 
Polymers are macromolecules having a molecular weight range between 10,000 and several 
million Daltons and consist of a number of repeating units in the structure. They can cause a 
prolonged drug release in order to extend the intake intervals or enteric resistance in order to 
protect the drug against the acidic media in the stomach. 
Shellac 
The oldest group of polymers for enteric resistance coating, consists only on shellac, which is of 
natural origin and has been used for hundred years for enteric coatings and taste masking as 
well as prolonged release (Hogan, 1995). Shellac is obtained from the resinous secretion of the 
insect Kerria lacca (Pearnchob et al., 2003). 
Due to higher coating levels shellac is able to retard the drug release, but these formulations 
lack of drug release in the gastric environment. Shellac consists mainly of a mixture of 
polyesters, basically composed of shelloic and alleuritic acid, which are responsible for its 
gastric resistance properties. However, as a product of natural origin it is subjected to batch-to-
batch variation of the quality in dependence of the purification process and the resulting content 
of wax, coloring material and other impurities. According to the literature coating materials such 
as shellac and resin do not fulfill modern requirements because they are not sufficiently soluble 
in the digestive tract (Lehman, 1997). 
Incorporation of hydrophilic polymers into the shellac formulation, according to the study 
conducted by Qussi and Suess, 2005, could prevent dissolution of drug in simulated gastric fluid 
for 2 hours and increase the drug release from pellets.  
Aqueous dispersion 
Aqueous dispersions are dispersed substances in the dispersing agent, water like gas in water 
(foam), fluid in water (emulsion), or solid in water (suspension). When the dispersed phase is a 
polymer, it is called polymer dispersion and the dispersed phase can be solid, fluid or any 
intermediate condition. The term latex is used for colloidal polymer dispersions. 
The aqueous systems have an advantage from an environmental standpoint and are less toxic 
and cheaper than organic systems.  
The particle size is the most important specification of latex and is between 10 and 1000 nm. 
Latexes are characterized by low viscosity even when they have high solid content like 30%.  
Methacrylic acid copolymers 
Methacrylic acid copolymers belong to a group of polymers which are insoluble in acid media 
and dissolve by salt formation above pH 5-6. They are full synthetic copolymers exhibiting an 
acidic carboxyl group which is responsible for the enteric resistance. The backbone is based on 
a continuous carbon chain stabilized by methyl groups resulting in poly(methyl methacrylate) 
(PMMA) which was also used crystal clear, unbreakable organic glass (Lehman, 1998).The 
enteric resistant polymer is available as Eudragit® L and S. Hence they are used for enteric film 
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coatings, since they are insoluble in dilute acids, gastric fluid and pure water, they dissolve in 
buffer solutions above pH 5.5 (L 100-55), pH 6 (L 100) and pH 7 (S 100). 
Methacrylic acid copolymers are produced by emulsion polymerization and subsequent spray 
drying. They are soluble in isopropyl alcohol, acetone, ethanol and methanol, also in mixtures 
with up to 40% water. 
These products are commercially available in the form of spray-dried powders, and in the form 
of aqueous dispersion with 30% solids (Eudragit L 30 D-55). 
Eudragit L 30 D-55 is an anionic copolymer based on methacrylic acid and ethyl acrylate, with 
free carboxyl groups in a ratio of 1:1 with the ester groups. The carboxylic groups begin to 
ionize in an aqueous media at pH 5.5 and above, rendering the polymer resistant to the acidic 
environment of the stomach, but soluble in intestinal fluid. 
2.7.5. Film coating equipment  
With aqueous dispersions, the process conditions such as spraying rate, drying temperature, 
amount of drying air and spraying pressure must be carefully chosen because if, as a result of 
processing conditions, the product bed temperatures are too low, they will be insufficient to 
achieve the desired filming above minimum film-forming temperature. The product temperature 
during coating should be approximately 20°C above the minimum film formation temperature in 
order for good film formation to occur (Dashevsky et al., 2005). On the other hand, excessively 
high product bed temperatures allow the dispersion agent to evaporate so rapidly that the film-
former is spray dried (Thoma and Bechtold, 1999). 
Different types of fluidized bed equipment used for coating process are presented in the Figure 
2.10 and Figure 2.11. 
2.8. Characterization of pellets 
In order to meet the requirements of size distribution, surface area, shape, surface roughness, 
density and friability, including the reproducibility of morphologic properties of the pellets, pellets 
have to be tested. 
2.8.1. Size distribution 
The size distribution of pellets should be as narrow as possible because it will ensure a 
minimum variation in coating thickness and coating performance within the batch. If the pellets 
are intended for compression, wide size distribution may lead to segregation and variations in 
content uniformity. 
The most common and widely used method for determination of size distribution is sieve 
analysis. The reasons for its extensive use are simplicity, low costs, low time consumption. 
Some of the disadvantages of this simple method are the inability of the sieve to detect variation 
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in the shapes of particles. The procedure involves the mechanical shaking of a sample through 
a series of sieve sizes and weighing these sieves before and after the analysis. Critical 
parameters of the method are sieve loading, type of motion (vibration or tap), intensity and 
duration of intensity. 
Another method for measurement of pellet size distribution is light scattering, and it is a method 
most suitable for spherical particles. In laser diffraction method particles pass through a beam of 
light, they scatter the light, which is directed onto a diode array detector directly opposite the 
incident light. Sizing of the particles is based on the angle of diffracted light, with small particles 
diffracting at wider angles than larger particles. 
Assuming a log-normal distribution, a plot of particle size versus the cumulative percentage of 
undersize particles can be used to determine the geometric mean weight diameter dg, the size 
corresponding to the 50% value, which is also equal to the mean diameter Randall, 1995. When 
making a log-probability plot it is common to find that experimental data are scattered, specially 
the one with very small and very large particles. For this reason when determining the best 
straight line, it is recommended by some authors that only experimental points within the 20 to 
80% range are used (Fonner et al., 1981). 
2.8.2. Shape and surface roughness 
In order to obtain good performance of coated pellets it is necessary to have spherical and 
smooth particles suitable for subsequent coating, usually for achieving modified-release. The 
commonly used method is the analysis of microscopic or non-microscopic pictures of interest.  
Scanning electron microscopy (SEM) is a technique of choice for measuring the shape and 
surface smoothness of the pellets to support visually the other qualitative and quantitative 
results (Costa et al., 2004).  
2.8.3. Porosity  
The morphology of pellets and total structure can change in any variation in formulation or 
material properties, affecting porosity, which is considered to have a great influence on coating, 
flow and packing during tablet or capsule filling Rashid, 2001. It also influences the rate of 
release of drug from pellets by affecting the capillary action of dissolved drug (Rashid, 2001). 
The pores can be analyzed, qualitatively, by scanning electron microscopy and, quantitatively 
by mercury porosimetry (Mehta, 1989). 
The “PoreSizer” measures the volume distribution of pores in material by mercury intrusion or 
extrusion. It is a 30,000 psia (207MpA) mercury porosimeter covering the pore diameter range 
from approximately 360 to 0.006 μm / 3 nm to 200 μm. The unit has two built-in low pressure 
ports (range of low pressure measurement 0 to 30 psia which corresponds to pore diameter 360 
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to 6 μm) and one high pressure chamber (with the high pressure measurement range of 0 – 30 
000 psia which corresponds to pore diameter 6 – 0.006 μm). 
Mercury has a high surface tension and is non-wetting to all materials with exception of a few 
noble materials. These properties cause a mercury surface in contact with a solid to assume the 
minimum surface area and the largest radius of curvature possible at a given pressure. An 
increase in pressure on the mercury shifts the balance between surface tension and surface 
area causing the radius of the curvature of the mercury contacting the solid to become smaller. 
When the radius is equal to that of a pore entrance, mercury fills the volume within the pore.  
The method is based on the capillary rise phenomenon in which excess pressure is required to 
force a non-wetting liquid into a narrow volume. The mercury is forced into the pores of the 
sample using an externally applied pressure, with the smallest pores requiring the highest 
pressure to effect the filling (Brittain et al., 1991). 
Mercury porosimetry is based on the capillary law governing liquid penetration into small pores. 
This law, in the case of a non-wetting liquid like mercury and cylindrical pores and open at both 
ends, is expressed by the following Washburn equation: 
 
ϕγ cos4)/1( PD −=  Equation 2.22 
 
Where: D  =  pore diameter 
P  =  applied pressure 
γ  =  surface tension 
φ  =  contact angle 
 
The surface tension (γ) and the contact angle (φ) of mercury were 485 dynes/cm and 130 – 140 
degrees, respectively.  
The total pore surface area (assuming that all the pores are cylindrical) can be calculated using 
the Equation 2.23 (Juppo et al., 1997): 
 
∫= VtotPdVS
0cos
1
θγ
 
Equation 2.23 
 
Where: P  = applied pressure  
V  =  volume of intruded mercury 
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Mean pore diameter (Dmean) is calculated by the following Equation 2.24: 
 
s
VD totmean 4=  Equation 2.24 
 
The bulb volume of the cell which is usually used for pellets is 5 cm3 for powders. 
2.8.4. Density of pellets 
Variation of density of pellets from batch to batch affects the potency of finished capsules, 
produces segregation during mixing and causes problems in batch size determination during 
coating. 
Bulk and tap density of pellets is measured using automated tapper, by measuring the volume 
of a known mass into a graduated cylinder, and is influenced by the diameter and size 
distribution of pellets. They are indicative of the packing properties of particles. 
True density indicates the extent of densification or compactness of substance. The 
pycnometric density is determined by measuring the volume occupied by a known mass of 
particles which is equivalent to the volume of gas displaced by the particles. In this case only 
open pores are included in the measured volume since the sealed pores are inaccessible to the 
gas (5.0, 2005).  
2.8.5. In-vitro dissolution testing  
Dissolution is defined as the process by which a solid substance enters in the solvent to yield a 
solution. A dissolution test measures the rate of release of the drug. Before the drug is 
absorbed from the gastrointestinal tract (GIT), it has to be released and dissolved first. For a 
development compound, dissolution testing is used primarily to help and evaluate new 
formulations by evaluating the drug release from dosage forms, evaluating the stability of these 
formulations, but for the commercial products dissolution testing is used primarily to confirm 
manufacturing and product consistency and to assess post-approval changes and the need for 
bioequivalence studies (Brown et al., 2004). 
The dissolution characteristics of drugs can be influenced by different factors such as the 
physical characteristics of the dosage form, the wettability of dosage unit, the penetration ability 
of the dissolution medium, the disintegration, deaggregation and swelling process of the dosage 
form. The basic steps in dissolution process can be divided in three steps. First step is 
described as a step in which dissolution media and/or components of dissolution media move 
towards the solid-liquid interface with certain velocity. It is assumed that the solid is surrounded 
by a layer of liquid with a certain thickness. At the solid’s surface adsorption takes place and this 
represents second step in dissolution mechanism. Third step is described with the molecular 
diffusion of the dissolved drug molecules from the surface towards the bulk solution. 
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According to this step classification, dissolution process can be either reaction limited or 
diffusion limited, depending which step in the process is slower. Both of these two steps depend 
on the agitation conditions, composition of dissolution medium and as previously mentioned 
drug and dosage form properties. 
Two main models for interpretation of dissolution mechanisms are diffusion layer and the 
interfacial barrier model. In both models assumption is made that there is a stagnant layer of 
liquid around the solid particles. Interfacial barrier model assumes that the rate limiting step of 
the dissolution model is the reaction at the solid-liquid interface (Macheras et al., 2006), 
meaning that the slower step is the transfer of drug from the solid phase to the solution. For the 
diffusion layer model, the step that limits the rate is the rate of diffusion of the dissolved drug 
molecules through the stagnant liquid layer to the bulk solution.  
Diffusion layer model is the most commonly used, but also some alterations have been 
proposed. 
Mathematical description of the dissolution process  
Different mathematical formulas that express the dissolution results as a function of some of the 
dosage characteristics are used in practice. 
Some basic principles of the dissolution process of a solid dosage form are given by the film 
theory (Nernst, 1904). Be a solid immersed in an agitated liquid, surrounded by a stagnant liquid 
layer with a thickness h. At the solid’s surface, the concentration of dissolved solid is equal to its 
saturation concentration S. Be c the concentration of the dissolved solid in the agitated 
dissolution medium. At the steady state, Fick’s first law can be employed (see Equation 2.25). 
 
x
cDJ ∂
∂−= Equation 2.25
 
where J is the diffusion current, defined as the amount of substance passing vertically through 
an unit surface area per time. D stands for the diffusion coefficient, whereas ∂c/∂x represents 
the constant concentration gradient corresponding to the slope (C-S)/h (see Figure 2.18). 
Considering the dissolved mass m and the surface area of the dissolving solid O, the Fick’s law 
can be expressed according to Noyes Whitney (Noyes and Whitney, 1897) (see Equation 2.26). 
 
)( cS
h
OD
dt
dm −= Equation 2.26
 
Dividing both member of Equation 2.26 through the volume of the dissolution media V, Equation 
2.27 is obtained. 
 
)( cS
hV
OD
dt
dc −= Equation 2.27
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Figure 2.18. Fick’s low graphic illustration 
 
 
If the middle distance between the discussed molecules is negligible compared to the diameter 
of the molecules, Einstein relation can be applied (see Equation 2.28). 
 
r
kT
rN
RTD
a πηπη 66
== Equation 2.28
 
where NA indicates the Avogadro number, R the universal gas constant, k the Boltzmann 
constant, T the temperature, η stands for the viscosity of the dissolution medium and r for the 
radius of the molecule. It is redundant to say that the molecular mass of a certain compound in 
a molecular-disperse solution does not have a big influence on the diffusion coefficient D, since 
the radius of a spherical particle corresponds approximately to the third root of its molecular 
mass. Another theory, called the surface renewal or penetration theory (Danckwerts, 1951), 
proposes the existence of a dynamic (and not stagnant) laminar layer h, meaning that the 
surface would be continually replaced by fresh liquid.  
 
Mechanisms of release from coated pellets 
In the case of release from pellet dosage forms coated with polymers insoluble in GIT may 
occur in three different mechanisms (Dressman and Bernhard, 1994): 
a. solution/diffusion through the continuous plasticized polymer phase; 
b. solution/diffusion through plasticizer channels;  
c. diffusion though aqueous pores. 
Solution/diffusion through the continuous plasticized polymer phase assumes that the polymer 
forms a phase in which the plasticizer and other additives are homogeneously dispersed. The 
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diffusion of a solute molecule within an amorphous polymer phase is an activated process 
involving the cooperative movements of the penetrant (drug) and the polymer chain segments 
around it. It is by this stepwise process that hindered molecular diffusion occurs. Release by 
diffusion/solution through the plasticized polymer phase is presented in Figure 2.19. 
Based on the Fick’s law (Equation 2.25), the release rate in presence of the above mentioned 
mechanism can be described by the Equation 2.29. 
 
)( bs
m CC
P
J −= δ Equation 2.29
 
where J ist the flux (release rate per unit surface area of coating) Cs and Cb are the 
concentration of drug at the coating interface and the bulk, respectively, and δ is the coating 
thickness. The permeability coefficient of the coating polymer Pm can be written as: 
 
KDKDPm '== τβ
ε
Equation 2.30
 
where D ist the molecular diffusivity of the drug, K the distribution coefficient of the drug 
between the polymer membrane and fluid in the core (imbibed water), ε the volume fraction of 
the chain opening, β a chain immobilization factor and τ the tortuosity factor. The frequency with 
which a diffusion step occurs depends on the size and shape of the drug, tightness and bonds 
between adjacent polymer chains and the stiffness of the polymer chain. Further below its glass 
transition temperature (Tg), the less permeable the polymer. Plasticizers lower the Tg, increase 
free volume and increase diffusivity. Accordingly, this mechanism is dominant in continuous film, 
flexible polymers which lacks pores. 
Overall permeability of the polymer to the drug will depend on the ability of the drug to partition 
into the polymer as well as its ability to diffuse through the polymer. 
 
 
 
Figure 2.19. Drug release from coated pellets via solution/diffusion through the polymer film 
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The second mechanism occurs when the plasticizer is not uniformly distributed in the coating 
polymer and its content is high where plasticizer takes the form of a continuous phase in the 
form of patched channels. This mechanism is shown in Figure 2.20 and the release rate for this 
model can be described by the Equation 2.31, which derives from the Equation 2.30 replacing 
Pm, the permeability of the coating polymer, with Ppl, the permeability of the plasticizer. 
 
     
 
Figure 2.20. Drug release from coated pellets via solution/diffusion through plasticizer channels 
 
 
 
pl
pl
plpl
pl K
D
P τ
ε= Equation 2.31
 
In this case, Kpl is the distribution coefficient of the drug between plasticizer and the core fluid 
(imbibed water), τpl the tortuosity of the plasticizer channels, and εpl the volume fraction of 
plasticized channels. For this mechanism to be dominant, the following condition must be 
satisfied: 
pl
pl
plpl
pl K
D
scmP τ
ε=≈ − /10 28 Equation 2.32
    
Diffusivity in the plasticizer will generally be lower than in water since plasticizers tend to be 
relatively viscous. Assuming a Dpl ≈ 10-6 cm2/s, a plasticizer load of 40% with half forming 
channels (ε = 0.2) and a low tortuosity (τ = 2), the ability of the drug partition should be at least 
0.1. In the reality, this mechanism was demonstrated to be too slow to explain the release rates 
observed. 
 
Diffusion through aqueous pores intervenes when a continuous, but inhomogeneous coating 
layer is punctuated with pores. This mechanism is more likely to be operative for the coatings 
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formed from aqueous dispersions and when the pellets come in contact with an aqueous 
medium, these pores fill with solution thus facilitating the diffusion of the drug. During the 
coating and curing processes, the pseudolatex particles often do not fuse completely, thereby 
creating a porous coating. The pores may be of 1μm size and the release mechanism is 
illustrated in Figure 2.21.  
 
     
 
Figure 2.21. Drug release from coated pellets via diffusion through aqueous channels  
. 
 
For diffusion through aqueous pores, the permeability coefficient Pp is given by: 
  
p
pp
pl
D
P τ
ε= Equation 2.33
 
Where Dp is the aqueous diffusivity of the drug, εp the volume fraction of the aqueous channels, 
and τp their tortuosity. The partition coefficient K is the unity in this case. 
For diffusion through aqueous pores to be the mechanism driving the release rate, P should be 
in the order of 10-8 cm2/s. If SEM consistently indicates the presence of pores in the coating, it is 
likely that diffusion through the pores will contribute significantly to the overall release rate 
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3. Objective of the study 
 
 
 
In order to shorten the development time which presents today’s focus of pharmaceutical 
industry and obtain early assessment of stability, the main purpose of the study was to 
investigate and gain understanding about the factors affecting the stability of lansoprazole 
delayed release pellets.  
 
Since there was a need to investigate the thermal behavior of lansoprazole in order to clarify the 
differences reported in the literature and to determine a reliable method for determination of the 
melting point of lansoprazole followed by decomposition of the substance, which makes a 
determination of the melting point very difficult. 
 
Study will try to clarify the influence of type of neutral pellet (Suglets® and Etispheres®), type of 
stabilizing agent and presence of protective coating on surface morphology, porosity and 
stability of enteric coated pellets containing acid-liable drug (lansoprazole). The influence of 
type of neutral core on the stability of pellets has not yet been investigated. 
 
Possibility of stabilizing lansoprazol using Na-CMC and rotary processor (direct pelletization) will 
be investigated. Since the process has been characterized as a multivariable process the study 
will include an optimization of factor settings of two process variables, spray rate and rotor 
speed and one formulation variable, drug loading on geometric mean diameter of pellets and 
moisture content at the end of liquid addition phase using statistical optimization techniques in 
order to obtain spherical lansoprazole pellets of acceptable size. Experiments will be planned 
using statistical design of experiment (DoE) and the data obtained analyzed to yield valid and 
objective conclusions.  
 
Furthermore, the objective of the study is to determine the temperature effects in the presence 
of moisture on the degradation rate constant of lansoprazole applying accelerated degradation 
with Arrhenius testing as a comparative technique in stability prediction of pellets prepared 
using different pelletization techniques. 
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4. Materials and Method 
 
4.1. Materials 
4.1.1. Drug substance 
 
Lansoprazole  
Batch no. F51217 and F41403, Cipla, Mumbai, India 
(See Figure 4.1) 
 
 
 
Figure 4.1. Chemical structure of lansoprazole 
 
 
Empirical formula: C16H14F3N3O2S  
1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-2-[[[3-Methyl-4-(2,2,2-
trifluoroethoxy)-2-pyridyl]-methyl]sulfinyl]benzimidazoles 
 
Appearance: White to brownish white odorless crystalline powder  
Molecular weight: 369.36 
Melting point: 166°C with decomposition (producer reference) 
BCS: Class II 
pKa: 8.78 and 3.82 
logP: 2.761 ± 0.779 (25°C)* 
Stability: unstable at pH below 7 
* SciFinder Scholar, Calculated properties for lansoprazole, Advanced Chemisrty Development 
(ACD/Labs) Software, V8.14 for Solaris 1994 – 2008. 
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4.1.2. Excipients  
Neutral sugar pellets, Suglets®  
Batch no. 503 P, NP Pharm, Bazainville, France 
Appearance: White spherical granules with sweet taste, soluble in water  
Particle size: 850 – 1000 µm  
Components: saccharose (up to 92%) and maize starch 
Manufacturing date: 03/2005 
 
Neutral microcrystalline cellulose pellets, Ethispheres® 850  
Batch no. 609 ZZ, NP Pharm, Bazainville, France 
Appearance: White spherical granules, insoluble in water, high physico-chemical inertness 
(improves stability of finished products) 
Particle size: 710 - 1000 µm 
Manufacturing date: 04/2006 
 
α-Lactose monohydrate, Lactosum D-80®   
Molkerei Meggle Wasserburg GmbH, Wasserburg, Germany 
Particle size: 200 mesh (54%< 32 µm, 86%< 63 µm, 96%< 100 µm) 
 
Hydroxypropilcellulose (HPC), Klucel LF® 
Hercules Inc., Wilmington, Delaware, USA 
Viscosity: 5% aqueous solution 75 – 150 cps 
 
Hydroxypropilmethylcellulose (HPMC), Methocel E5® 
Colorcon, Budapest, Hungary 
Viscosity: 2% aqueous solution 5-g cps 
 
Magnesium carbonate, heavy 
Calmags GmbH, Germany  
 
Sodium dihydrogenphosphate dodecahydrate 
Merck KGaA, Darmstadt, Germany 
 
Ethyl acrilate methyl methacrylate polymer, Eudragit L 30 D-55® 
Röhm Pharma Polymers, Darmstadt, Germany 
30% aqueous dispersion of anionic polymethacrylate for enteric coating 
Film solubility: above pH 5.5 
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Shellac, Marcoat 125® 
Aqueous Shellac solution, Emerson Resources, INC-Syntapharm Group, Product no. 
0802200701 
Appearance: Clear amber solution 
Odor: Characteristic sweet odor 
Solids: Dewaxed Orange Shellac NF 
Solid content: 25% ± 1% by weight 
pH: 7.2 ± 0.3 
Specific gravity: 1.04 ± 0.01 
 
Balocel® 
Pharmatrans Sanaq AG, Basel, Swizerland 
Powder premix for pelletization  
Constituents: 50% microcrystalline cellulose, 35% lactose monohydrate, 15% sodium 
carboxymethylcellulose 
 
Polysorbate 80, Tween 80® 
Seppic GmbH, Cologne, Germany 
Dispersing agent 
 
Tryethylcitrate, Eudraflex® 
Merck KGaA, Darmstadt, Germany 
Plasticizer 
 
Glycerol monostearate 40-50, Imwitor® 900K 
Sasol, Hamburg, Germany  
Glyceryl monostearate 40 – 55% 
Glidant 
 
Lansoprazole USP standard  
Lot. GOD307, USP Rockville, MD 
USP reference 
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4.2. Characterization of drug substance and neutral pellets 
4.2.1. Solubility of lansoprazole 
Solubility experiments were performed with a large excess of the substance. It was anticipated 
that decomposed lansoprazole could be replaced with the intact substance during experiment 
(Kristl et al., 2000).  
Excess of the substance was tested for solubility in water using agitation method, in 100 ml 
flasks at temperature of 25°C ± 0.1°C in a water shaking bath for 48 h, with shaking amplitude 
of 66. Samples were taken after regular time intervals and quantified by UV/VIS spectrometry 
described in chapter 4.5.6 at 284 nm. 
Standard calibration curve was prepared from stock solution of lansoprazole which was 
prepared weighing 10 mg of lansoprazole in 100 ml volumetric flask, adding 1 ml of methanol 
and filling up to the volume with distilled water. Different concentrations were prepared diluting 
the standard stock solution with water and quantified.  
In order to assure working in the sink conditions solubility of lansoprazole was also determined 
at 37°C in phosphate buffer pH 6.8 using the same procedure. Sink conditions were defined as 
follows: the total concentration of the drug dissolved should not be significantly higher than 10% 
of their saturated concentration (Gibaldi and Feldman, 1967). 
4.2.2. Fürrier-transform infrared spectroscopy (FTIR) of lansoprazole 
FTIR spectra of lansoprazole was obtained using PerkinElmer FTIR spectrophotometer 
(Waltham, Massachusetts, USA) using diffuse reflectance technique (KBr disc technique) as a 
part of qualitative analysis by comparing it with the spectra of lansoprazole USP standard. 
Samples of lansoprazole powder and lansoprazole USP standard were previously ground and 
mixed with KBr, an infrared transparent matrix. The KBr discs were prepared by compressing 
the powder and the scans were obtained in the mid-infrared regions of the spectrum form 4000 
– 400 cm-1 at resolution of 1 cm-1.  
4.2.3. Thermal properties of active substance 
4.2.3.1. Differential-scanning calorimetry (DSC) 
The samples (2.5 – 5.0 mg) were placed in aluminium sample pans with holes, 50 μm, sealed 
and scanned from 60°C up to 220°C/300°C (40°C above the determined signal) with different 
heating rates (2.5°C/min, 5°C/min, 10°C/min, 20°C/min, 30°C/min and 40°C/min) in a Perkin 
Elmer Pyris 1 DSC/Diamond DSC, in order to see the effect of scanning rate on the thermal 
behavior of the studied substance. 
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4.2.3.2. Thermogravimetric analysis (TGA) 
Since thermogravimetrical analysis measures changes in sample weight as a function of time or 
temperature. Desolvation and decomposition processes are frequently monitored by TGA (Fiese 
and Hagen, 1986). Loss of mass that occurred due to heating was determined under conditions 
that gave maximum noticeable degradation during the DSC studies. Comparing TGA and DSC 
data recorded under identical conditions can greatly help in the interpretation of thermal 
processes. 
The samples (14 - 15 mg) were placed in sample pan holder and scanned from 60°C up to 
230°C (40°C above the determined signal) with different heating rates (5°C/min, 10°C/min, 
20°C/min, 30°C/min and 40°C/min) in a Perkin Elmer Pyris 6 TGA under the dynamic flow of 
nitrogen (100 ml/min) and the loss of mass recorded. 
Also, samples were scanned from 60°C up to 350°C (120°C higher temperature range than the 
previous scanning) with four different heating rates (1°C/min, 2.5°C/min, 10°C/min and 
20°C/min) in order to examine if there is another thermal event which can be visible on the TGA 
curve. 
4.2.3.3. Hot-stage microscopy (HSM) 
Degradation during thermal analysis may provide misleading results and for that reason HSM 
has been used in order to clarify the thermal behavior. Behavior of lansoprazole upon heating 
was visualized by Hot-stage microscope using a hot stage unit (Lynkam THMS 600) optical 
microscope (Olympus BX 51) with 10x magnification. A small amount of lansoprazole was 
placed on a glass slide, covered with the cover glass and heated from 60°C up to 220°C with 
the heating rates of 1°C/min, 2.5°C/min, 10°C/min and 20°C/min.  
4.2.4. Powder X-ray diffractometry of lansoprazole 
Powder X-ray diffractometry of lansoprazole samples was performed with an Siemens, Model D 
5005, X-ray diffractometer over 5-60°2θ range at a scan rate of 1°/min where the tube anode 
was Cu with Kα= 0.154 nm monochromatized with a graphite crystal. The pattern was collected 
with 40kV of tube voltage and 40 mA of tube current in step scan mode (step size 0.05, 
counting time 1 s/step) (Zhang et al., 2007).   
4.2.5. Particle size measurement 
In order to determine appropriate method for determination of particle size distribution by laser 
diffraction, two methods were used. Dry powder laser diffraction method was proposed by 
producer of the substance (Batch no. F51217, Cipla, Banglore, India), and wet laser diffraction 
method which is in some cases more appropriate for determination of particle size distribution of 
pharmaceutical substances. Particle size distribution measurement has been performed on 
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Mastersizer 2000 (Malvern Instruments) using dry powder feeder unit Scirocco 2000 and wet 
unit Hydro 2000. 
Dry powder laser diffraction has been conducted with optical characteristics of particle refraction 
index 1.500, absorption 0.001. Vibration feed rate was set to 50% and dispersion medium 
pressure (air pressure) was set to 2 bars. 
In wet method as dispersant medium, water was used. Since lansoprazole has low wettability, 
10% polysorbatum 80 solution is used as surface active substance to obtain good dispersion of 
substance Wet powder laser diffraction measurement has been conducted with optical 
characteristics of particle refraction index 1.500, absorption 0.001. Weight residual was 0.499%, 
and pump for dispersion medium was set on 1750 rpm. 
For determination of particle size distribution of neutral pellets, dry powder feeder unit was used 
with different measurement settings. Optical characteristics were set to particle refraction index 
2.500 with the absorption 0.1. An obscuration value in the range of 1-10% in all measurements 
as obtained (2.9%). Vibration feed rate was set to 50% with air as dispersion medium, with 
pressure of 2 bars. With the software (Malvern) the particle size distribution, including mean and 
median particle size was calculated from raw data. 
4.2.6. Bulk and tapped density 
Bulk (poured) density and tapped density was measured using automated tapper (Stav, J. 
Engelsmann, Ludwigshafen, Germany). 100 g mass of sample, giving the volume between 50 
and 250 ml, was poured into the graduated cylinder. The volume noted, without any tapping of 
the cylinder, is the bulk volume. After fitting, cylinder was tapped 500 times and the volume was 
noted. Sample was further tapped until 1250 times and again the volume was checked. If the 
difference between the volume after 500 and 1250 tapps was higher than 2 ml sample was 
tapped 1250 times more, giving the volume after 2500 times of tapping. The relative bulk 
density (ρbulk) and relative tapped density (ρtapped) were calculated as ratio of volume and mass 
used for determination, respectively.  
Hausner ratio (R) and Carr’s index (CI) USP, 2006a were calculated using the Equation 4.1 and 
Equation 4.2: 
bulk
tappedH ρ
ρ=  Equation 4.1 
100)( ⋅= −tappedbulktappedCI ρ ρρ Equation 4.2 
 
where:   H = Hausner ratio 
ρbulk = bulk density (g/cm3) 
ρtapped =  bulk density (g/cm3) 
CI = Carr index (%) 
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4.2.7. Scanning electron microscopy 
SEM pictures of lansoprazole powder were sputtered with gold palladium and than observed 
with a scanning electron microscope (SEM) Philips ESEM XL 30 FEG at a voltage of 10 KV, 
using magnification of 300, 3000 and 10000. 
SEM pictures of neutral pellets were obtained after a neutral pellet and cross section of pellet 
was sputtered with gold palladium and than observed with a scanning electron microscope 
(SEM) Philips ESEM XL 30 FEG at a voltage of 5 and 10 KV, using magnification of 100, 300, 
1000 and 3000. 
4.2.8. Specific surface area measurement 
Brunauer, Emmett and Teller (BET) surface measurements were performed using NOVA 2000, 
Version 8.00, Quantachrome. The samples of lansoprazole powder (≈ 900 - 1000 mg, n=3) 
were placed in glass sample cell (outer diameter 9 mm with bulb) with glass rod and degassed 
under vacuum for 24 hours, on degassing temperature of 25°C. Additional sample of non-
degassed sample was analyzed to get an idea about the way the surface area is affected if the 
sample has not been pre-treated.  
Surface area measurement of neutral pellets (sugar pellets and MCC pellets) was conducted in 
triplicate. Samples of sugar pellets in weight of 1.5520 – 1.5550 g were degassed under 
vacuum for 24 hours on 25°C, in sample cell without bulb (outer diameter 9 mm). Mass of 
sample of MCC neutral pellets was 0.5210 – 0.5340 g and they were degassed using the same, 
previously described procedure for sugar pellets. 
Multipoint measurement was carried out using N2 as adsorbate gas, on temperature of liquid 
nitrogen (-196°C) in the limited range of the adsorption isotherm, usually in the P/Po range of 
0.05 to 0.35.  First step in the calculation of specific surface area was calculation of weight of 
monolayer Wm using the BET plot Equation 4.3:  
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Equation 4.3 
 
In which W is the weight of gas adsorbed at a relative pressure P/P0 and Wm is the weight of 
adsorbate constituting a monolayer of surface coverage. The term C, the BET C constant, is 
related to the energy of adsorption in the first adsorbed layer and consequently its value is an 
indication of the magnitude of the adsorbent/adsorbate interactions (Quantacrome).  
From the slope s and intercept i of the BET plot, Wm can be calculated: 
 
WmC
Cs 1−=  Equation 4.4 
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WmCi
1= Equation 4.5 
ismW += 1 Equation 4.6 
Further step in the application of the BET method is the calculation of the surface area. The 
total surface area of the sample can be expressed as: 
 
M
NAWSt csm=
 
Equation 4.7 
Where N is Avogardo’s number (6.023 x 1023 molecules/mol) and M is the molecular weight of 
the adsorbate. 
Specific surface area of the solid is calculated using the following equation: 
 
W
SS t=
 
Equation 4.8 
4.2.9. True density 
True density of lansoprazole powder and neutral pellets (n=3) was determined using helium 
pycnometer (Mycromeritics Accupyc 1330, Norcross, GA, USA). Mass of sample was 
approximately 1.6 g for lansoprazole powder, which presented 2/3 of the sample cell volume, 
while mass of neutral pellets for the analysis was approximately 5 g. Purging procedure was set 
to number of purges 5 and purge fill pressure was set to 1.5 bar (19.5 psia). For the 
measurement number of runs was 5, with run fills pressure of 1.5 bar (19.5 psia) and 
equilibration rate: 0.01 - 0.001 psia/min. 
 
4.3. Preparation of pellets using solution/suspension layering 
4.3.1. Active and protective layering 
Following eight different formulations have been prepared (see Table 4.1) using 
solution/suspension layering technique. Lansoprazole loaded pellets were prepared by layering 
a drug-binder (HPC, 4 w/w%) suspension onto sugar spheres (Suglets®, saccharose 92% and 
maize starch) or MCC pellets (Etispheres®) in bottom spraying fluidized-bed Unilab-5 (Hüettlin, 
Schopfheim, Germany) with the 1.0 mm nozzle, until the desired drug loading (8.8% w/w) was 
achieved.  
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Table 4.1. Formulations under study 
 
First phase of the process was active layering onto the neutral spheres. Formulation of active 
suspension is presented in the Table 4.2. 
 In order to maximize the interactions between drug and neutral pellets, the size ratio of 
micronized lansoprazole powder and neutral pellets was 1:100. Since lansoprazole has a low 
wettability (Kristl and Vrecer, 2000), and it is known that successful interaction between the drug 
and the binder solution is greatly influenced by the wettability of the drug, sodium lauryl sulfate 
was included in the formulation as a wetting agent. Also, adsorbents prepared by depositing 
lansoprazole and surfactants on porous adsorbants (as solid dispersions) have been employed 
to improve the dissolution and oral bioavailability.  
Neutral pellets (sugar of MCC, see Table 4.1) were loaded into the fluidized bed in quantity of 
3.5 kg and heated on 37°C for 15 minutes. Active layering solution was prepared in a way that 
the first part consisted of HPC which was dissolved in distilled water, in quantity necessary to 
obtain 4.1 w/v% solution and left over night, prior to coating (see Table 4.2). 
 
Table 4.2. Active layering formulation part I 
 
Second part of the active solution was prepared according to the formulation presented in Table 
4.3.  
 
Run  Pellet type 
Protective coat 
(HPMC) Alkaline agent 
1 Sugar Yes Mg carbonate 
2 MCC Yes Mg carbonate 
3 Sugar No Mg carbonate 
4 MCC No Mg carbonate 
5 Sugar Yes Sodum phosphate 
6 MCC Yes Sodum phosphate 
7 Sugar No Sodum phosphate 
8 MCC No Sodum phosphate 
Substance Proportion solids (w/w %) 
HPC 2.64 
Water* - 
*evaporated during the coating  
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Active layering formulation I and II were mixed for 15 minutes using a propeller mixer type 
(Eurostar digital, IKA®-WERKE) and sprayed with spray rate of 10 – 23 g/min until the desired 
drug loading was achieved (8.8% drug load). 
 
*evaporated during the coating  
** not used in the same trials (see Table 4.1) 
 
Prepared lansoprazole-loaded pellets were dried in the fluidized bed for 20 minutes on 
temperature of 40°C, and further on coated with the protective coating containing hydroxypropyl 
methylcellulose 7 w/v% (seal-coating) with spray rate of 15 – 21 g/min. The amount of HPMC 
used for each layering was always dissolved in the distilled water a day prior to coating.   
 
Table 4.4. Protective layering formulation 
Substance Proportion solids (w/w %) 
HPMC** 61.59 
Water* - 
* evaporated during coating, **not used for all trials (see Table 4.1) 
 
Pellets were dried for 20 minutes on 40°C and intended for further coating with enteric polymer 
(Chapter 4.3.2). 
Process parameters for all three phases of pellet preparation (active layering, protective layering 
and enteric coating) are presented in Table 4.5. 
 
 
 
 
Table 4.3. Active layering formulation part II 
 
 
Substance Proportion solids (w/w %) 
Sugar spheres** 61.59 
MCC spheres** 61.59 
Lansoprazole 8.80 
Lactose monohydrate 3.52 
Sodium laurylsulphate 0.26 
Magnesium carbonate heavy**  0.3 
Dinatriiphosphas dodecahydrate** 0.70 
Water* - 
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Table 4.5. Process parameters used for solution/suspension layering 
 
 
 
4.3.2. Enteric coating of drug loaded pellets 
4.3.2.1. Enteric coating with Shellac 
In order to determine the coating level needed for obtaining gastric resistance with Shellac 
aqueous solution, 10%, 15% and 20% of shellac solid substance has been applied on 
lansoprazole pellets from run 8 (see Table 4.1).  
Enteric coating fomulation consisted of 34% (w/w) aqueous Shellac solution (25% solid Shellac 
substance), 33% w/w HPMC (5 cPoas) and 33% w/w of polyethylene glycol 6000 (Macrogolum 
6000) as a plasticizer (see Table 4.6). First Shellac aqueous solution was mixed with plasticizer 
for 15 minutes and than HPMC was added to formulation in the form of 5% w/w aqueous 
solution which was prepared a day before. Mixing of the final solution was performed for 2 hours 
at 51 rpm’s (Eurostar digital, IKA®-WERKE). Enteric coating with Shellac was performed in 
bottom spraying fluidized bed Unilab-5 (Hüettlin, Schopfheim, Germany) with the 1.0 mm nozzle 
diameter. It was necessary to add 1% of talc into the product container because of the 
electrostatic charge and retention of pellets on the walls of product container. 500 g of pellets 
was loaded in fluidized bed with reduction insert for the product container and coated with 
shellac solution up to the weight of 10%, 15 % and 20 % of solid shellac. After achieving a 
desired weigh gain, pellets were dried in between stages and samples of pellets were removed 
using a sampling tube, and coating was continued. 
 
 
 
 
 
Process phase 
Process parameters 
Active layering Protective coating Enteric coating 
Inlet air volume (m3/h) 230 230 230 
Inlet air temperature (°C) 45 45 – 53 40 
Atomizing air pressure (bar) 1.0 – 1.17 1.16 0.5 -1.27 
Microclimate pressure (bar) 0.1 – 0.25 0.3 0.3 – 0.5 
Product temperature (°C) 37 - 40 37 – 40 28 - 30 
Spray rate (g/min) 10 -23 15 - 21 15 - 32 
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Table 4.6. Shellac coating formulation 
 
Since shellac is completely insoluble in water, a film formed from shellac may not be permeable 
enough to provide the targeted release profile. Therefore, water-soluble additives may be added 
to provide a channel in membrane for permeation in aqueous environment Qussi and Suess, 
2005. The process parameters for the coating are stated in Table 4.7. 
 
Table 4.7. Process parameters for coating with shellac (Unilab-5) 
 
Draying of pellets was perfomed on inlet air temperature of 33 °C, for 20 minutes at the air flow 
of 135 m3/h. Samples of pellets coated with shellac were tested on gastric resistance in 0.1N 
HCL (pH 1.2) and on dissolution in phosphate buffer pH 6.8. 
4.3.2.2. Investigation of coating level of methacrylic acid copolymer  
In order to determine the coating level needed for obtaining gastric resistance, pellets from the 
run 5 (see Table 4.1) were coated in different weight gains (20%-26% w/w) of solid enteric 
polymer and samples of pellets were removed at 2% weight gain increments. Enteric coating 
suspension (20% solids w/w) contained Eudragit L 30 D-55 as enteric coating polymer (20% of 
dry polymer), triethyl citrate as plasticizer, glycerol monostearate as a glidant, and polysorbate 
as dispersing agent (formulation presented in Table 4.8). 
Substance Proportion solids (w/w %) 
Shellac solution (34% w/w aqueous solution) 25 
HPMC (5% w/w aqueous solution, 5 cPoas) (on dry polymer) 33 
Polyethylene glycol 6000 (plasticizer)(on dry polymer) 33 
Solid content of the spray solution 15.6 
Process parameters 
Inlet air volume (m3/h) 130 
Inlet air temperature (°C) 34 – 36 
Atomizing air pressure (bar) 0.37 – 0.41 
Microclimate pressure (bar) 0.14 – 0.18 
Product temperature (°C) 21 – 23 
Spray rate (g/min) 10 – 20 
Process time (min) approx. 210 min 
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Enteric coating was performed in bottom spraying fluidized bed Unilab-5 (Hüettlin, Schopfheim, 
Germany) with the 1.0 mm nozzle diameter. Preparation of the enteric coating suspension was 
performed according to the product sheet guidelines for Eudragit L 30 D-55 Degussa,  using a 
Ultra-Turrax® T50 basic and propeller type mixer Eurostar digital (IKA®-WERKE). Enteric 
coating dispersion was gentle stirred during the coating process. Process parameters for enteric 
coating are presented in the Table 4.5.  
 
Table 4.8. Enteric coating formulation 
 
Samples of prepared pellets were tested on gastric resistance in 0.1N HCL (pH 1.2) and 
modified acid stage media acetate buffer (pH 4.5), and on dissolution in phosphate buffer pH 
6.8 in order to determine necessary quantity of enteric polymer to achieve gastric resistance. 
Further more, the influence of quantity of enteric coating polymer on stability of lansoprazole 
pellets was investigated using Arrhenius testing.  
4.3.2.3. Coating of pellets with Eudragit L 30 D-55 
Eudragit L 30 D-55 (20% of solid polymer) was applied on pellets prepared according to the 
Table 4.1, using the same procedure described previously in Chapter 4.3.2.1. Process 
parameters are presented in the Table 4.5. 
 
4.4. Preparation of pellets using direct pelletization 
4.4.1. Optimization of pellet size using experimental design 
The objective of the study was to obtain spherical lansoprazole pellets of acceptable size, for 
pellets are intended for further coating.  
In order to determine the optimum levels of spray rate, rotor speed and drug load for the 
production of desired size and shape of the pellets, and since the moisture content is influenced 
by previously mentioned factors (Chapter 2.4.1.4), all other process parameters, as well as the 
quantity of MCC in the formulation and the amount of binder solution, were determined in pre-
Substance Proportion solids (w/w %) 
Eudragit L 30 D-55 (30% aqueous dispersion) 20 
Triethyl citrate (on dry polymer substance) 10 
Glicerol monostearate (on dry polymer substance) 5 
Polysorbate 80 (on GMS substance)(80% dispersion) 40 
Solid content of the spray suspension 20 
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experiments and were kept constant through out all the experiment. Drug load was interesting 
because lansoprazole is a low wettable substance and the obtained content of drug in pellets 
could provide valuable information on the process. Furthermore, since there was no possibility 
of power consumption measurement, moisture content measurement was conducted at the end 
of the liquid addition phase, supposing that it could reveal us the level of moisture necessary for 
successful pelletization. Even though, the inlet air humidity is an important parameter and 
influences powder bed moisture content, this parameter was noncontrollable during the 
experiments since the equipment could not condition the inlet air.  
Drug containing pellets were prepared in fluidized bed rotary processor (GPCG-1, Glatt GmbH, 
Binzen, Germany) using direct pelletization technique. Since the quality of statistically designed 
experiment depends on the good parameter settings, preliminary experiments were performed 
to establish suitable settings for the process and formulation variables. Using the settings found 
on the basis of the pre-experiments, a Vertex-Centroid design for the optimization of pellets size 
was performed. 
Pelletization procedure 
The starting materials were sieved through 0.5 mm sieve, mixed for 6 minutes in Turbula mixer, 
type T2C (Willy, Bachofen AG, Basel, Switzerland) and 600 g of powder mixture was loaded 
into the equipment. Formulations for the two drug loading levels are presented in the Table 4.9. 
From the Table 4.9 it can be seen that lactose monohydrate has been used as filler in order to 
keep the mass of loaded powder constant. It was assumed that difference of only 8% in the 
quantity of lactose monohydrate will have no influence on the pellets characteristics. 
Temperature and flow rate of fluidizing air were set to 28°C and 80 m3/h in all experiments. After 
the fluidizing air was initiated, air gap has been set to approximately 2.8 kPa by elevating the 
rotor plate and rotation of rotor plate has been started.  
 
Table 4.9. Excipient proportions used in the study 
 
Excipients 
Proportion (w/w %) 
8% drug load 
Proportion (w/w %) 
16% drug load 
MCC  35 35 
Lactose monohydrate 38.5 30.5 
NaCMC  10.5 10.5 
Magnesium carbonate heavy 7 7 
Sodium lauryl sulphate 1 1 
Balocel quantity was kept constant for all runs (70 w/w %) 
 
Powders were mixed for 5 minutes in preheated equipment and than HPC binder solution (4% 
w/v) was sprayed tangentially onto the moving powder mixture presented in the Table 4.9, 
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through 0.8-mm nozzle diameter. The spray rate and the drug load were varied according to the 
design (see Table 4.12). The amount of binder solution which was necessary to obtain pellets 
was 470 g. It was determined in pre-experiments and kept constant for all experiments along 
with the other process variables.  
 
Table 4.10.Process parameters during process phases (GPCG-1) 
 
Process phase 
Process parameters 
Binder addition Spheronization Drying 
Air flap (%) 40 40 43 
Air flow (m3/h) 80 80 80 
Inlet air temperature (°C) 28 28 35 
Atomizing air pressure (bar) 2.5 - - 
Pressure difference product (kPa) 2.8 - 3.1 2.6 - 2.8 2.5 – 2.8 
Rotor speed (%) Design 80 – 90 50 
Time (min) 21 - 35 7 10 - 15 
 
Immediately after stopping the liquid addition, samples of about 2 g were drawn with the 
sampling tube of the equipment for the determination of the moisture content and the nozzle 
was removed. Moisture content was determined using infra-red balance (Mettler LP16 drying 
unit, Mettler PE360, Mettler Toledo). One gram of the sample was tested on moisture content at 
temperature of 105°C for 15 minutes. 
After addition of determined quantity of binder solution, process was transferred to 
spheronization phase, followed by drying phase. Process parameters of all three phases are 
presented in the Table 4.10.  
A Vertex-Centroid Design, quadratic (D-optimal), was used to find the optimal levels for spray 
rate, rotor speed and drug load on chosen dependent variables, geometric mean diameter by 
weight and moisture content. The independent variables and their levels are shown in the Table 
4.11. The geometric mass mean diameter was calculated according to the procedure and 
equation given by (Fonner et al., 1981). Generated design and evaluation of the results was 
conducted using Stavex.  
 
Table 4.11. Independent variables and their levels  
 
 
Factors 
 
 
Level - 
 
Level + 
Spray rate (rpm) A 6 10 
Rotor speed (%) B 50 80 
Drug load (%) C 8 16 
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Design consisted of all possible combinations off all factors, at all levels. Table 4.12 presents a 
matrix design with 14 generated runs which were carried out in randomized order. 
 
Table 4.12. Composition of experimental formulations (runs) Vertex-Centroid Design, quadr.; (D-opt.) 
 
Run Spray rate Rotor speed Drug load
  rpm % %
1 6 50 8
2 6 50 16
3 6 80 8
4 6 80 16
5 10 50 8
6 10 50 16
7 10 80 8
8 10 80 16
9 10 65 12
10 8 80 12
11 8 65 16
12 6 50 12
13 6 65 8
14 8 50 8
 
 
Influence of MCC and lactose ratio on production and properties of pellets 
As a part of preliminary investigation influence of quantity of lactose monohydrate, which was 
used as water soluble filler necessary to obtain the same mixture loading, on size and 
properties of pellets was investigated. Even though the difference of MCC and lactose 
monohydrate loading in the design was 8% (w/w) (see Table 4.9) wider range has been tested. 
Influence of 15% of difference of lactose monohydrate in the formulation on pellet size, porosity, 
true density and dissolution was tested (see Table 4.13). 
 
Table 4.13. Tested formulations on influence of quantity of lactose monohydrate 
 
Excipients 
Proportion (w/w %) 
Trial 1 
Proportion (w/w %) 
Trial 2 
MCC  35 35 
Lactose monohydrate 34.5 49.5 
NaCMC  10.5 10.5 
Magnesium carbonate heavy 7 7 
Sodium lauryl sulphate 1 1 
Lansoprazole 12 12 
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Production of pellets was performed using process parameters described in binder addition 
phase in Table 4.10 with the spray rate of 10 rpm’s and rotor speed of 65%. Quantity of binder 
solution was kept constant at 470 g, as described previously in the pelletization procedure. 
4.4.2. Protective coating of pellets 
Protective coating of optimized pellets obtained with direct pelletization was performed only on 
the pellets from run 9 (Table 4.12), since these pellets had desired pellets size (range of 500 
microns) and sphericity (Table 5.12).  
Protective coating was performed on a small scale fluidized bed Mini-Glatt (Glatt GmbH, Binzen, 
Germany) using a bottom spraying technique, without Wurster insert, with the nozzle size 0.5 
mm. Batch size of 80 g of pellets was coated with 2.0 % (w/w) hydroxypropylmethyl cellulose 
solution. Coating of pellets with the solutions containing higher amount of binder was not 
applicable with Mini – Glatt. Before coating it was necessary to add 1.0 % (w/w) of talc to pellets 
to decrease the electrostatic charging and prevent retention of pellets on the walls of fluidized 
bed. Pellets were coated up to the weight gain of 4% using process parameters described in 
Table 4.14. Binder solution was applied using pump (Flocon 1003 Periflo), with the hose size 
4.8 mm in diameter and the quantity of applied binder was measured using balance (PG5002-S 
Delta-Range, Mettler – Toledo). Temperature inside the fluidized bed was monitored with 
temperature sensor Testo 925 (Testo GmbH, Lenzkirch, Germany). 
 
Table 4.14. Protective coating process parameters with the Mini - Glatt 
Process phase 
Process parameters 
Coating Drying 
Inlet air pressure (bar) 
(m3/h)* 
0.45 – 0.55 
28.5 – 32.7* 
1.4 
68.7* 
Inlet temperature (°C) 33 – 34 35 
Atomizing air pressure (bar) 1 – 1.2 - 
Spray rate (g/min) 1.05 – 1.4 - 
Fluidized bed temperature (°C) 24 – 26 33 
Duration of process (min) 170 25 
*Values expressed in m3/h according to the equation: y=42.284x+9.479 R2=0.9077, y: m3/h, x: bar 
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4.4.3. Enteric coating of pellets 
Enteric coating suspension was applied on selected pellets according to the scheme presented 
in Table 4.17. Enteric coating dispersion in the quantity of 20% solids was not applicable in the 
case of Mini-Glatt, because of the continuous blockage of the nozzle and for this reason enteric 
dispersion containing 10% solids has been applied (same composition as described in Table 
4.8 with addition of distilled water to adjust 10% solids). Coating was conducted on bottom 
spraying fluidized bed Mini-Glatt (Glatt GmbH, Binzen, Germany), without Wurster insert, using 
a 0.8 mm nozzle. Batch size of 60 g of pellets was coated until 20% of solid enteric polymer has 
been applied using the same pump type, temperature sensor and balance as described for 
protective coating (Chapter 4.4.2). Process parameters for enteric coating on Mini-Glatt are 
presented in the Table 4.15. 
 
 
Table 4.15. Enteric coating process parameters (Mini-Glatt) 
 
Process phase 
Process parameters 
Coating Drying 
Inlet air pressure(bar) 
(m3/h)* 
0.3 – 0.9 
22.2 – 47.5 
1.2 
60.2 
Inlet temperature (°C) 30 – 32 35 
Atomizing air pressure (bar) 1.5 – 1.7 - 
Spray rate (g/min) 0.38 - 
Fluid bed temperature (°C) 25 – 27 33 
Duration of process (min) 210 20 
*Values expressed in m3/h according to the equation: y=42.284x+9.479 R2=0.9077, y: m3/h, x: bar 
 
The process had to be interrupted for several times because of the nozzle blockage and 
agglomeration of the pellets.  
4.5. Characterization of drug-loaded pellets 
4.5.1. True density  
The true density of pellets was determined using an AccuPycTM 1330 Helium Pycnometer 
(Micromeritics, Norcross, USA) with a sample cell of a known volume 12.0530 cm3. The mass of 
the sample was calculated as a difference between mass of filled pycnometer sample cell and a 
mass of empty pycnometer sample cell. The volume was determined by purging the sample 10 
times with helium. First 5 runs were considered as an equilibrating procedure. Average value for 
density was taken from the next 5 runs. The procedure was carried out three times for each 
sample and mass of sample was approximately 5 grams. 
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4.5.2. Size distribution of pellets 
Laser diffaction method 
Particle size distribution measurement of pellets prepared with solution/suspension layering has 
been performed on Mastersizer 2000 (Malvern Instruments, Worcestershire, UK) using dry unit 
Scirocco 2000. The measurement was carried out 3 times for each sample. 
Dry powder laser diffraction has been conducted with optical characteristics of particle refraction 
index 2.500, absorption 0.1. An obscuration value in the range of 1-10% in all measurements as 
obtained (2.8 – 3.0%). Vibration feed rate was set to 50% with air as dispersion medium with 
pressure of 2 bars. With the software (Malvern) the particle size distribution, including mean and 
median particle size was calculated from raw data. 
Sieve analysis 
The size distribution of pellets produced by direct pelletization, for the particle size optimization, 
was determined by sieve analysis of 100 g of sample using a vibrating sieve (Retsch, S&H AG, 
Arlesheim, Germany). The sieves of 0.9, 0.125, 0.180, 0,250, 0.355, 0.500, 0.710, 1.0 mm were 
shaked for 10 minutes on vibration amplitude of 55. 
4.5.3. Shape and surface morphology of pellets 
Coated and uncoated pellets and the cross-section of the pellets were sputtered with gold 
palladium and than observed with a scanning electron microscope (SEM) Philips ESEM XL 30 
FEG at a voltage of 5 and 10 KV using magnifications of x60, x120, x300, x1000. 
4.5.4. Porosity of pellets 
Porosity measurement of pellets, with and without enteric coating, was conducted on a 
PoreSizer 9320 System (Micromeritics) with software version 2.05. The PoreSizer measures the 
volume distribution of pores in material by mercury intrusion or extrusion. Empty penetrometer 
for powders (penetrometer no. 920-61708-01) was calibrated (n=3) and determined bulb volume 
was 5.2927cm3. Approximately 2 g of sample (2/3 of the volume of the penetrometer) were filled 
in penetrometer. Sample was evacuated until the pressure reached 50µm Hg and than mercury 
was introduced. Low pressure run was conducted in a left low pressure port until the pressure 
reached 25 psia. Mass of penetrometer with the sample and mercury was checked on a 
balance and noted, and than penetrometer was transferred to the high pressure chamber, 
where the mercury was introduced in the pores with the pressure up to the 30 000 psia. 
4.5.5. Measurement of pellet pH 
Measurement of pH slurry of pellets was conducted using pH meter (Metrohm, pH Meter 744) 
after calibration with standard calibration solutions of pH 4.05 and pH 7.09. The uncoated 
pellets were ground into fine particles using mortar and pestle and quantity of 2 g of pulverized 
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material was mixed for 5 minutes in 20 ml of distilled water, and pH of prepared slurry of pellets 
was measured (Bruce et al., 2003). 
4.5.6. Assay 
HPLC  
Lansoprazole content in pellets (n=3) prepared using solution/suspension layering was 
determined using high pressure liquid chromatography (HPLC) under following conditions: 
mobile phase water:acetonitrile:triethylamine (60:40:1) with pH of 7.0; diluent 
water:acetonitrile:triethylamine (60:40:1) pH of 10.0; flow rate about 1 mL/min; detection 
wavelength 285 nm. Internal standard solution 4'-ethoxyacetophenone was prepared dissolving 
3 g of 4'-ethoxyacetophenone (Sigma Aldrich) in 400 ml of acetonitrile, HPLC grade (Merck, 
I285991 612). This method was official method described in USP 28 (USP, 2006b). 
Resolution solution was prepared in concentration of 0.1 mg/ml of USP lansoprazole and USP 
lansoprazole related compound A RS [2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-
pyridyl]methyl]sulfonyl]bezimidazole] (C16H14F3N3O3S, Mw 385.36, USP standard, lot no. ROB 
311, USP) in diluent. Obtained resolution between two major peaks was 7.  
Lansoprazole standard solution was prepared in concentration of 3.0 mg/ml in a mixture of 0.1M 
sodium hydroxide and acetonitrile (3:2). 25 ml of the solution and 5 ml of internal standard 
solution was diluted up to 50 ml with a diluent, and furthermore diluted with diluent to obtain 
concentration 0.1 mg/ml of lansoprazole. 
Volume of 10 µL of resolution solution, standard solution and final solution were injected in 
HPLC (Shimadzu LC-2010A) using Hypersil BDS column (C18, 4.6-mm × 25-cm column, 5-µm, 
Thermo Scientific, Waltham, US). 
Mass of pellets equivalent to 300 mg of lansoprazole were weighed to a 300 ml conical flask. 60 
ml of 0.1N NaOH was added and sonicated until complete disintegration. After disintegration 20 
ml of ACN and 20 ml of internal standard solution was added, shaked well and centrifuged for 
15 minutes on 4000 rpm’s. Supernatant was diluted with diluent to obtain concentration of 
lansoprazole about 0.1 mg/ml. 
Quantity of lansoprazole (mg) was calculated using Equation 4.9: 
 
Rs
Ru
D
LC ⋅  Equation 4.9 
 
where L is the labeled quantity of lansoprazole in mg, C is concentration in mg/ml of 
lansoprazole standard in the standard solution, D is the concentration in mg/ml of lansoprazole 
in the sample preparation, based on the labeled quantity of lansoprazole in the pellets taken 
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and the extend of dilution; and Ru and Rs are the peak responses ratios obtained from the 
sample and standard preparation, respectively. 
UV/VIS spectrophotometry 
Second method which was employed for determination of lansoprazole content in pellets 
prepared by direct pelletization is UV/VIS spectrophotometry proposed by (ölzaltin, 1999). 
Lansoprazole stock solution was prepared by dissolving 100 mg of lansoprazole in 60 ml of 0.1 
N NaOH and adjusting to 100 ml with phosphate buffer pH 6.6. Further dilutions were performed 
with 0.01 N NaoH solution.  
The mixture of 0.1 N NaOH and phosphate buffer pH 6.6 (3:2) was used as a reference 
solution. Absorbance was measured UV/VIS Spectrophotometer Beckman DU 530 on 
wavelength of 292 nm.   
A sample of pellets equivalent to the mass of 15 mg of lansoprazole (n=3) was weighted and 
transferred to a 100 ml volumetric flask. 0.1 N NaOH was added in the quantity of 60 ml and the 
mixture was sonicated for 15 minutes, and than filled up to the volume of 100 ml with phosphate 
buffer pH 6.6. Further dilutions, for the linear range were made with 0.01 N NaOH. 
Resulting pellets from the direct pelletization which were intended for accelerated stability 
testing were tested on content using both techniques in order to confirm published UV/VIS 
spectrophotometry method. 
4.5.7. Gastric resistance and dissolution of coated pellets  
Samples of pellets in determined size (n=6) were tested for dissolution according to the USP 
monograph for “Delayed Release Lansoprazole Capsules” in SOTAX AT7 (SOTAX AT/, 
Allschwil/Basel, Switzerland) dissolution paddle apparatus. Rotating speed of paddles was 75 
rpm and temperature of medium was kept at 37°C ± 0.5°C.  
Non-encapsulated samples were tested on gastric resistance in 500 ml of 0.1 N HCl with pH 1.2 
for 60 minutes. Buffer stage medium consisted of 900 ml which was a mixture of acid stage 
medium or modified acid stage medium and phosphate buffer concentrate with adjusted pH to 
6.8. 
Samples were removed from the dissolution media in different time intervals during 60 minutes 
of acid stage and further 60 minutes of buffer stage testing.  An equal volume of dissolution 
medium, warmed to 37°C, was added after each sampling in order to keep a constant volume.  
Quantity of drug release was determined using UV/VIS Spectrophotometer Beckman DU 530 on 
wavelength of 306 nm for the acid stage, and 286 and 650 nm for the buffer stage.  
In the USP 28 monograph for “Delayed Release Lansoprazole Capsules” it is stated that no 
more than 10% release of lansoprazole in one hour in 0.1 N HCl and no less than 80% release 
of lansoprazole after one hour in phosphate buffer pH 6.8 is allowed. 
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4.5.8. Gastric resistance and dissolution of pellets in modified acid stage 
medium pH 4.5   
Enteric performance and dissolution of lansoprazole pellets is routinely evaluated using USP 
delayed release method in acid media at pH 1.2 in order to determine the effective quantity of 
enteric polymer and buffer media at pH 6.8. While this method may be appropriate for general 
enteric performance, the in-vivo stomach pH for patients may be significantly different. As a 
result of drug action, the gastric acid secretion will be reduced and it has been reported that in-
vivo stomach pH for PPI patients on a multiple dose regimen is higher (>pH 4) and modified bio 
relevant media, which better simulates the gastric environment, has been suggested (Fegely et 
al., 2006; Rohss et al., 2004). Non-encapsulated samples were tested in 500 ml modified acid 
stage medium, consisting of acetate buffer with pH 4.5. 
Buffer stage medium consisted of 900 ml which was a mixture of modified acid stage medium 
(acetate buffer pH 4.5) and phosphate buffer concentrate with adjusted pH to 6.8. 
Samples of pellets in determined size (n=6) were tested for dissolution according to the USP 
monograph for “Delayed Release Lansoprazole Capsules” in SOTAX AT7 (SOTAX AT, 
Alschwill, Basel, Switzerland) dissolution paddle apparatus. Rotating speed of paddles was 75 
rpm and temperature of medium was held at 37°C ± 0.5°C.  
Samples were removed from the dissolution media in different time intervals during 60 minutes 
of acid stage and further 60 minutes of buffer stage testing. An equal volume of dissolution 
medium, warmed to 37°C, was added after each sampling in order to keep a constant volume.    
Quantity of drug release was determined using UV/VIS Spectrophotometer Beckman DU 530 on 
wavelength of 286 nm.  
In the USP monograph for “Delayed Release Lansoprazole Capsules” it is stated that no more 
than 10% release of lansoprazole in one hour in 0.1 N HCl (in this test modified acid stage 
medium) and no less than 80% release of lansoprazole after one hour in phosphate buffer pH 
6.8 is allowed. 
4.6. Effect of temperature on degradation rate constant in solid state and 
prediction of shelf-life  
In this study isothermal stability testing of a product, with addition of moisture effect on stability, 
and the prediction of shelf-life using an Arrhenius equation has been employed. First it was 
necessary to determine the order of decomposition reaction and generally accepted method in 
stability is least squares linear regression.  
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4.6.1. Solution/suspension layered pellets 
Accelerated stability testing was performed on lansoprazole delayed release pellets containing 
20% enteric coating (calculated on solid polymer) prepared using solution/suspension layering 
(see Table 4.1) in order to evaluate the effect of presence of different alkaline compounds (pH 
adjusters), presence and absence of protective coating, and influence of type of neutral core on 
chemical stability of lansoprazole at different storage conditions. Accelerated stability testing of 
pellets in open glass bottles was performed at thermostatically-controlled ovens at temperatures 
of 30°C, 40°C, 55°C and 60°C at 79% RH.  
Accelerated stability testing was also conducted on pellets from run 5 with enteric coating 
polymer in quantity of 20, 22, 24 and 26%, at previously described temperature and humidity 
conditions, to investigate the effect of percentage of Eudragit L 30 D-55 on stability of 
lansoprazole in solid dosage form. 
Non-encapsulated samples were collected at different time intervals and examined on 
lansoprazole content using HPLC conditions described in chapter 4.5.6.  
4.6.2. Pellets prepared with direct pelletization 
For the comparison of the stability of lansoprazole in pellets prepared using different 
techniques, pellets prepared in the run 9 (see Table 4.12) using direct pelletization procedure 
were investigated, since they had desired pellet size and acceptable sphericity. Pellets were 
prepared using rotary processor (GPCG-1, Glatt, Germany) with the drug load of 12%, spray 
rate of 10 rpm’s, and rotor speed of 65 %. Other process parameters were as described 
previously in Table 4.10. Same accelerated stability conditions described previously (Chapter 
4.6.1) have been applied. Formulation variables which have been taken into consideration are 
presence and absence of magnesium carbonate heavy, presence and absence of protective 
coating (HPMC formulation presented in Table 4.4). Pellets core formulations are presented in 
the Table 4.16. 
 
 
Table 4.16. Direct pelletization core formulations for stability studies 
Ingredients 
Proportion (w/w % 
Formulation I 
Proportion (w/w %) 
Formulation II 
Lansoprazole 12 12 
MCC  35 35 
Lactose monohydrate 34.5 41.5 
NaCMC  10.5 10.5 
Magnesium carbonate heavy 7 - 
Sodium lauryl sulfate 1 1 
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Further more, pellet cores with formulation I and II were coated according to the scheme 
presented in the Table 4.17 using the procedure described in Chapter 4.4.2 and 4.4.3. 
 
 
Table 4.17. Scheme of pellet formulations from direct pelletization under stability study 
 Protective coating  Enteric coating  Trial no. 
Formulation I yes Yes 1 
 no Yes 2 
Formulation II no Yes 3 
 yes Yes 4 
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5. Results and Discussion 
 
5.1. Solubility of lansoprazole 
Solubility study of lansoprazole was conducted at times beyond the equilibration to verify that a 
state of true equilibrium is reached. Estimation of solubility in water and phosphate buffer pH 6.8 
was performed in different time intervals in order to determine the real thermodynamic 
equilibrium.  
The solubility of lansoprazole in water at 25°C and phosphate buffer pH 6.8 at 37°C is 
presented in Table 5.1. 
 
Table 5.1. The solubilities of lansoprazole in water at 25°C and phosphate buffer pH 6.8 at 37°C 
Medium Solubility (µg/ml) ± RSD (%) (time) 
Water (n=3) 34.478 ± 0.413 (18 h) 33.571 ± 5.46 (24 h) 
pH 6.8 (n=3) 44.162 ± 8.259 (24 h) 43.892 ± 1.46 (32 h) 
 
 
The solubility of lansoprazole in water at 25°C was very low. It was not surprising since it was 
known that lansoprazole has low water solubility and that solubility of lansoprazole increases 
with the increase in pH. The system equilibrium concentration was achieved in 24 hours of 
measurement and the average sample concentration from 18 to 24 hours differed by less than 
2%. Averaged solubility was 34.0245 µg/ml in water at 25°C. No reference in the literature on 
the experimentally determined solubility of LSP in unbuffered water at 25°C was found. Kristl 
and Vrecer, 2000, found that the solubility of LSP at 25°C in pH 7 is 29.55 µg/ml. 
The concentration of lansoprazole in buffer solution at a temperature of 37°C and pH of 6.8, 
averaged 44.162 µg/ml and was achieved in 24 hours. Obtained results were higher than the 
results obtained previously by Zhang et al., 2008. They found that solubility of LSP at 37°C in 
phosphate buffer pH 7.4 is 32.101 µg/ml. The results show that LSP becomes increasingly 
ionized with the increase in pH. 
5.2. FTIR and X-Ray diffractometry 
In order to confirm the identity of lansoprazole, FTIR spectroscopy and PXRD was conducted.  
The infra-red spectrum of lansoprazole powder was in agreement with the infra-red spectrum of 
lansoprazole USP standard. Both powder samples showed the same characteristic absorption 
peaks at 3240, 2984 and 2930, 1476 and 1458, 1282 and 1268, respectively, denoting 
stretching vibrations of –NH, aromatic –CH-, –NH bending and aromatic C-O stretching (Cipla, 
   Results and Discussion 
 
  76 
2005a; Zhang et al., 2007). Corresponding FTIR spectrum is presented in the Appendix in 
Figure 8.1. 
Lansoprazole shows characteristic peaks at 12.557°, 14.499°, 16.952°, 17.884°, 18.892°, 
22.264° and 27.854° (Zhang et al., 2007). Lansoprazole X-ray diffractogram is presented in 
Appendix in the Figure 8.2. 
 
5.3. Thermal properties of lansoprazole 
Although the drug is commercially available on the market, literature reports on thermal 
characterization and melting behavior of the drug substance are contradictory. US 
Pharmacopoeia 25 states that lansoprazole melts at about 166 C, with decomposition USP, 
2006b. For lansoprazole a range of melting point was reported (Tm=178 – 182°C) (O'Neill, 1996) 
however the producer of the lansoprazole used in the present work reported a melting point of 
168 - 169°C (Cipla, 2005b) and no measurement conditions were provided. In the study of 
Zhang et al., 2008, DSC curve of lansoprazole obtained on heating rate of 5°C/min exhibits a 
sharp endothermic peak at 178.6°C. 
The reason for these contradictory reports could be that the melting behavior of sulfoxides 
known as proton pump inhibitors is uncommon showing significant heating rate dependence 
and melting of the substance is followed by decomposition of the substance, which makes a 
determination of the melting point very difficult. The other reason for inconsistency of reported 
data could be that different methods for determination have been applied. As a result, there is 
confusion in the melting point values quoted in the literature.  
In a recent study, Rosenblatt et al., 2005, reported on the thermal behavior of one proton pump 
inhibitor – omeprazole. Using thermal and chromatographic analyses, the authors reported that 
the melting point depression at low heating rates is due to eutectic behavior of the drug with its 
decomposition products formed at low heating rates. At heating rates above 20°C/min, the 
melting point of omeprazole becomes independent of the heating rate due to absence of 
decomposition products. Furthermore, no differential scanning calorimetric data on the influence 
of scanning rate on the thermal behavior of lansoprazole were available. Kotar et al., 1996, 
have declared that lansoprazole exists in two polymorphic forms designated as form A and form 
B. Form B is unstable and is completely converted to the stable form A under physical stress 
(milling) or even after some time at ambient temperature. DSC curve of the form A showed only 
an endothermic peak at 180°C, while the form B showed one exothermic peak at 102°C and 
one endothermic peak at 180°C. In the literature no DSC curve has been found or provided by 
Kotar et al., 1996.  
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Obtained DSC curve of lansoprazole (see Figure 5.1) on all heating rates exhibited two different 
events. Endothermic peak corresponds to the melting of the drug and it is immediately followed 
by sharp symmetric exothermic peak. High heating rates (20 - 40°C/min) led to endothermic 
peaks at higher temperatures, while lower heating rates (2.5 - 10°C/min) led to a shift of the 
peak to lower temperatures, what can be seen in the Figure 5.2. Difference between the onset 
temperature obtained with the lowest heating rate and with the highest applied heating rate was 
around 15°C. The most pronounced shift of the melting peak between two consequent 
measurements was found to be 6.5°C and it was observed between heating rates of 2.5°C/min 
and 5°C/min (see Figure 5.2), while with the application of higher heating rates this difference 
decreased to 1°C. From this values can be seen that higher heating rates led to a smaller 
difference in the melting point between consecutive measurements (see Figure 5.2).  
However, even the highest applied heating rate of 40°C/min did not show independence on the 
heating rate and the shift of the melting point (Tonset = 187°C) was still observed in comparison 
with the melting point obtained with 30°C/min (Tonset = 188°C). 
Same dependence of the heating rate was observed with the USP standard of lansoprazole 
(Figure 5.2). 
 
 
 
Figure 5.1. Shift of the DSC curve of lansoprazole using different heating rates 
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Figure 5.2. Onset temperature of the endothermic event observed by DSC 
 
From the Table 5.2 can be seen that the onset temperatures obtained from the USP standard of 
lansoprazole differ from the ones obtained with the sample of lansoprazole, but also show high 
heating rate dependence. Difference can be explained with the purity and the smaller particle 
size of lansoprazole USP standard.  
 
Table 5.2. Comparison of onset temperatures obtained by DSC and Hot-stage microscope 
 
Heating rate 
(°C/min) 
Onset temperature 
endothermic DSC (°C) 
Cipla 
Onset temperature DSC 
(°C) USP  
Melting temperature  Hot 
Stage (°C) Cipla 
2.5 173.04  170.94 174.30 
5.0 179.56 176.46 179.00 
10 182.76 179.98 183.50 
20 185.74 182.35 184.30 
30 187.01 184.08 185.70 
40 188.22 185.25 186.50 
 
 
Contrary to the findings of Rosenblatt et al., 2005, for omeprazole, lansoprazole exhibited 
variation in the melting point values even at the high heating rates. This indicated that in the 
case of lansoprazole, the heating rate dependence was larger than in the case of omeprazole. 
For the endothermic peak it was found that the height of the peak increased with the increase in 
heating rate, and even the lowest applied heating rate (2.5°C/min) did not lead to its 
disappearance. This finding was contrary to the findings of Rosenblatt et al., 2005, who noticed 
that heating rate of 2.5°C/min and lower, lead to disappearance of the endothermic peak in 
lansoprazole, meaning that decomposition in the sample starts very early and no melting point 
can be detected, but no DSC curve was provided. Also, they reported that exothermic peak was 
clearly visible at 30°C/min, while in our case exothermic peak was observed on all heating rates 
in the form of sharp symmetric peak.  
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At heating rate of 2.5°C/min, the observed melting peak temperature was 173.04°C ± 0.17 
(Tonset = 173.04°C ± 0.06) with an apparent heat of fusion of 89.08 J/g ± 1.84. The exothermic 
effect was peaked at 175.33 ± 0.14 (Tonset = 174.75°C ± 0.12) with enthalpy value of 138.46 J/g 
± 0.69. With an increase in the heating rate, increase in the peak height, as well as an increase 
in the enthalpy, was observed for both endothermic and exothermic event. At heating rate of 
40°C/min, melting peak temperature was 190.85°C ± 0.03 (Tonset = 188.22°C ± 0.09) with an 
apparent heat of fusion of 166.56 J/g ± 11.51. Peak temperature of exothermic event at 
40°C/min was 195.41 ± 0.11 (Tonset = 191.88°C ±0.01) with enthalpy value of 248.38 J/g ± 5.08. 
More detailed results of thermal events are presented in the Appendix (Table 8.1 and Table 
8.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. DSC thermogram with heating rate of 2.5°C/min of lansoprazole Cipla and lansoprazole USP 
standard (light blue) 
 
Lansoprazole was further investigated by thermogravimetric analysis, which reveals a weight 
loss upon heating of the sample. The total weight loss is the difference between the initial 
weight and the final constant weight of the dry solid. The temperature, at which weight loss 
began, depended on the heating rate applied (see Figure 5.4). Two regions were observed in 
the obtained TGA profiles. The first region, assuming that the only volatile component is water, 
should present a weight loss connected with the water content and its starting point depended 
on the heating rate applied. At the lowest applied heating rate of 1°C/min the weight loss started 
at around 70°C and reached a weight loss of 6% until the inflection point. For the highest 
heating rate applied (10°C/min) presented in the Figure 5.4, water loss region was not 
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observed. According to the results of Karl Fisher titration, sample of lansoprazole contained 
0.06% of water, so the weight loss found at the 1°C/min, may not be related to water loss, but to 
the weight loss of substance caused by early decomposition. 
The second region of TGA curve presented a decomposition of the product. From the Figure 5.4 
can be seen that heating the sample up to the temperature of 300°C a considerable weight loss 
of substance from 27% up to the 53% of weight occurred, which confirmed a decomposition of 
the substance. For lower heating rates, weight loss began at lower temperature (around 177°C 
for 1°C/min) and reached higher values of weight loss (53% for 1°C/min) comparing to the 
values obtained with the higher heating rates (190°C for 20°C/min heating rate with weight loss 
of 27%).  
 
 
 
 
Figure 5.4. TGA curve of lansoprazole: heating range from 60°C to 350°C, with 1°C/min-green line, 
2.5°C/min-dark blue, 10°C/min-light blue line and 20°C/min red-line 
 
 
For comparison of thermogravimetric results with the values obtained with DSC (see Figure 5.5) 
temperature of 1% weight loss was determined.  
For the lower heating rates (2.5°C/min, 5°C/min, 10°C/min and 20°C/min) the temperature of 
1% weight loss is almost identical to the onset temperature of exothermic event obtained with 
DSC. From the Figure 5.5 can be seen that for the higher heating rates of 30°C/min and 
40°C/min, a small difference in temperature values of 1% weight loss from the onset values of 
DSC exotherm is observed. 
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Figure 5.5. Comparison of the DSC onset temperatures with the values of 1% weight loss measured with  
TGA 
 
 
In the case of the onset values of endothermic peak, the temperature of 1% weight loss showed 
smaller difference on lower heating rates (2.5°C/min, 5°C/min and 10°C/min), but the difference 
become bigger with the increase in the heating rate.  
The 1% weight loss, as a part of decomposition process, starts at the higher temperature than 
the melting of the substance (presented in Figure 5.5) and corresponded to the onset values of 
exothermic event obtained with DSC. Since the temperature of 1% weight loss is higher than 
the onset temperature of endothermic peak, even at the low heating rates, presence of a sharp 
symmetric peak at all heating rates can be explained.  
Possible decomposition of the substance prior to reaching the onset temperature of melting, 
and formation of eutectic of lansoprazole and its degradation products on low heating rates, 
could be an explanation of the melting point depression, as it was observed for omeprazole by 
Rosenblatt et al., 2005. In addition to this assumption, goes the fact that the smallest difference 
between the onset temperature of melting and temperature of 1% weight loss was observed at 
low heating rates of 2.5°C/min, 5°C/min and 10°C/min (see Figure 5.5).  
Melting behavior, which was visually observed with the hot-stage microscope, found the melting 
temperature of LSP to be smaller than the one obtained with the DSC. The result was not 
surprising since the hot-stage microscopy presents only a visual tool for investigation of thermal 
properties. Therefore, it is subjected to variability prone to inter-individual observation.  
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a) 64,2°C       b) 179.0°C 
              
c) 182.4°C      d) 183.7°C  
Figure 5.6. Melting and decomposition of lansoprazole observed by Hot-stage microscopy with applied 
heating rate of 5°C/min: a) unheated sample, b) beginning of melting, c) melting of the substance with 
decomposition and d) end of melting 
 
 
HSM confirmed that the endothermic event observed on DSC corresponded to the melting of 
the substance. In the Figure 5.6 a process of melting and decomposition of lansoprazole at the 
heating rate of 5°C/min is presented. It can be seen that at the same time with the melting, 
decomposition of the substance occurred, what can possibly be seen as liquefaction and 
darkening of the crystals (Figure 5.6, C). The process of decomposition prior to melting was 
even more pronounced when the lower heating rates of 1°C/min and 2.5°C/min were applied.  
In the case when the higher heating rate was applied (40°C/min) process of melting presented 
in the Figure 5.7 did not reveal presence of simultaneous process, since no darkening of the 
crystals was evident. 
Melting point of lansoprazole was also determined using a simple capillary method described in 
European Pharmacopoeia with Kofler bench (Mettler Toledo DR45). Repeated measurement of 
three samples gave the value of 166°C. Apparatus automatically registers the melting point and 
for this reason influence of the operator is excluded. 
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a) 59.7°C       b) 185.1°C 
             
c) 187.0°C      d) 188.4°C 
Figure 5.7. Melting and decomposition of lansoprazole observed by Hot-stage microscopy with applied 
heating rate of 40°C/min: a) unheated sample, b) beginning of melting, c) melting of the substance and d) 
end of melting 
 
Using the combination of DSC, TGA and Hot-stage microscopy it could be confirmed that the 
endothermic event obtained by DCS measurement corresponded to reported literature melting 
point range by O`Neill et al., 1996, and exothermic event can be assigned to decomposition 
process. Applied heating rates beyond 20°C/min leave no space for formation of eutectic and 
shift of the melting peak became less pronounced. 
In conclusion, a very dynamic method and exactly standardized measurement conditions, 
particularly with regards to heating rate (e.g., in DSC), have to be employed to enable reliable 
determination of a melting point of these decomposable substances. Even though lansoprazole 
melting point was highly influenced by heating rate, higher heating rates should be employed 
since they give lower variability of results (Table 8.1 and Table 8.2 in Appendix). Presence of 
exothermic peak at 102°C, characteristic for polymorphic form B reported in the work of Kotar et 
al., 1999, was not observed on all applied heating rates, and for this reason it can be concluded 
that LSP had polymorphic form A. 
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5.4. Powder characterization of drug substance 
The powder characteristics, including values for particle size, different densities (bulk, tapp and 
true density), and specific surface area are presented in Table 5.3. 
 
Table 5.3. Lansoprazole powder characteristics  
Characteristic of powder Obtained values ± RSD (%) 
Particle size (μm) (n=3) 
d (0.1) 
d (0.5) 
d (0.9) 
 
1,298 ± 0.36 
3,752 ± 0.55 
9,129 ± 0.32 
True density (g/cm3) (n=3) 1.509 ± 0.08 
Bulk density (g/cm3) (n=3) 0.385 ± 0.75 
Tapp density (g/cm3) (n=3) 0.505 ± 0.66 
Hausner ratio  1.312  
Carrs index (%) 23.76 
Specific surface area (m2/g) (n=3) 1.458 ± 12.27 
 
 
Even though the sizing of some powders can be fraught with problems (like nonreproducible 
results caused by cohesive nature of powders, poor control of ambient humidity, variable rate of 
introduction of particles, etc.) reported by Heng and Chan, 1997, and the measurement using 
the wet method is more preferred (Randall, 1995) dry powder feeder was used. Dry powder 
laser diffraction method for particle size measurement, which was proposed by producer of the 
substance, was determined to be more appropriate than the wet laser diffraction method, since 
the wet laser diffraction method showed a presence of agglomerates (see Figure 5.8). The air 
flow stream, which was used as a carrier in dry laser diffraction method, seemed to be more 
efficient in breaking the agglomerates present in the sample. 
From Table 5.3 it can be seen that 90% of drug substance had particle size under 9 µm, while 
50% of drug substance had particle size under 4 µm. In order to have a successful drug 
layering, the suspended material must be small in relation to the size of the substrate onto 
which it is being applied or the potency will be compromised, the overall yield will be low, a 
higher binder content may be needed and the resulting surface will be rough and porous. 
Particle size of the drug substance in relation to the substrate has to be 1:50 in order to have a 
good potency and yield (Jones, 2005b). Li et al., 1989, emphasized the importance of particle 
size and overall particle size distribution of drug on the yield and surface of indomethacin pellets 
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prepared with solution layering. They found that the finer powder under 10 μm gives the higher 
yield and smoother surface of pellets.  
Considering the SEM photographs (see Figure 5.9) low particle size and presence of 
agglomerates were confirmed. Lansoprazole particles appeared to be aggregates composed of 
plate-like crystals of equivalent size. 
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Figure 5.8. Particle size distribution of lansoprazole powder measured with dry and wet laser diffraction 
method 
 
Measurement of bulk density and specific surface area is very sensitive to sample preparation, 
especially if the powder used has a small particle size like lansoprazole. The flowability of the 
powder is related to the particle size and shape. Hausner ratio and Carrs index are measures of 
the relative importance of interparticulate interactions. In a free-flowing powder, such 
interactions are generally less significant, and the bulk and tapped densities will be closer in 
value. For poorer flowing materials, there are frequently greater interparticle interactions, and a 
greater difference between the bulk and tapped densities will be observed (USP, 2006a). 
From the SEM pictures (see Figure 5.9)  and the values obtained for densities, according to the 
classification by Wells, 1988, for Hausner ratio and Carr classification for Carr’s index powder 
can be characterized as a poorly flowable. A Hausner ratio of less than 1.20 indicates good 
flowability of the material, whereas a value of 1.5 or higher suggests a poor flow (Wells, 1988). 
The Carr index values of 5-10, 12-16, 18-21, and 23-28 indicated, excellent, good, fair and poor 
flow properties of the material, respectively. 
From characteristics of the powder it can be concluded that the drug layering onto the neutral 
core could be conducted using solution/suspension technique, while powder layering technique 
could be compromised with low flowability of the drug, if the process of drug addition is not 
optimized. 
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   a)       b) 
 
 
c) 
 
Figure 5.9. SEM photographs of surface of lansoprazole powder a) magnification x300 b) magnification 
x3000 c) magnification x10000 
 
5.5. Properties of sugar and MCC neutral pellets 
Substrate morphology and porosity plays and important role in the process of coating of 
multiparticulate systems. Higher substrate surface requires a higher quantity of deposited 
material to achieve the same action as a substrate with lower surface value (for example: 
dissolution).  
The properties of neutral pellets (sugar and MCC) including values for particle size, true density, 
specific surface area and porosity are presented and summarized in Table 5.4.  
From the summarized properties of neutral pellets (Table 5.4) and SEM pictures (see Figure 
5.11 and Figure 5.10) it can be seen that the neutral pellets differed in size, shape and surface 
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properties. Sugar pellets were bigger in size and more spherical in shape. More than 50% of 
sugar pellets had a size around 981 µm, while 50% of MCC pellets had 834 µm.   
 
Table 5.4. Properties of neutral pellets (n=3) 
Obtained values ± RSD (%) 
Property of pellets (n=3) 
Suglets® Ethispheres® 
Particle size (μm)  
d (0.1) 
d (0.5) 
d (0.9) 
 
721.21 ± 0.21 
981.04 ± 0.24 
1347.63 ± 0.23 
 
618.23 ± 1.22 
876.30 ± 1.28 
1241.59 ± 1.09 
Specific surface area (m2/g)  2.09 ± 1.44 0.50 ± 16.97 
True density (g/cm3)  1.52 ± 0.023 1.45 ± 5.26 
Porosity (%)  12.74 ± 0.39 15.33 ± 12.31 
 
According to the porosity values obtained for sugar and MCC pellets, neutral sugar pellets had 
lower porosity of 12.74% compared to MCC pellets which had porosity of 15.33%. The porosity 
of core particles is more critical in aqueous coating processes with latexes, while with the 
organic coating solution there is a good chance of filling the pores and stabilizing the surface 
area in the first phase of coating process (Lehman, 1994).  
Specific surface area of MCC pellets appeared to be significantly lower than the specific surface 
area of sugar pellets. This value correlated with the values obtained for particle size and 
porosity, since both of these properties contribute to the surface area. 
From the SEM pictures MCC pellets (Figure 5.10) also seemed to be spherical and smoother 
than the sugar pellets, from a visual point of view (see Figure 5.10, A). 
 
  
a) b) 
Figure 5.10. SEM photographs of MCC spheres: a) surface, magnification x100, b) surface, magnification 
x300  
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a) b) 
 
  
c) d) 
 
Figure 5.11. SEM photographs of sugar spheres: a) surface, magnification x30, b) surface, magnification 
x70, c) cross section, magnification x70, d) surface, magnification x2000 
 
During the active layering phase of neutral pellets in solution suspension technique of pellet 
preparation, sugar pellets were more sensitive to the spray rate than the MCC pellets. Lower 
spray rates had to be applied until the first layer was formed since pellets became sticky. The 
reason for this behavior could be found in sucrose being soluble in water, since the aqueous 
solution of binder was used. At the beginning of the coating process of MCC pellets in the 
fluidized bed, electrostatic charge was formed until the core was sufficiently moistened.  
 
5.6. Dissolution of pellets with shellac as enteric coating polymer 
In order to decide on the type and the coating level of enteric polymer necessary to obtain 
gastric resistance, pellets were coated with aqueous shellac dispersion containing 10%, 15% 
and 20% of solid shellac polymer. Gastric resistance and dissolution of lansoprazole from 
shellac coated pellets in 0.1N HCl and phosphate buffer pH 6.8 is presented in Figure 5.12. 
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Figure 5.12. Dissolution profiles of Shellac coated pellets (Run 1): a) untreated pellets in pH 1.2 and pH 
6.8, b) cured pellets (40°C, 8 hours) in pH 1.2. The bars represent standard error of the mean (n=6) 
 
Higher coating levels of solid shellac resulted in better gastric protection of the drug, but release 
of the drug in the buffer stage could not be achieved. Lower coating levels could not prevent the 
drug release in acid media, but the drug release in buffer media was higher. As it is shown in 
the Figure 5.12 a), coated pellets containing 10% and 15% of solid shellac could not prevent the 
release of lansoprazole in simulated gastric media with pH 1.2. Pellets containing 10% of 
enteric coating polymer released 38.7%, while pellets with 15% coating level released 12.2% of 
lansoprazole. Only pellets containing 20% w/w of shellac were able to meet the requirements of 
US Pharmacopoeia for lansoprazole delayed release (t60min≤10%) with the 7.4% of drug release 
in the 0.1N HCl. The reason for this high release in pH 1.2 could be explained by the presence 
of HPMC, a water soluble excipient which acts as a pore former (described in Chapter 4.3.2.1). 
Qussi and Suess, 2005, demonstrated that incorporation of 25% w/w of HPMC in the 
shellac/plasticizer coating solution increases porosity tenfold and the coating system could not 
prevent release of the drug in the acid media, but the drug release in pH 7.4 was complete. On 
the other hand, none of the coated pellets showed instant and complete drug release in the 
phosphate buffer media with the pH of 6.8 (t60min≥80%). Our result was contrary to the literature 
data. In the literature, Pearnchob and Siepmann, 2003, obtained a gastric protection with water 
soluble salt of shellac at a coating level of 10%, also achieving a rapid drug release in pH 6.8. 
Influence of thermal treatment on dissolution of shellac coated pellets was further investigated, 
even though a high concentration of plasticizer has been used. The curing procedure is often 
used to achieve complete film formation and to avoid changes in drug release during storage 
due to a further coalescence of particles, decrease in polymer mobility and reduction of free 
volume. While the majority of published studies (Pearnchob and Bodmeier, 2003; Siepmann et 
al., 2008) refer to curing as a procedure which slows drug release, in the case of lansoprazole 
pellets coated with shellac curing had an opposite effect. Curing time for 8 hours on 40°C on a 
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tray doubled the amount of drug released compared to untreated pellets (Figure 5.12, a). Pellets 
with 10%, 15% and 20% of solid shellac released (t60min) 84, 38 and 25% of drug in acid media, 
respectively. Possible explanation of the curing result could be that curing caused a leakage of 
the enteric coating and migration of lansoprazole through the pores to the surface of pellets, 
resulting in an increase of drug release (Figure 5.12, b), since it is reported by Bruce et al., 
2003, that depending on the drug solubility in the polymer drug can migrate into the coating.  
The results showed that the coating level is an important parameter and that low coating level 
can result in release of drug in acidic media, while high drug loading can lengthen the 
dissolution time in the intestinal area. Slow release of lansoprazole from shellac coated pellets 
in pH 6.8 could be attributed to the fact that the pKa value of shellac lies in the range of 6.9 – 
7.5 (Qussi and Suess, 2005). Possibly, highest coating level applied in this study (20% of solid 
polymer) with the 33% w/w of hydrophilic polymer could lead to a complete dissolution of drug in 
the buffer pH 7.4. 
Therefore no further investigation has been conducted in order to optimize the enteric coating 
formulation of shellac for dissolution in pH 6.8. Even though, the study of Riedel and Leopold, 
2005, showed that shellac, applied as enteric coating polymer had the lowest influence on 
benzimidazoles, omeprazole, another type of enteric polymer had to be chosen to achieve 
gastric resistance of pellets. 
5.7. Influence coating level of Eudragit L 30 D-55 on properties of pellets 
Obtained SEM photographs of pellets coated with different levels of anionic copolymer based 
on methacrylic acid and ethyl acrilate (1:1) (Eudragit L30 D-55) are shown in Figure 5,13.  
The morphology and surface of the pellets is clearly dependable on the type and the amount of 
applied layer. With the application of the consecutive layers on the surface of sugar pellets, 
surface became smoother and sphericity was maintained (see Figure 5,13).  
Increase in particle size of pellets coated with different amount of enteric coating polymer is 
presented in Table 5.5. 
  
Table 5.5. Particle size of lansoprazole pellets with different coating level of Eudragit L30 D-55 (n = 3) 
% (w/w) of solid enteric polymer d (0.1) ± RSD (%) d (0.5) ± RSD (%) d (0.9) ± RSD (%) 
20 832.66 ± 0.72 1118.42 ± 0.65 1485.76 ± 0.53
22 850.78 ± 1.57 1140.63 ± 1.49 1510.28 ± 1.33
24 854.72 ± 0.24 1145.87 ± 0.19 1516.4 ± 0.13
26 852.64 ± 1.25 1143.82 ± 1.36 1513.14 ± 1.23
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a) b) 
c) d) 
 
Figure 5.13. SEM photographs of surface of neutral sugar pellet magnification a) x70 and b) x2000, 
surface of lansoprazole pellet with pellet with 26% of enteric coating magnification c) x70 and d) x2000 
 
 
 
Increase in size from the neutral sugar pellet to the enteric coated pellets containing 20% of 
enteric polymer was approximately 130 μm (12.3% increase in size) and further addition of 
successive layers up to 26% of solid enteric coating polymer led to increase of 163 μm (14.3% 
increase).  
According to the literature data, it is necessary to apply films of approximately 20 to 30 μm 
thickness to achieve a mechanical stability and enteric resistance (Lehman, 1994). 
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a) b) 
Figure 5.14. SEM picture of cross section of a) sugar neutral pellet and c) lansoprazole pellet with 26% of 
solid enteric polymer with magnification of x200 
  
Values for the porosity, apparent density and average pore diameter obtained by mercury 
porosimeter are presented in the Table 5.6. Results showed that all tested pellets, regardless of 
the percentage of applied enteric coating polymer, had pores within the same range of size and 
the only significant difference in the cumulative volume of intruded mercury has been observed 
between pellets coated with 26% (solid enteric polymer) and pellets with lower quantity of 
methacrylic acid copolymer. Pellets containing 26% of solid enteric polymer had the lowest 
average pore diameter of 16.1 nm.  
 
Table 5.6. Experimental data obtained using mercury porosimeter 
Enteric coating 
(% of solid 
polymer) 
Average pore 
diameter 
(nm) ± RSD (%) 
Bulk density (g/ml) 
± RSD (%) 
Apparent 
(skeletal) density 
(g/ml) ± RSD (%) 
Porosity 
(%) ± RSD (%) 
20 17.9 ± 0.64 1.1487 ± 2.27 1.284 ± 2.34 10.55 ± 4.71 
22 18.1 ± 3.36 1.1164 ± 1.03 1.252 ± 1.36 10.81 ± 3.78 
24 17.9 ± 4.74 1.1237 ± 0.70 1.249 ± 0.65 10.05 ± 0.94 
26 16.1 ± 1.29 1.1210 ± 1.76 1.226 ± 1.27 8.61 ± 5.4 
 
Incremental intrusion volumes were plotted against pore diameters that represented pore size 
distribution. Figure 5.15 shows the pore size distribution of pellets with increased enteric 
polymer coating level. The figure demonstrates that no change in pore distribution was 
observed with the increase in coating level from 20% to 24%, while the mean pore diameter 
decreased with the application of 26% of enteric polymer. 
In Figure 5.16, the total intrusion volume was plotted against pore diameters showing the 
intrusion profile of pellets with different coating levels. The intrusion volume of mercury was 
significantly lower for the pellets coated with the 26% than the 20, 22 and 24% (w/w calculated 
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on solid polymer) of enteric polymer. Porosity was significantly affected with addition of enteric 
polymer at coating level higher than 24% (w/w calculated on solid polymer). 
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Figure 5.15. Pore size distribution of pellets with different coating levels of enteric polymer 
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Figure 5.16. Cumulative intrusion volume vs. pore diameter of pellets with different coating levels of 
enteric polymer 
 
In addition to the physicochemical properties of drug, the coating level can play an important 
role in determining the release rate of the drug from the coated pellets. The lansoprazole 
release in pH 6.8 from Eudragit L30 D-55 coated pellets decreased with increasing coating level 
because of the increased diffusion path length at higher coating level. The release profiles were 
sigmoidal in shape, with the lag phase presenting the gastric resistance of pellets, and did not 
differ significantly (p<0.05). As expected, pellets containing 20% of solid enteric polymer 
showed a faster release rate than those containing 26% of solid enteric polymer. 
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All four formulations of pellets containing from 20% (w/w) up to 26% (w/w) of solid enteric 
polymer showed release profiles which were according to the criteria stated in the USP (see 
Figure 5.17). USP is stating that no more than 10% release of lansoprazole in one hour in 0.1 N 
HCl and no less than 80% release after one hour in phosphate buffer pH 6.8 is allowed. Pellets 
containing 20% of solid enteric polymer showed highest and the fastest release in pH 6.8, with 
the drug release of 100.4% (Figure 5.17), while pellets containing 24% had the slowest and the 
lowest release (96.8%).  
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Figure 5.17. Effect of coating level on the lansoprazole gastric resistance in 0.1N HCl and dissolution in 
phosphate buffer, pH 6.8. The bars represent standard error of the mean (n=6) 
 
 
Eudragit L30 D-55 belongs to a group of polymers which are only conditionally gastroresistant 
around or below pH 5. Since in-vivo stomach pH for PPI patients on a multiple dose regimen is 
higher (>pH 4) than the official pH in USP monograph for the enteric resistance testing, pellets 
were tested in the modified bio relevant media which better simulates the gastric environment. 
Gastric resistance of pellets in the modified acid media of pH 4.5 is presented in Figure 5.18. 
Gastric resistance (t60min≤10%) was achieved for all coating levels in the modified acid stage 
medium with pH 4.5. Release profiles were not significantly different (p<0.05). 
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Figure 5.18. Effect of coating level on the lansoprazole gastric resistance in modified gastric media, pH 
4.5 and dissolution in phosphate buffer, pH 6.8. The bars represent standard error of the mean (n=6) 
 
From the results can be concluded that the porosity of pellets in the range of 8.6 to 10.8% did 
not play an important role in the gastric resistance of pellets in both tested acid stage media. 
For further studies coating level of 20% of enteric polymer was used for the reasons of time 
investment (reduced processing time) and lower costs.  
5.8. Properties of lansoprazole pellets prepared with solution/suspension 
layering 
Observed visually, the pellets were spherical and intact in shape, and no obvious surface 
defects could be observed in either one of the process stages (Figure 5.19 and Figure 5.20).  
 
a) b) 
Figure 5.19. SEM photographs of lansoprazole pellets of a) surface from run 1 with magnification x70 and 
b) surface from run 1 with magnification x2000 
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a) b) 
Figure 5.20. SEM photographs with magnification x200 of cross section of lansoprazole pellets with 
active, protective and enteric coating containing a) sugar as neutral core from run 1 and b) MCC as 
neutral core from run 6. Arrows point the layers. 
 
It was observed that the pellets from runs 3, 4, 7 and 8 (Table 4.1) after application of the 
enteric coating have changed the color form yellowish white to light beige, which was not the 
case with the pellets from other runs. Color change from pale yellowish white to dark reddish 
brown with the decrease in lansoprazole content has been observed by Tetsuro et al., 1992, 
when lansoprazole was stored on 40, 50 and 60°C for 3 months. DellaGreca et al., 2006, have 
investigated the chemical behavior of lansoprazole in aquatic environment, but failed to 
characterized it, assuming that it consists of a mixture of very liable degradation products. 
Stroyer et al., 2006, investigated stability and discoloration of physical mixtures of the 
benzimidazole, omeprazole, and enteric polymers on 40°C and 75% RH for 1 month. Mixtures 
stored at ambient temperature over desiccant showed no discoloration, while mixtures stored at 
accelerated conditions showed discoloration at different extend. From the previously mentioned 
studies discoloration of lansoprazole in pellets could be connected with the absence of the 
protective coating, even though they contained a stabilizing agent. Present alkaline agents did 
not stabilize lansoprazole sufficiently and the degradation of lansoprazole under the influence of 
free carboxyl groups of enteric polymer occurred.  
Because the neutral pellets were uniform in size it was expected that the distribution of layered 
pellets will also be narrow, since it is one of the requirements to have a good reproducibility of in 
vitro release. Increase in size for sugar pellets containing active, protective and enteric coating 
was approximately 16% (Table 5.7). For MCC neutral pellets, the same quantity of polymer 
resulted in smaller increase in size, around 10% to achieve pellets containing active, protective 
and enteric coating. Decrease in particle size of neutral pellets leads to the significant increase 
in the surface area available for polymer deposition, and therefore the same quantity of polymer 
applied on pellets gives layers of different thickness. Study of Wesdyk et al., 1990, 
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demonstrated that the film thickness of various size of beads coated in fluidized bed is not 
uniform and the larger beads received a thicker film than did the smaller beads. 
It can be seen that the d(0.5) size (Table 5.7) for pellets with the same core, containing the 
same layers, were comparable, meaning that the applied layers were uniform in thickness (run 1 
and run 5, run 3 and run 7 for sugar core pellets; run 2 and run 6, run 4 and run 8 for MCC core 
pellets).  
 
Table 5.7. Particle size of lansoprazole pellets prepared with solution/suspension layering 
Run d (0.1) ± RSD (%) d (0.5) ± RSD (%) d (0.9) ± RSD (%) 
1 838.63 ± 1.59 1125.52 ± 1.54 1490.09 ± 1.40 
2 707.18 ± 0.21 961.93 ± 0.08 1326.59 ± 0.10  
3 818.22 ± 0.36 1100.70 ± 0.35 1465.75 ± 0.30 
4 701.08 ± 0.07 954.34 ± 0.06 1318.13 ± 0.09 
5 852.64 ± 0.70 1143.82 ± 0.63 1513.14 ± 0.52 
6 712.76 ± 1.25 969.04 ± 1.43 1333.87 ± 1.35 
7 816.25 ± 0.02 1098.26 ± 0.004 1463.04 ± 0.01 
8 698.79 ± 0.30 951.04 ± 0.24 1313.35 ± 0.19 
 
Using Karl Fischer titration method, different levels of water content in the enteric coated pellets 
were determined, even though the same process parameters were used. From the Table 5.8 it 
can be seen that the pellets which contained MCC as neutral core had a higher water content 
than the pellets containing sugar as neutral core. Pellets from the run 6 had the highest water 
content of 3.8%, while pellets from the run 7 had the lowest of 1.9%.  
 
Table 5.8. Properties of lansoprazole pellets prepared with solution/suspension layering 
Run Intermediate porosity (%) 
pH of slurry 
of pellets 
Water content 
(%) (n=2) 
True density 
(g/cm3) ± RSD (%) 
Porosity after 
coating (%) ± 
RSD (%) 
1 10 8.9 2.0 1.39 ± 0.02 8 ± 20.04 
2 14 8.8 2.6 1.34 ± 0.18 13 ± 7.35 
3 13 8.8 2.4 1.39 ± 0.04 8 ± 29.00 
4 16 8.7 3.4 1.34 ± 0.10 12 ± 16.53 
5 10 7.8 2.6 1.36 ± 0.00 8 ± 29.00 
6 16 7.6 3.8 1.34 ± 0.05 12 ± 13.14 
7 11 7.8 1.9 1.40 ± 0.02 8 ± 19.06 
8 16 6.4 2.9 1.34 ± 0.03 14 ± 9.78 
      
 
Difference in the true density of the pellets containing same composition, with and without 
protective coating, is observed only between the run 5 and run 7 (see Table 5.8). All other 
pellets had the same true density and no influence of protective coating on true density was 
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observed. Pellets containing sugar as a neutral core had a little higher values of true density 
(1.36 to 1.40 g/cm3) than the pellets containing MCC (1.34 g/cm3).  
The release profiles of tested pellets were not significanlty different (p<0.05) and were sigmoidal 
in shape with the lag phase presenting the gastric resistance of pellets (see Figure 5.21), while 
the presence of lag phase in the phosphate buffer has not been observed. Small difference in 
the size of pellets and the thickness of the coatings did not have a significant influence on 
release of the drug. All tested pellet formulations showed similar release profiles, which were 
according to the criteria stated in the USP, see Figure 5.21. USP is stating that no more than 
10% release of lansoprazole in one hour in 0.1 N HCl (t60min≤10%) and no less than 80% 
release after one hour in phosphate buffer pH 6.8 is allowed (t60min≥80%). After gastric 
resistance test all formulations showed immediate release of lansoprazole in pH 6.8. The 
slowest release of drug was observed with pellets from run 2 and run 6, both containing MCC as 
neutral core and protective coating. These findings were in agreement with the literature, as 
many publications asserted the advantages of preparation of solid dispersion by deposition of 
drug onto inert pellets in order to improve the solubility of poorly water soluble drug (Sethia and 
Squillante, 2004; Leuner and Dressman, 2006; Sun et al., 2007). Study of Chokshi et al., 2007, 
showed that preparation of drug in a form of solid dispersion also improves wettability of the 
drug, what in the case of lansoprazole plays an important role since Kristl and Vrecer, 2000, 
found that the contact angle of lansoprazole is 79.9°, indicating a low wettable substance. In 
addition, Zhang et al., 2008, confirmed the inhibition of lansoprazole crystalinity and presence of 
amorphous form in the PVP solid dispersion which improved a dissolution of the drug.  
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Figure 5.21. Gastric resistance of lansoprazole pellets in pH 1.2 and dissolution in pH 6.8. The bars 
represent standard error of the mean (n=6) 
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Figure 5.22. Influence of protective coating on dissolution of pellets 
 
In the case of pellets containing sugar as a neutral core influence of HPMC coating on 
dissolution was not observed (Figure 5.22). Pellets with MCC core and HPMC coating (run 2 
and run 6) showed a small delay in drug release in comparison to pellets without protective 
coating (run 4 and run 8). This finding was associated with the starch content in Suglets® (6% 
w/w), which moderately accelerated the dissolution processes. 
5.9. Accelerated degradation stability testing of solution/suspension 
layered pellets 
Accelerated degradation study and Arrhenius shelf-life prediction is used as a comparative 
technique in obtaining the information on the most important formulation parameter in obtaining 
stable lansoprazole pellets. Since the order of reaction had to be determined from the stability 
data, results were fitted to the zero and first order model, since those are the one which are 
likely to occur (Chapter 2.3). More in depth linear regression analysis has been carried out using 
Analysis Toolpak in Excel in 95% confidence interval.  
To verify the validity of the kinetic model and to measure the linearity, correlation coefficient (R2) 
and standard errors (or standard deviation of the residuals) were compared.  
For all four temperatures there was a small difference in the correlation coefficient (R) and 
coefficient of determination (R2) of the two models. The standard error or the standard deviation 
of the residuals, which is based on the deviation of the data points from the line, was in all 
cases higher in the case of zero order, and it increased with the increase in temperature. For 
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
Run 2
Run 4
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
Run 6
Run 8 
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
Run 1 
Run 3
0
20
40
60
80
100
120
0 20 40 60 80 100 120
Time (min)
D
ru
g 
re
le
as
ed
 (%
)
Run 5
Run 7
   Results and Discussion 
 
  100 
the lowest applied temperature of 30°C standard error for the zero order was in the range of 0.9 
to 3.3, while for 60°C it was in the range of 10 to 25 for the zero order.  
Analysis of variance of all tested models showed that all proposed relationships are statistically 
significant and the lowest significance F value (p<0.05 probability that the observed fit could be 
generated by random means alone) was obtained for zero order model. Coefficients obtained 
for intercept and variable models showed lower standard deviations, with lower p-value in the 
case of first order kinetics. The weighted residuals plots can be very useful in the evaluation of 
the chosen model. The basic approach is to look for a pattern in a plot and the best result is a 
plot with no discernible pattern (Bourne, 2006). The presence of trend could be explained with a 
small number of observations and in this case the residual analysis would represent only the 
experimental error. However, the model parameters taken into consideration were ambiguous 
and were not always optimal for the same order. For example, first-order model seemed to fit 
better to the stability data obtained on 55°C than the zero-order.  
It has been reported that the most often degradation kinetics in solid dosage form appears to be 
a zero-order (Connors et al., 1986c; Connors et al., 1986b). Tested stability data showed that 
both models can be approximated by straight line kinetics and that it is hard to distinguish 
between the zero-order and the first-order kinetics. The resulting apparent zero-order model 
was considered to be the best descriptive for the given stability data and it was assumed to 
occur in the product since a high moisture content was present and that degradation of 
lansoprazole occurred only in the moisture layer.  
The results obtained from stability studies that were performed on 8 formulations of 
lansoprazole pellets on 30°C, 40°C, 55°C and 60°C at 79% RH are illustrated graphically in 
Figure 5.23. The Figure 5.23 shows that the storage at 30°C, 40°C, 55°C and 60°C at 79% RH 
resulted in gradual decomposition of lansoprazole in all tested pellets. 
Decrease in lansoprazole content followed apparent zero-order kinetics and apparent zero-
order rate constants for each temperature were calculated. However, not many zero-order 
degradation kinetics exist in pharmaceutics, but some drugs in certain dosage forms, such as 
suspensions, follow zero-order kinetics. This approximation was in concordance with the study 
by Tabata et al., 1992, as it was hypothesized that the degradation content of lansoprazole 
would be proportioned to the product of the degradation rate constant (k) and the total solubility 
(S). He defined apparent zero-order degradation rates of drugs in the solid state can be 
expressed with following equation (Tetsuro et al., 1992): 
 
kxSdt
leLansoprazod ∝− )( Equation 5.1
Similar approach to solid-state degradation has been described by Connors et al., 1986c, that 
the degradation in solid state is a function of both the solubility of the drug and the amount of 
available solvent.  
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Figure 5.23. Decrease in lansoprazole content on temperatures of 30, 40, 55 and 60°C on 79% RH 
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Tabata et al., 1992, assumed that the degradation of lansoprazole only occurs in the dissolved 
fraction of drug. It was suggested that lansoprazole is unstable in the presence of liquids in 
which the drug is at least partly soluble. 
Solution 
 
 
 H2O k  
  
 Solubility S 
 
The rate of decomposition was increased by storage of the pellets at high temperatures what is 
presented in the Table 5.9. The rate of lansoprazole decomposition (k) showed the maximum 
value when the pellets were stored at 60°C. The rate of decomposition was obtained from the 
slope, after plotting the data according to the apparent zero order kinetics. 
 
Table 5.9. Effect of temperature and humidity on the rate of decomposition of tested pellet formulations 
Trial T[°C] k (M/day-1) R2 
Run 1 30 0.211 0.957
  40 0.164 0.845
  55 4.371 0.908
  60 14.996 0.914
Run 2 30 0.332 0.972
  40 0.831 0.937
  55 6.226 0.885
  60 14.76 0.884
Run 3  30 0.292 0.960
 40 0.431 0.815
  55 5.676 0.827
  60 15.04 0.914
Run 4 30 0.436 0.951
  40 0.833 0.961
  55 6.895 0.948
  60 14.028 0.817
Run 5 30 0.376 0.962
  40 0.584 0.716
  55 4.279 0.784
  60 13.586 0.958
Run 6 30 0.494 0.960
  40 0.587 0.917
  55 6.313 0.797
  60 14.238 0.890
Run 7 30 0.505 0.955
  40 1.287 0.967
  55 7.068 0.989
  60 14.293 0.949
Run 8 30 0.601 0.966
  40 1.519 0.967
  55 7.050 0.964
  60 14.178 0.801
Lansoprazole 
(solid) 
Lansoprazole 
(solid) DEGRADATION 
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The Arrhenius plots of the stability data at four storage temperatures was obtained by plotting 
the lnk versus the 1000/T for all tested formulations and it is presented in the Figure 5.24.  
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Figure 5.24. An Arrhenius plot showing the stability of 8 tested pellet formulations 
 
By extrapolation, the k value at 25°C for each of the tested pellet formulations is calculated and 
presented in the Table 5.10. Apparent activation energy Ea can also be calculated from the 
slope of resulting line, according to the Equation 2.1. 
 
Table 5.10. Rate of decomposition, predicted shelf-lives and half-lives at 25°C  
 
Formulation Ea (J/mol) k(Mday
-1) 
(n=3) R
2 t0.5(days) t0.9(days) 
Run 1 26.397 0.04338 0.865 1152.5 230.5 
Run 2 16.731 0.13688 0.985 365.3 73.1 
Run 3 20.312 0.08943 0.941 559.1 111.8 
Run 4 15.062 0.11666 0.973 428.6 85.7 
Run 5 16.702 0.13734 0.937 364.1 72.8 
Run 6 15.062 0.16690 0.921 299.6 59.9 
Run 7 11.837 0.24488 0.993 204.2 40.8 
Run 8 9.829 0.31090 0.994 160.8 32.2 
 
Linear regression can be extrapolated to the room temperature and thus half-life and shelf-life of 
the product at the room temperature can be predicted (see Table 5.10, Equation 2.7 and 
Equation 2.8). The visual assessment of discoloration of pellet surface was conducted during 
the whole testing period. The color change of pellets to brown on 55°C and 60°C was observed 
at the first testing interval, 0.5 days and 3 days, respectively. Pellets from the runs 4, 7 and 8 
had a slightly lighter color than the pellets from other runs. Pellets on these temperatures have 
stick to the walls of the bottle and at the end of the testing period changed their color to black. 
R2 = 0.936 
R2 = 0.985 
R2 = 0.973 
R2 = 0.921 
R2 = 0.993 
R2 = 0.941 
R2 = 0.865 
R2 = 0.993 
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Pellets at temperature of 30°C and 40°C have only slightly changed their color during the whole 
testing interval to light beige.  
Results presented in Table 5.10 show that calculated apparent activation energy for all pellets 
formulation lies between 10 J/mol and 26 J/mol. Such a low apparent energy of activation can 
be explained with very drastic experimental conditions on which pellets were exposed. In the 
study of Carstensen et al., 1987, on decomposition of aspirin in solid state in the presence of 
limited amounts of moisture, activation energy is calculated to be 18 kcal/mol. Pellets containing 
magnesium carbonate heavy in the combination with the sugar neutral pellets had better shelf-
lives than the ones containing MCC neutral pellets. Pellets containing protective coating 
regardless of the type of neutral core had better shelf-lives than the ones without it. Longest 
shelf-life of 230.5 days was predicted for run 1 containing sugar (Suglets®) as neutral core, with 
protective coating and magnesium carbonate heavy as alkaline agent. The least stable 
formulation was run 8 (32.2 days), with microcrystalline cellulose (Etispheres®) as neutral core, 
with no protective coating and sodium dihydrogenphosphate as alkaline agent. Predicted shelf-
life for this formulation was seven times lower than the predicted shelf-life for the pellets from 
run 1.  
In the previous work of Tetsuro et al., 1992, it has been suggested that lansoprazole degrades 
when a proton attacks the sulfoxide in the structure and lansoprazole seems to be especially 
sensitive to such attack compared to the other members of the 2- (2-pyridylmethyl) sulfinyl-
benzimidazole family of drugs. It has been suggested that stabilization of lansoprazole in the 
solid state can be achieved by using different pH adjusters which are capable of providing pH ≥ 
7 when present alone in water in the core of pellets containing substituted benzimidazoles. 
Lansoprazole is unstable also under strongly basic conditions, but its degradation is minimized 
under weakly basic conditions. Therefore the degradation of lansoprazole in dosage forms can 
be minimized when formulated with stabilizing compounds suitable to produce such a weakly 
basic pH (Tabata et al., 1992). But not only suppression of proton attacks can stabilize 
lansoprazole. The mechanism of stabilization is also connected with the solubility of 
lansoprazole in the moisture adsorbed layer. In the strictest sense, the term pH is not defined in 
a solid system. For it to have a meaning there must be some water mediation (Carstensen, 
2000). With addition of pH adjusters it is possible to control the pH of the microenvironment. 
Incorporation of pH adjusters has been utilized to maintain the micro-environmental pH in a 
range that will decrease drug solubility and improve stability during manufacture and storage.  
Solubility of lansoprazole increases with increase in pH. In order to stabilize lansoprazole we 
need the material which will buffer the environment in the alkaline region and in the same time 
solubility of lansoprazole should be as low as possible. According to the study of Tabata et al., 
1992; Kristl and Vrecer, 2000, solubility of lansoprazole increases slowly up to pH 9, but after 
pH 9 rapid increase in solubility is evident. DellaGreca et al., 2006 and Lagerstörm et al., 1984, 
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in their studies confirmed that degradation of LSP is accelerated in acid conditions while the 
drug is quite stable in solutions at pH 7 and 9. Tabata et al., 1992, proposed that region from pH 
7 to pH 9 presents a suitable region for stabilization of lansoprazole in the dosage form.  
 
 
Figure 5.25. Relationship between pH and kxS of lansoprazole 
 
The Figure 5.25 shows that the minimum degradation of lansoprazole occurs in the environment 
of pH 9 (Tabata et al., 1992). 
Pellets containing magnesium carbonate heavy as alkaline agent had lower rate of degradation 
and better shelf-life prediction. Pellets with sodium dihydrogenphosphate as alkaline material 
had lower predicted shelf-lives. Measured pH of the slurry of pellets showed that with 
magnesium carbonate heavy it was possible to obtain microenvironment of approximate pH of 
9, while using sodium dihydrogenphosphate pH of microenvironment was in the range of 6.4 to 
7.8 (Table 5.8). Calculated apparent activation energy showed strong correlation of 0.748 with 
microenvironmental pH (measured pH of the pellets slurry). Obtained result was in conformance 
with the work of Tetsuro et al., 1992. They found a negative correlation between pH and LSP 
degradation rate constant in solution and that magnesium carbonate. This indicates that 
measurement of pH of slurry of pellets can help identifying possible problems in stability of 
lansoprazole.  
Pellets containing sugar as a neutral core and the same alkaline material, showed lower 
porosity and lower rate constants, in comparison with pellets containing MCC as neutral core. 
Suglets® containing sucrose and maize starch, showed stabilizing effect on lansoprazole pellets, 
contrary to literature data. Tetsuro et al., 1992, conducted a compatibility study of lansoprazole 
with crystalline cellulose, sucrose and corn starch on 40°C and 75% RH for one week. Quantity 
of remaining lansoprazole is highest in the case of crystalline cellulose 99.7%, while in the case 
of sucrose and corn starch quantity of lansoprazole is 99.2% and 99.4%, respectively. One of 
the reasons for better stability of pellets containing sugar core could be that sugar is soluble in 
water and during the process surface of the core becomes sticky and incorporates the active 
drug forming a less porous layer. This is supported by the SEM pictures of pellets with sugar as 
   Results and Discussion 
 
  106 
a neutral core (Figure 5.14). From Table 5.8 can be seen that the pellets with sugar neutral core 
had lower intermediate porosity, in range of 10% to 13 % compared to pellets manufactured 
with microcrystalline cellulose which had porosity from 14% to 16%. Negative correlation has 
been found between the calculated Ea and intermediate porosity of pellets (-0.518) leading to 
the conclusion that the higher the intermediate porosity the lower the Ea and lower predicted 
stability of pellets. Better stability of lansoprazole in pellets with sugar core could also be 
explained with the property of MCC to absorb water and retain it in the core of the pellet Fielden 
et al., 1992, resulting in the higher moisture content which can be seen in the Table 5.8. Pellets 
containing MCC core had higher moisture content than the pellets containing sugar core, 
enabling a closer contact of water with the drug.  
Measurement of true density of pellets showed no difference between pellets with the same 
formulation and no influence of protective coating on density was observed. Only pellets from 
run 7 (without protective coating) showed higher density than pellets from run 5, which had the 
same formulation but no protective coating.  
Calculated activation energy for pellets which contained protective coating was higher for pellets 
having the same formulations, but no protective coating. This difference was more pronounced 
in pellets containing MCC pellets as neutral core. Presence of protective coating in the case of 
sodium dihydrogenphosphate as alkaline material has significant influence on stability of 
lansoprazole pellets. In the case of pellets containing sodium dihydrogenphosphate as alkaline 
material and protective coating, with the same neutral core, showed lower rate constants and 
had higher shelf-life predictions in comparison with the ones without protective coating (run 5 vs. 
run 7 and run 6 vs. run 8).  
Exposing lansoprazole pellets to RH of 79% resulted in protrusion of moisture and its adsorption 
on the surface, dissolution of lansoprazole in the formed moisture layer, probably resulting in 
hydrolysis of the dissolved lansoprazole. Since the solubility of lansoprazole increased with 
increase in pH and apparent activation energy depended on the solubility of the substance in 
the moisture layer, it would be expected to have a higher degradation of lansoprazole in pellets 
with magnesium carbonate heavy (pH 9) than with the sodium dihydrogenphosphate (pH 7). But 
if we take into account that lansoprazole degraded rapidly in the environment with pH lower 
than 7, pH of 9 is more favorable for stability. No correlation between the moisture content of 
starting pellets and stability of pellets was determined. This suggests that the total amount of 
water present in the system is not the driving force for the degradation of the drug. Instead only 
the water that comes in the contact with the drug and that is available for chemical reaction is 
the important parameter, what is in accordance with the study of Stroyer et al., 2006. Sugar core 
stabilized lansoprazole in a way of forming less porous active layer on the surface, disabling a 
contact of water and the active substance. Presence of the protective layer has been justified 
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since it increased the stability of lansoprazole acting as a physical barrier between the drug and 
the free carboxyl groups of enteric coating polymer. 
Confirmation of the predicted shelf-life and applicability of Arrhenius equation in the prediction of 
stability of lansoprazole pellets should be confirmed with the actual stability data accumulated in 
time. However, performed stability study with Arrhenius prediction was helpful in obtaining 
information on the most important formulation parameters and the optimum formulation of 
lansoprazole pellets for stability. 
5.10. Influence of coating level of enteric polymer on stability of pellets 
Stability data at three storage temperatures (30, 40 and 55°C) of pellets with different quantity of 
enteric coating polymer (20%, 22%, 24% and 26%) are presented in Figure 5.26. Data were 
plotted according to the zero order kinetics, and further on, obtained slope values (k) were 
plotted in a form of natural logarithm versus 1000/T to obtain the Arrhenius plots (see Figure 
5.27). 
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Figure 5.26. Decrease in lansoprazole content on temperatures of 30, 40, 55 on 79% RH in pellets 
containing different coating levels of enteric polymer Eudragit L 30 D-55 
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Figure 5.27. An Arhenius plot of pellets with different coating levels of enteric polymer  
 
 
Higher coating levels of enteric polymer had a negative influence on the stability of tested 
pellets. From Table 5.11 can be seen that pellets which contained lowest percent of enteric 
coating polymer (20% w/w solid polymer) had highest calculated energy of activation and 
longest predicted shelf-lives, even though they showed highest porosity after coating. Obtained 
result supported a decision on coating lansoprazole pellets with 20% of solid enteric polymer.  
 
Table 5.11. Rate of decomposition, predicted half-lives at 25°C and calculated energy of activation for 
pellets from run 5 with different coating levels of enteric polymer 
Formulation k (Mday
-1) 
n=3 r
2 t0.5 (days) Ea (J/mol) 
Porosity after coating 
(%) 
      
20 0.02923 0.984 1710.6 33.207 11 
      
22 0.05086 0.936 983.1 28.761 11 
      
24 0.12262 0.995 407.8 23.832 10 
      
26 0.10888 0.897 459.2 23.010 9 
      
 
5.11. Pellets prepared with direct pelletization 
5.11.1. Optimization of pellet size using experimental design 
In this study, the factorial design “with D optimization” was chosen (where D stands for 
determinant of the results matrix), which fits particularly to investigate the perimeter and the 
central point of the experimental domain. A Vertex-Centroid Design, quadratic; (D-opt.), was 
used to find the optimal levels for spray rate, rotor speed and drug load on chosen dependent 
variables, geometric mean diameter and moisture content. Figure 5.28 presents a Vertex-
Centroid design points for the optimization procedure. 
R2= 0.976 
  
R2= 0.984 
  
R2= 0.936 
  
R2= 0.995 
  
R2= 0.897 
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Figure 5.28. Vertex-Centroid design points 
 
Preliminary investigation 
The levels of different formulation and process variables were determined by a serious of 
preliminary experiments. Pelletization of powder mixture (see Table 4.9) with water, without the 
presence of binder, was found to be inadequate since no pellet formation occurred, even when 
the high spray rates were applied. In order to influence the bonding mechanism, second step of 
preliminary investigation included addition of solid HPC as a binder to the powder mixture and 
pelletization with water. Obtained pellets with spray rate of 8 rpm’s had an average particle size 
of 206 µm and with the spray rate of 12 rpm’s approximately 346 µm. Pelletization of powder 
mixture with the HPC (4% w/v) solution with the spray rate of 8 rpm’s was found to be 
appropriate when the fluidizing air flow was set to 80 m3/h and the inlet air temperature was 
28°C. Resulting pellets had average particle size of 500 µm.  
In the preliminary experiments different spheronization times in the range of 5 – 15 minutes 
were investigated since it is known that the sphericity of a pellet is a function of spheronization 
time. It was observed that spheronization beyond 8 minutes led to pellets adhesion to the walls 
of product container. As a part of preliminary investigation influence of amount of water soluble 
excipient on size and properties of pellets, was investigated. Fraction of pellets in size of 500 
microns was tested on true density, porosity and dissolution to determine if the difference of 
15% w/w) of water soluble excipient (lactose monohydrate) influences properties of obtained 
pellets. Difference in 15% of lactose monohydrate did not influence the true density of pellets. 
Pellets from the trial 2 had higher median particle size than the pellets obtained in the trial 1, 
even though the quantity of binder solution used in both trials was the same. Pellets from the 
trial 1 had median particle size of 448.2 μm while pellets from the trial 2 had median particle 
size of 531.0 μm. Observed difference could be assigned to lactose ability to absorb water 
increasing the pellet size, since pellets containing higher quantity of MCC tend to shrink after 
the removal of water as it was described by the “crystallite-gel” (Kleinebudde, 1994; Paterakis et 
al., 2002). Pellets from the trial 2 containing more lactose had higher porosity (15.4%) than the 
pellets from the trial 1 (13.0%). Since the quantity of water soluble excipient in the optimization 
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phase differed only 8% (w/w) in the formulations with the different drug loads, and the tested 
range was 15% (w/w), it was assumed that lactose will have no influence on pellet 
characteristics. 
5.11.1.1. Response variable 1: Geometric mass mean diameter 
The results for geometric mass mean diameter and moisture content at the end of binder 
addition phase of pellets produced according to the experimental design are listed in the Table 
5.12. The geometric mean diameter by weight is determined using a procedure described in 
Chapter 2.8.1. 
 
Table 5.12. Vertex-Centroid Design, quadratic; optimization 
 Factor 1 Factor 2  Factor 3 Response 1   Response 2 
Run A: Spray rate B: Rotor speed  C: Drug load GMD   Moisture content 
 rpm  %   %  μm   % 
1   6  50     8  120.6   16 
2   6  50   16  204.4   23   
3   6  80     8  259.4   23 
4   6  80   16    91.8   5 
5 10  50     8  510.7   32 
6 10  50   16  916.9   31 
7 10  80     8  235.8   28 
8 10  80   16  350.1   32 
9 10  65   12  448.2   32 
10   8  80   12  150.2   16 
11   8  65   16  191.6   12 
12   6  50   12    96.7   5 
13   6  65     8    84.3   4 
14   8  50     8  182.3   19 
 
From the results it can bee seen that not all experiments resulted in pellets. In this study, only 
the size beyond 250 µm was referred to as pellets. Five experiments gave satisfactory results 
regarding the particle size (runs 3, 5, 6, 8 and 9), but not all pellets were spherical. Scanning 
electron microscopy photographs of pellets obtained in all trials according to the experimental 
design, in size range of 355 and 500 microns are presented in the Figure 5.29. Pellets obtained 
in trials 5, 6, 9, 12, 13 and 14 were considered most spherical ones from the visual point of 
view, since sphericity has not been calculated.  Pellets with the smoothest surface were 
obtained in trials 5, 6, 8 and 9 (Figure 5.29) with high spray liquid addition rate. SEM 
photographs showed similar surface structure of pellets obtained in trials 1, 3, 10, 11, 12, 13 
and 14 which seemed to be more fibrous and porous than the surface of the pellets obtained in 
other runs. These pellets were prepared using low and medium levels of spray rate. The run 2 
seemed to have a mix of pellets with different surface characteristics, including fibrous and 
smooth surface pellets. Presence of pellets with different surface characteristics in run 2 can be 
accounted to a combination of low spray rate and low rotor speed which could lead to non-
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uniform addition of binder liquid to the powder mass, which has been reported by Liew et al., 
2000.  
 
 
 
 
 
  
Figure 5.29. SEM photographs of pellets obtained with direct pelletization (from run 1 to run 14, 
respectively) 
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In this study, the whole set of data was analyzed by ANOVA using STAVEX 5.0 program and 
statistical significance of the main effects as well as the interaction effects was determined 
(p<0.1). Following second order polynomial equation was selected for estimating the response 
variables: 
 
329318217
2
36
2
25
2
14332211 xxaxxaxxaxaxaxaxaxaxaay o +++++++++=  Equation 5.2
 
 
Where y is response, a0 intercept, ai coefficients computed from the responses of the 
formulations (the effect of the factor xi), x1 spray rate, x2 rotor speed, x3 drug load, xixj interaction 
effect, xi2 curvature effect. 
The estimated values of geometric mass mean diameter (GMD) and regression coefficients 
postulated by Equation 5.2 are presented in Table 5.13. In the left column, the single factors 
and their combinations are listed, whereas their influence on the response variables is 
expressed with the p-value. A p-value<0.1 indicates a significant effect of the factor on the 
analyzed response variable (Aicos, 1999). 
 
Table 5.13. Model equation for geometric mean diameter 
Parameter Estimated p-value 
Regression 
coefficients 
Factor description 
Intercept + 144.383   0.0063 + 929.8             intercept               
* S + 175.909 0.0001 - 209.6      SPRAY RATE                
* R - 93.310 0.0008 - 8.182      ROTOR SPEED                
* D + 56.051 0.0053 + 14.19      DRUG LOAD                  
* S2     + 107.992 0.0087 + 27.00      SPRAY RATE square          
* R2     + 79.687 0.0242 + 0.3542     ROTOR SPEED square         
* D2     + 0.383 0.9873 + 0.02396    DRUG LOAD square           
* S*R    -113.407 0.0006 - 3.780      SPRAY RATE * ROTOR SPEED  
* S*D    + 74.200 0.0029 + 9.275      SPRAY RATE * DRUG LOAD     
* R*D    - 69.190 0.0037 - 1.153      ROTOR SPEED * DRUG LOAD    
Goodness of fit (R2)   0.9934 
Corrected goodness of fit (R2c)   0.9786 
 
After the analysis has been carried out, corrected goodness of fit was R2c = 0.9786, meaning 
that the model has a very good fit. There was no evidence for non-normality of model deviations 
and ANOVA showed that the residuals are identically distributed for all levels of the factors.  
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The effects of the three factors on the geometric mass mean diameter were found statistically 
significant (p<0.1) what confirmed the application of optimization design (Table 5.13). According 
to the model, spray rate had the highest influence on the geometric mean diameter (p<<0.1). 
Many studies (Vecchio et al., 1994; Paterakis et al., 2002) have shown the importance of the 
spray rate in controlling the size of the pellets. The model showed that the rotor speed also had 
a crucial effect on the response variable with the p value<<0.1, which was in agreement with the 
findings of several previous studies of Rashid et al., 1999; Korakianti, 2002.  
If the interactions are considered, most significant effect on the GMD had the interaction of 
spray rate and rotor speed (p<<0.1).  
After the evaluation of the model has been carried out, plotting of response variable versus 
factors has been generated for the easier interpretation of the results. Surface plots of 
geometric mean diameter vs. spray rate (x-axe), rotor speed (y-axe) and drug load with the fixed 
value of 16% is presented in Figure 5.30.  
 
 
 
 
Figure 5.30. Surface plot of geometric mean diameter, spray rate (x-axis), rotor speed (y-axis) at fixed 
level of drug load to 16% 
   Results and Discussion 
 
  114 
 
Figure 5.31. Surface plot of geometric mean diameter, drug load (x-axis), rotor speed (y-axis) at fixed 
level of spray rate (10 rpm) 
 
Pellets with low geometric mean diameter have been obtained with low spray rate of the binder 
liquid and high rotor speed, while pellets with high geometric mean diameter have been 
obtained with high spray rate and low rotor speed. From the surface plot (Figure 5.31) it can be 
seen that combination of high spray rate and low rotor speed led to higher geometric mean 
diameter of pellets. Only trials with the spray rate of 10 rpm gave satisfactory geometric mean 
diameter of pellets, in the range of 300 – 1000 μm (run 5, 6, 8 and 9). Generally, it was 
expected that a higher liquid addition rate would result in larger agglomerates and lower 
porosity since there is shorter time for liquid to evaporate (Chapter 2.4.1.4) as it is described in 
the study of Kristensen and Schaefer, 2000; Paterakis et al., 2002. It was found by Menon et al., 
1996, that granule growth is directly proportional to the spray rate and inversely proportional to 
the inlet air temperature.  
The effect of the drug load on geometric mean diameter is found to be dependent on the rotor 
speed (Figure 5.31). Increase in the drug load, with the high rotor speed level (higher than 70%) 
at fixed level of spray rate, does not lead to an increase of the geometric mean diameter. Higher 
drug loading, in the combination with the low rotor speed led to a production of pellets with the 
higher geometric mean diameter (see Figure 5.31).  
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Figure 5.32. 4D contour plot of geometric mean diameter (as colour) versus several variables on the axes 
x, y and z 
 
Combination of all three factors with the predicted value of geometric mean diameter is 
presented in a 4D contour plot (Figure 5.32). The spray rate level of 9 rpm‘s, rotor speed of 62% 
and drug load of 14% yields pellets with particle size of 408 μm with 20.8% moisture content. 
As mentioned above, high rotor speed had a negative influence on the geometric mean 
diameter which could be accounted to a faster movement of powder bed leading to higher 
friction between the pellets and between the pellets and wall of the container, consequently, 
decreasing the size. 
Global optimum for the geometric diameter was computed, but it was necessary to carry out a 
confirmatory experiment to check the correspondence between theory and practice. In order to 
evaluate the prediction power of the model in the 90% confidence interval, confirmatory 
experiments have been conducted. 
Two confirmatory runs have been conducted. One in the proposed range of optimization, in 
order to establish whether the optimized predicted value of GMD lies in the confidence interval, 
and the other one in the chosen area (in the range size of 500 μm pellets) from the contour 
plots. 
First confirmatory run, run no. 15, with the spray rate of 10 rpm, rotor speed of 60% and 12 % 
drug loading has predicted the value of 506 µm for geometric mean diameter of obtained 
pellets. The second confirmatory run estimated optimum of 914.5 µm, with the spray rate level 
of 10 rpm, rotor speed 50% and drug load of 16% (confirmatory run 16). 
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The results of the confirmatory experiments were 452 µm for the run 15 and 911 µm for the run 
16. Experimentally obtained values for geometric mean diameter were within the confidence 
range so the predicted values have been confirmed.  
5.11.1.2. Response variable 2: Moisture content 
According to the Equation 5.2 estimated effects and p-values moisture content (MC) are 
presented in Table 5.14. 
 
Table 5.14. Model equation for moisture content 
Factor Estimated 
effects 
p-value 
Regression 
coefficients 
Factor description 
Intercept + 11.5146  0.1960  + 141.8             intercept               
* S  + 9.5326  0.0259  - 12.81    SPRAY RATE                
* R - 0.9079  0.7584  - 2.595      ROTOR SPEED                
* D - 0.5150  0.8609  - 1.838      DRUG LOAD                  
* S2     + 4.0002  0.5478  + 1.000      SPRAY RATE square          
* R2     + 5.2025  0.4418  + 0.02312    ROTOR SPEED square         
* D2     + 2.2383  0.7323  + 0.1399    DRUG LOAD square           
* S*R    + 0.0508  0.9877  + 0.001694      SPRAY RATE * ROTOR SPEED  
* S*D    0.9794  0.7669  + 0.1224      SPRAY RATE * DRUG LOAD     
* R*D    -2.4254  0.4759  - 0.04042      ROTOR SPEED * DRUG LOAD    
Goodness of fit (R2)    0.7773  
Corrected goodness of fit (R2c)    0.2762  
 
 
Goodness of fit for this variable was R2 = 0.777, but the corrected goodness of fit for this 
variable was R2c = 0.276, what indicated a poor fit of the model.  
The most significant effect on the moisture content had spray rate with the p-value less than 0.1 
(p<0.1) and correlation of 0.786. Water content at the end of the liquid addition phase, as a 
resulting variable of process factors, had proved to be the critical one for the formation of 
pellets. Results correlated well with literature data, confirming that the pellets growth is 
facilitated by the increased deformability of the agglomerates caused by higher water content 
(Kristensen et al., 2000). Figure 5.33 shows that the water content at the end of liquid addition 
phase correlates with the pellet size (correlation 0.763). Higher water content led to the 
formation of bigger pellets.  
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Figure 5.33. Correlation between the water content at the end of liquid addition phase and size of pellets 
 
Surface plots of the moisture content, as dependant variable, are presented in the Figure 5.34 
and Figure 5.35.  As it is presented in the Figure 5.34 lower rotor speed and higher spray rate 
led to the higher moisture content. This corresponds to the result obtained for the geometric 
mean diameter discussed in Chapter 5.11.1.1.  
 
Figure 5.34. Surface plot of moisture content, spray rate (x-axis), rotor speed (y-axis) at fixed level of drug 
load to 16% 
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Figure 5.35. Surface plot of moisture content, drug load (x-axis), rotor speed (y-axis) at fixed level of 
spray rate (10 rpm) 
 
A difference in the moisture content at the end of liquid addition was observed for the low spray 
rate applied and no connection with the rotor speed or drug load could be observed, while the 
higher spray rates showed no such differences. When the spray rate of 6 rpm’s was applied, 
with the rotor speed of 50% and the drug loads of 8, 12 and 16%, measured moisture content 
was 16, 5 and 23%, respectively. The same inconsistency in the moisture content has been 
observed for the higher rotor speed of 80%, with the drug load of 8 and 16%. Measured 
moisture content was 23% for the drug load of 8% and 5% for the drug load of 16%. With the 
higher spray rates applied, 8 and 10 rpm’s, inconsistency and big difference in the measured 
moisture content has not been observed. These findings led to a conclusion that there is a 
possibility of confounding of another factor which influences the moisture content of the powder 
bed. This influence has been found to be extreme in the case when the low spray rate is 
applied, while in the case of a high spray rate this influence is minor. Since the inlet air humidity 
was noncontrollable parameter and its effect on the moisture content of powder bed was not 
measured, lack of fit of the model could be explained and inlet air humidity can be assumed as 
a confounding factor. Further investigation on the influence of inlet air humidity on pellet 
properties is described in more details in Chapter 5.11.1.3. 
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5.11.1.3. Dissolution of pellets obtained by experimental design 
Pellets obtained from the experimental design were tested on dissolution in phosphate buffer 
(procedure described in Chapter 4.5.7) in fraction size form 355 – 500 μm, in order to minimize 
the effect of pellets size on dissolution of drug. Figure 5.36 shows the release profiles in pH 6.8 
of all tested pellets without being exposed to 0.1N HCl for one hour, since no enteric coating 
has been applied in this stage. 
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Figure 5.36. Dissolution profiles of pellets obtained using experimental design. The bars represent 
standard error of the mean (n=3) 
 
Lowest drug release of 24% was observed with pellets from the run 1 prepared with the 
combination of low levels of all three factors (Table 5.12). The immediate release profile with the 
highest quantity of drug released (99%) was achieved with pellets from the run 14 prepared with 
spray rate of 8 rpm’s, rotor speed of 50 % and drug load of 8%. From the Figure 5.36 it can be 
seen that obtained dissolution profiles could be categorized in two groups. First group consists 
of pellets which had incomplete or retarded release of lansoprazole in comparison to the 
lansoprazole powder (Figure 5.36, LSP). Run 1, 2, 5, 7 and 8 showed incomplete release of 
lansoprazole in phosphate buffer pH 6.8 (below 60%). Second group includes pellets from run 
3, 4, 9, 10, 11, 12, 13 and 14, which showed a higher drug release than lansoprazole powder 
itself. Quantity of drug released in 60 minutes in pH 6.8 for second group was more than 80%. 
From the results presented in the Figure 5.36 no valid conclusion could be drawn on the optimal 
settings of spray rate, rotor speed and drug load on the dissolution of pellets. Since a correlation 
of 0.507 between a date of production of pellets and dissolution in phosphate buffer pH 6.8 has 
been observed, and a negative correlation of 0.583 between moisture content at the end of 
liquid addition rate and dissolution, it was assumed that the differences in the dissolution 
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profiles could be assigned to the difference in the moisture content and with this to the inlet air 
humidity differences. In the case of runs with the spray rate of 6 rpm’s, pellets with the lower 
moisture content at the end of liquid addition had better dissolution than the ones with the 
higher moisture content. In the case of pellets prepared with 10 rpm spray rate, dissolution 
varied slightly with the difference in the moisture content and in between runs, since there was a 
small difference in the moisture. It was assumed that incomplete release (or retarded release) is 
due to the higher moisture content of the bed during pelletization caused by the higher inlet-air 
humidity (noncontrollable process parameter as mentioned in Chapter 5.11.1.2). In order to 
confirm this assumption two trials have been conducted to simulate the effect of in-process bed 
humidity on the release. This assumption could also clarify the lack of fit of the model for the 
moisture content.  
5.12. Properties and stability testing of pellets prepared with direct 
pelletization 
Preparation of core pellets using direct pelletization and further coating gave pellets, as judged 
from visual examination and SEM pictures (Figure 5.37), which could generally be described as 
nonspherical.  
 
a) 
 
b) 
 
c) 
 
d) 
Figure 5.37. Scanning electron microscopy pictures of enteric coated pellets from direct pelletization with 
magnification x300: a) trial 1, b) trial 2, c) trial 3 and d) trial 4 
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The loss of sphericity of core pellets could be ascribed to the coating process parameters, since 
the process had to be interrupted for several times. As judged from the SEM pictures during the 
enteric coating process of all trials agglomeration of pellet units and deposition of material onto 
the surface occurred. Obtained pellets showed a higher porosity than the pellets obtained with 
solution suspension layering. Water content of coated pellets was in the range of 2.64 to 3.09%. 
pH slurry of uncoated pellets revealed that with magnesium carbonate heavy as alkaline agent it 
was possible to obtain microenvironmental pH 9.9, while with powder mixture (Balocel®) 
obtained pH was 8.2. 
 
Table 5.15. Properties of enteric coated pellets obtained with direct pelletization 
 
Formulation Porosity after coating (%) 
True density (g/cm3)± 
RSD (%) 
pH of slurry of 
pellets 
Water content 
(%) ± RSD (%)  
Trial 1 13 1.42 ± 0.0027 9.9 2.64 ± 0.01 
Trial 2 12 1.47 ± 0.0005 9.8 2.93 ± 0.13 
Trial 3 10 1.44 ± 0.0004 8.2 3.09 ± 0.08 
Trial 4 13 1.42 ± 0.0012 8.2 3.01 ± 0.07 
 
The results obtained from forced stability studies that were performed on lansoprazole pellet 
formulations prepared with rotary processor (see Table 4.16 and Table 4.17) on 30°C, 40°C, 
55°C and 60°C at 79% RH are illustrated graphically in Figure 5.38. 
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Figure 5.38. Decrease in lansoprazole content on temperatures of 30, 40, 55 and 60°C on 79% RH in 
pellets prepared by direct pelletization 
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Rapid decrease of lansoprazole in pellets obtained by direct pelletization was most pronounced 
at temperature of 60°C. Pellets from the trial 1 had the highest calculated apparent energy of 
activation with the predicted shelf life of 59.2 days. Pellets from the trial 1 contained a 
magnesium carbonate heavy as alkaline agent and protective coating. Pellets from the trial 3, 
without alkaline agent and without protective coating, had lowest stability with calculated shelf 
life of 12.2 days.  
 
Table 5.16. Rate of decomposition of lansoprazole in pellets from direct pelletization, predicted shelf-lives 
and half-lives at 25°C  
Formulation k(Mday
-1) 
(n=3) R
2 t0.5(days) t0.9(days) Ea (J/mol) 
Trial 1 0.1689 0.937 296.1 59.2 104.9 
Trial 2 0.3512 0.985 142.4 28.5 93.3 
Trial 3 0.8218 0.973 60.8 12.2 76.5 
Trial 4 0.8057 0.921 62.1 12.4 77.2 
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Figure 5.39. An Arhenius plot of pellets prepared with direct pelletization (run 09) 
 
Dissolution profiles of tested pellet formulations (Table 4.16 and Table 4.17) with 20% of 
Eudragit L 30 D-55 (w/w calculated on solid polymer) are presented in Figure 5.40. The release 
data showed that application of 20% of solid enteric polymer was not equally suitable to obtain 
desired performance, as in the case of solution suspension layering, since the coating did not 
prevent a release of drug in pH 1.2. From SEM pictures (Figure 5.37) it is visible that the 
complete film formation on the surface has occurred.  
 
R2 = 0.972 
R2 = 0.987 
R2 = 0.989 
R2 = 0.988 
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Figure 5.40. Gastric resistance in pH 1.2 and dissolution in pH 6.8 of enteric coated pellets from the run 9. 
The bars represent standard deviation of the mean (n=6) 
 
The reason for low performance of enteric coating could be found in the smaller size of pellets 
and higher porosity, having a direct influence on surface area of pellets, which required a higher 
quantity of enteric polymer to achieve the same performance like in the case of 
solution/suspension layered pellets. This result is in line with literature data, since several 
studies reported that smoother pellets are consistently better and more homogeneously 
coatable than those featuring rough, irregular surface (Lehman et al. 1994; Beckert et al., 1996). 
Additionally, the interruption of the process for several times because of the nozzle blockage, 
could lead to a spray drying of dispersion droplets and deposition of material on the surface of 
pellets. Pellets from the trial 1 had slowest release in acid medium while pellets from trial 2, 3 
and 4 showed an immediate release of drug. The study of Pisek et al., 2005, reported that 
preparation of lansoprazole pellets in rotary processor in MCC matrix system lowers the 
dissolution profile of lansoprazole and that the MCC matrix system represents a sustained 
release carrier system for the low soluble drugs if no disintegrants are added (Pisek et al., 
2005). Contrary to these findings, in our study, we were able to obtain immediate release pellets 
of lansoprazole using MCC matrix system. This could be explained with the presence of sodium 
carboxymethyl cellulose (10.7% w/w in the pellet formulation) in Balocel® powder premix which 
could act, depending on the processing time and moisture content of the powder bed, as a 
disintegrants. Thoma and Bechtold, 1999, reported that pellets containing undercoat, which 
smoothes the core surface reducing the surface area, require a lower amount of gastric 
resistant dispersion polymer. In addition, the presence of subcoat was suggested to minimize a 
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diffusion of the drug into the coating, especially if the drug is soluble in the polymer (Felton, 
2007). This explains lower drug release in acid media of pellets from trials 1 and 4 compared to 
trials 2 and 3. Optimization of the enteric coating process and determination of coating level 
necessary to obtain enteric resistance was not further conducted.  
In conclusion, low stability prediction of the pellets obtained by rotor processor could also be 
attributed to a porous enteric coating layer and it’s incapability to protect the drug from the 
moisture. Additional optimization of the enteric coating should be conducted in the further 
studies.  
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6. Conclusion and Outlook 
 
In the pharmaceutical industry formulations nowadays are usually developed under high-time 
pressure on the basis of “trial and error” experiments which often result in a non-robust product 
Leuenberger and Lanz, 2005. They are variable and complex systems influenced not only by 
formulation parameters, meaning the properties of active substance and excipients, but also in 
the large number of processes involved in manufacturing. 
The main purpose of the study was to investigate and gain understanding about the factors 
affecting the stability of lansoprazole delayed release pellets and the processes used. Pellets 
were prepared using two different pelletization techniques solution/suspension layering and 
direct pelletization in rotary processor. Arrhenius relationship has been introduced in the study, 
as a comparative technique for a prediction of stability of obtained pellets. 
Thermal characterization of lansoprazole, as decomposing substance has proven to be very 
difficult. Immediate decomposition of LSP in a form of a sharp exothermic peak on DSC 
thermogram, which is unusual for decomposition processes, can lead to a false conclusion. 
Application of DSC in combination with TGA and HSM in investigation of LSP thermal behavior 
proved to be crucial in revealing the real nature of LSP. Using combination of DSC, TGA and 
HSM it was confirmed that the endothermic event obtained by DCS measurement corresponded 
to reported literature melting point range by O'Neill, 2006, (Tm=178 – 182°C) and exothermic 
event could be assigned to decomposition process. TG analysis revealed a weight loss prior to 
melting when low heating rates were applied, which was not connected with the loss of water, 
postulating the assumption of formation of eutectic with decomposing substances. HSM has 
revealed that the shift of the melting peak is caused by a formation of eutectic of LSP and its 
degradation products, leading to a shift of the peak with the increase in the heating rate. Even 
though lansoprazole melting point is highly influenced by heating rate (from 2.5°C/min to 
40°C/min difference of 15°C), higher heating rates should be employed since they give lower 
variability of results. Applied heating rates beyond 20°C/min leave no space for formation of 
eutectic and shift of the melting peak became less pronounced. In conclusion, a very dynamic 
method and exactly standardized measurement conditions, particularly with regards to heating 
rate, (e.g., in DSC) have to be employed to enable reliable determination of a melting point of 
these decomposable substances. 
It has been reported by some authors (Sethia and Squillante, 2004; Leuner and Dressman, 
2006; Sun et al., 2007) that deposition of solid dispersions on the surface of neutral core 
improves solubility of poorly water-soluble drugs by formation of high-energy amorphous phase. 
Subsequent layering of initial neutral pellets in solution suspension layering technique has 
proven to be a lengthier process than the direct pelletization. Obtained pellets were uniform in 
size, with narrow size distribution and smooth surface. Neutral sugar pellets (Suglets®) proved 
   Conclusions and Outlook 
 
  126 
to be advantageous over MCC neutral pellets (Etispheres®), in terms of processing and stability 
of pellets. Pellets containing sugar neutral core had lower intermediate porosity and better shelf-
life predictions than MCC pellets. Negative influence of intermediate porosity on stability of 
lansoprazole pellets had been found. Lower shelf-life prediction of pellets containing MCC 
neutral core can also be connected with the higher surface area, since MCC neutral pellets 
were smaller in size and had higher porosity, and contained a higher level of entrapped 
moisture. Porosity of enteric coated pellets was insufficient for the estimation of the drug stability 
in pellets, since porosity values in a range of 8% to 14% did not seem to have an influence on 
stability of pellets. Lowest tested amount of enteric polymer (20% w/w calculated on solid 
polymer) showed satisfying gastric protection of the drug and the best stability results, in 
comparison to pellets containing higher coating levels (22%, 24% and 26%). Application of 4% 
weight gain of HPMC as a subcoating to the active layered pellets slightly delayed the release 
of lansoprazole in phosphate buffer pH 6.8, which suggested that the subcoat did act as a 
barrier to prevent contact between the drug and free carboxyl groups of enteric polymer. The 
release profiles of pellets prepared by deposition of solid dispersion on the neutral core were 
not significantly different and the release of the drug was according to the USP requirements. A 
critical formulation parameter for stability of lansoprazole pellets was microenvironmental pH. It 
has been confirmed that the mechanism of stabilization of lansoprazole was not only 
suppression of proton attacks but also a limitation of its solubility in the moisture layer since it 
was found that in the pellets, lansoprazole degraded following apparent zero-order kinetics. 
Stability issues related to pH sensitivity of lansoprazole in the pellets formulation have proved to 
be closely connected with the microenvironmental pH and the presence of protective coating. 
Since lansoprazole degrades in acidic, neutral and strongly basic conditions and its solubility 
increases with increase in pH, incorporation of pH adjusters has been utilized to maintain the 
micro-environmental pH in a range that will increase drug stability during manufacture, and 
storage and keep the solubility at the lowest level. Even though the microenvironmental pH is 
not exactly defined in the solid system, it has been confirmed that the pH range of 9 to 10 leads 
to a significantly better stability results than the pH range of 6 to 7. When pH adjusters which 
are buffering in the weak basic or neutral range are used, protective coating has proven to be 
crucial for stability. The other reason for usage of protective coating is prevention of chemical 
interaction leading to instability of the active ingredient. The formulation with best shelf-life 
prediction (230.5 days) on 25°C on 79% RH contained neutral sugar pellets (Suglets®), 
magnesium carbonate heavy as buffering agent and protective coating. 
Direct pelletization in the rotary processor as a multivariable process needs to be highly 
controlled and the application of experimental design techniques presented a useful tool for 
development of robust process. The influence of process variables like rotor speed, spray rate 
and inlet-air humidity should be taken into account in preparing acceptable MCC drug loaded 
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pellets, in terms of size, shape and dissolution. On the basis of the results of experimental 
design, combination of high spray rate with lower rotor speed had a positive effect on pellets 
size. Optimal formulation was predicted (90% confidence interval) by a model generated by 
STAVEX and combination of 10 rpm’s spray rate, 50% rotor speed and 16% (w/w) drug load 
gave pellets in size of 911μm. The study has confirmed that moisture content at the end of liquid 
addition phase correlated with the size of the pellets and presents the most critical factor for the 
formation and size of the pellets. Higher moisture content at the end of liquid addition favored 
an increase in pellet size. Combination of process factors should be set at levels which 
promotes higher powder bed moisture in order to achieve bigger pellets. Moisture content up to 
30% showed no significant influence on size increase, while presence of 30% moisture 
increased the size by twofold. Dissolution of pellets prepared by direct pelletization could be 
influenced by powder bed moisture content, especially in the case when swellable substances 
were used as excipients. Presence of MCC and sodium carboxymethylcellulose in Balocel® 
powder premix, which is known as a viscosity increasing agent with ability to absorb water, 
showed dissolution modifying properties depending on the powder bed moisture. Inlet-air 
humidity had a direct influence on the powder bed moisture when a low spray rate was used, 
which further influenced a dissolution of lansoprazole from pellets. The study confirmed that by 
changing one process parameter, inlet-air humidity, in rotary processor it was possible to obtain 
pellets from immediate to retarded release of the drug. This led to the conclusion that even 
though a comprehensive pre-experimental planning has been conducted, another property of 
pellets which was not investigated could be affected by another variable which could not be 
controlled. Screening design, prior to optimization, should be applied whenever it is possible 
and importance of inlet air-humidity should not be disregarded. In terms of formulation variables 
drug load and quantity of water soluble excipient plays an important role in pellet properties. 
Addition of 15% (w/w) of water soluble excipients to a powder mixture Balocel® changed the 
properties of pellets, like porosity and true density. Balocel® has shown good pelletization 
properties but the addition of binder solution was necessary to obtain pellets. Contrary to the 
literature data (Pišek et al., 2005) Pisek et al., 2005, it was possible to obtain immediate release 
lansoprazole pellets from the MCC matrix system. Obtained pellets showed a higher porosity 
than the pellets obtained with solution suspension layering. 
The solution-layered pellets required a 20% weight gain of solid enteric polymer (Eudragit L30 
D-55) to achieve a gastric resistance, whereas the direct pelletization pellets required a higher 
coating level of enteric polymer. The higher coating levels required for the direct pelletization 
pellets compared to the solution layered pellets to achieve gastric resistance was attributed to 
the higher surface area of pellets. 
Solution suspension layered pellets showed better stability predictions than pellets obtained 
with direct pelletization. Lower stability results obtained for the direct pelletization pellets could 
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be accounted to the higher surface area and porosity, partially caused by incomplete enteric 
coating, leaving more space for moisture to penetrate into the core. This should not exclude the 
usage of rotary processor in production of lansoprazole pellets, since further optimization of 
enteric coating could give pellets with significantly better stability. 
It can be concluded that when a pellet formulation of a low soluble micronized drug is 
considered, in terms of dissolution, preferred technique could be layering on neutral core. When 
the drug is layered onto the surface of neutral pellet, transformation of the drug to the high 
energy amorphous state leads to an accelerated dissolution. In the case of direct pelletization, 
when the drug is incorporated into the core of the pellets, dissolution profile depends on the 
composition of the pelletizing agent. When swellable substances are present in the powder 
premix, moisture content of the powder bed plays a major role in dissolution. With the higher 
moisture level, obtained by application of lower spray rates leading to a longer processing time, 
MCC and sodium carboxymethylcellulose swell incorporating a drug into the pellet, which 
results in a slow-down of dissolution rate. 
On the basis of present results it can be concluded that both techniques have some advantages 
and disadvantages.  
Even though the solution suspension layering, or the solid dispersion method, seems to be 
lengthier than the direct pelletization process, and with this more expensive, it has shown some 
advantages: 
- More controllable and simpler process 
- Less variability in the dissolution profiles 
- Pellets more uniform in size and potency are obtained, since atomized droplets produce 
denser layer around the substrate particles  
- Possibility of obtaining high potency pellets 
The advantage which was observed in preparation of lansoprazole pellets with Balocel® in 
rotary processor was that it is possible to obtain immediate and prolonged release dosage form 
with the same formulation used, changing only one process parameter, inlet-air humidity. 
Further studies are necessary to confirm this assumption. 
Although methods, as accelerated drug breakdown, cannot replace rigorous stability testing 
procedures on the product in which it is to be marketed, they do lead to a considerable saving of 
time at the product development stage. Applied accelerated stability testing can be used as a 
screening and comparative technique to obtain valuable information on factors influencing 
stability, as it has been done in this study.  
It has to be kept in mind that there are few facts which are limiting the significance of the 
performed stability test and the prediction of product stability. Firstly, degradation products were 
not quantified during the stability testing only nondegraded lansoprazole present in the system 
was determined. Secondly, experiments were conducted in an open system with a high excess 
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of moisture, which will not be the case in the more realistic storage conditions. Furthermore, the 
assumption has been made that the reaction order does not change with the increase in 
temperature and that the operating mechanism will be the same at room temperature. Predicted 
shelf-lives were not confirmed with actual data accumulated in time.  
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8. Appendix 
 
 
 
 
 
Figure 8.1. FTIR spectrum of lansoprazole and lansoprazole USP standard 
  
 
 
 
 
Figure 8.2. Powder X-Ray diffractogram of lansoprazole 
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Table 8.1. Results obtained for lansoprazole Cipla (n=3) 
 
Endothermic event 
Heating 
rate  Peak (°C) ± RSD(%) Peak Height (mW) ± RSD(%) Area (mJ) ± RSD(%) Onset (°C) ± RSD(%) Delta H (J/g) ± RSD(%) End (°C) ± RSD(%) 
2.5°C/min 174.39 ± 0.17 4.75 ± 5.18 226.29 ± 3.17 173.04 ± 0.06 89.08 ± 1.84 174.71 ± 0.19 
5°C/min 180.70 ± 0.12 20.63 ± 19.12 577.7 ± 6.58 179.56 ± 0.25 229.62 ± 5.18 181.25 ± 0.12 
10°C/min 184.33 ± 0.27 36.87 ± 0.27 592.53 ± 21.74 182.76 ± 0.38 236.61 ± 22.01 185.24 ± 0.26 
20°C/min 188.42 ± 0.68 53.91 ± 17.39 432.47 ± 9.55 185.74 ± 1.12 169.61 ± 11.28 189.84 ± 0.95 
30°C/min 189.52 ± 0.18 67.10 ± 5.82 454.97 ± 1.21 187.01 ± 0.15 181.50 ± 0.39 191.42 ± 0.17 
40°C/min 190.85 ± 0.03 82.21 ± 3.79 416.32 ± 10.58 188.22 ± 0.09 166.56 ± 11.51 192.92 ± 0.07 
    
Exothermic event 
Heating 
rate  Peak (°C) ± RSD(%) Peak Height (mW) ± RSD(%) Area (mJ) ± RSD(%) Onset (°C) ± RSD(%) Delta H (J/g) ± RSD(%) End (°C) ± RSD(%) 
2.5°C/min 175.33 ± 0.14 -6.85 ± 2.24 -349.94 ± 2.75 174.75 ± 0.12 -138.46 ± 0.69 177.61 ± 0.25 
5°C/min 181.68 ± 0.11  -17.44 ± 16.08 -718.78 ± 24.96 181.00 ± 0.11 -285.33 ± 23.59 185.07 ± 0.06 
10°C/min 185.39 ± 0.23 -31.22 ± 9.15 -864.38 ± 18.55 184.18 ± 0.15 -345.16 ± 18.83 188.89 ± 0.49 
20°C/min 191.49 ± 0.80 -32.69 ± 21.91 -582.72 ± 29.55 189.17 ± 0.65 -232.69 ± 32.53 198.00 ± 0.96 
30°C/min 193.41 ± 0.15 -40.19 ± 2.39 -557.22 ± 4.67 190.53 ± 0.17 -222.36 ± 5.45 201.37 ± 0.08 
40°C/min 195.41 ± 0.11 -52.09 ± 3.172 -621.73 ± 4.96 191.88 ± 0.01 -248.38 ± 5.08 204.36 ± 0.37 
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Table 8.2. Results obtained for lansoprazole USP standard (n=3) 
 
 
 
 
 
 
Endothermic event 
Heating 
rate  Peak (°C) ± RSD(%) Peak Height (mW) ± RSD(%) Area (mJ) ± RSD(%) Onset (°C) ± RSD(%) Delta H (J/g) ± RSD(%) End (°C) ± RSD(%) 
2.5°C/min 172.64 ± 0.15 3.64 ± 04.23 149.91 ± 2.49 170.94 ± 0.62 56.41 ± 1.96 173.21 ± 0.09 
5°C/min 178.46 ± 0.002 14.99 ± 12.30 654.14 ± 12.90 176.46 ± 0.16 258.5 ± 2.25 179.19 ± 0.04 
10°C/min 181.56 ± 0.013 19.65 ± 13.96 255.01 ± 18.28 179.98 ± 0.08 100.79 ± 14.45 181.91 ± 0.08 
20°C/min 184.66 ± 0.10 29.63 ± 3.54 227.17 ± 7.51 182.35 ± 0.15 89.56 ± 5.47 185.12 ± 0.18 
30°C/min 186.54 ± 0.27 42.51 ± 23.97 267.14 ± 25.77 184.08 ± 0.42 103.97 ± 24.78 187.23 ± 0.41 
40°C/min 189.52 ± 0.21 61.71 ± 4.07 464.51 ± 6.56 185.52 ± 0.13 192.75 ± 6.64 193.09 ± 0.24 
 
Exothermic event 
Heating 
rate  Peak (°C) ± RSD(%) Peak Height (mW) ± RSD(%) Area (mJ) ± RSD(%) Onset (°C) ± RSD(%) Delta H (J/g) ± RSD(%) End (°C) ± RSD(%) 
2.5°C/min 173.86 ± 0.14 -4.32 ± 35.5 -209.20 ± 19.10 173.18 ± 0.17 -77.48 ± 21.76 176.78 ± 0.35 
5°C/min 179.74 ± 0.03 -15.04 ± 12.36 -884.45 ± 7.82 178.66 ± 0.02 -349.56 ± 7.42 184.98 ± 0.73 
10°C/min 188.43 ± 0.10 -9.89 ± 7.55 -179.97 ± 0.184 182.44 ± 0.18 -71.75 ± 5.75 186.01 ± 0.21 
20°C/min 188.43 ± 0.10 -15.18 ± 4.90 -289.10 ± 2.01 186.16 ± 0.18 -114.11 ± 3.61 194.64 ± 0.39 
30°C/min 191.67 ± 0.26 -18.16 ± 10.57 -260.92 ± 26.50 188.80 ± 0.41 -101.93 ± 27.65 194.03 ± 2.11 
40°C/min 195.77 ± 0.003 -49.78 ± 8.30 -940.68 ± 5.81 191.09 ± 0.001 -390.29 ± 5.56 207.61 ± 0.81 
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